Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Italy
Clinical trial register · European Union · CTIS

Clinical Trials in Italy, 2026

The most recently authorised trials on the EU Clinical Trials Information System (CTIS), the single register for every trial run under the EU Clinical Trials Regulation (536/2014). CTIS holds a far larger historical archive than any one list can usefully show — this register states both numbers rather than picking one.

Download CSV
Source: EMA Clinical Trials Information System (CTIS). Showing the 2557 most recently authorised of 12561 total CTIS records — a stated recency window, not the full historical archive. Synced 06 Oct 2026, 03:17 UTC
2557
Shown in this register
most recently authorised
12,561
Total on CTIS
full historical archive
776
Phase III
within the shown window
Top member states
Spain 1059 France 917 Germany 897 Italy 756 Poland 605 Netherlands 555
Narrow the registerReset
Phase
Phase I 573 Phase I/II 216 Phase II 728 Phase III 776 Phase IV 264
Lead sponsor
AstraZeneca AB 66 Merck Sharp & Dohme LLC 50 Pfizer Inc. 48 Assistance Publique Hopitaux De Paris 48 Novartis Pharma AG 43
Member state
Spain 1059 France 917 Germany 897 Italy 756 Poland 605 Netherlands 555 Belgium 451 Czechia 340
All 28 states

Trials with a site in Italy

756 of 2557 shown studies
Download
Phase
Study
Lead sponsor
Area
Member states
Decision
Phase I/II
A phase 1/2 clinical study evaluating MDX2003 in participants with relapsed, progressive, or refractory B-cell malignancies
2026-526661-26-00Relapsed/Refractory B-cell Malignancies
Modex Therapeutics Inc.
Hemic and Lymphatic Diseases
Spain, Italy
01/10/2026
Phase II
PHOENIX - ECP: A Phase 2, Randomized, Controlled, Open-label, Multicenter Study to Evaluate the Efficacy and Safety/Tolerability of Extracorporeal Photopheresis (ECP) Versus Best Available Therapy (BAT) for the Treatment of Immune-related Colitis and/or Hepatitis with Inadequate Response to Corticosteroids in Participants with Unresectable or Metastatic Melanoma Treated with Immune Checkpoint Inhibitors (ICI)
2026-526261-14-00Immune-related Colitis or Hepatitis with Inadequate Respons…
DrugsAzathioprine·Vedolizumab·Infliximab
Therakos Europe Limited
Neoplasms
Austria, Spain, Italy, Germany, Netherlands
30/09/2026
Phase I
A phase I study of [177Lu]Lu-DWJ155 and [68Ga]Ga-DWJ155 in patients with solid tumors
2024-518348-19-00Advanced bladder cancer, Advanced Breast cancer (HER2+, HR+…
Novartis Pharma AG
Neoplasms
France, Italy, Spain, Portugal, Germany, Belgium
29/09/2026
Phase III
A Phase 3, Randomized, DoubleBlind, Placebo-controlled, Multicenter, Parallel-group Study to Evaluate the Efficacy and Safety of Once Daily Treprostinil Palmitil Inhalation Powder in Participants with Pulmonary Arterial Hypertension (PALM-PAH)
2026-525265-48-00Pulmonary Arterial Hypertension
DrugTreprostinil Palmitil
Insmed Inc.
Respiratory Tract Diseases
Germany, Hungary, Belgium, France, Italy, Sweden, Austria, Lithuania, Greece
29/09/2026
Phase I
Basket trial for B-cEll driven severe auToimmunE and aLoimmune diseases (chronic Graft vErsUs host diseaSe) treated with anti-CD19 CAR T-cell thErapy
2025-522821-37-00Dermatomyositis/Polymyositis (DM/PM), Systemic Sclerosis (S…
Azienda Ospedaliero-Universitaria Di Bologna IRCCS Istituto Di Ricerca E Di Cura A Carattere Scientifico, Ospedale Pediatrico Bambino Gesu
Skin and Connective Tissue Diseases
Italy
29/09/2026
Phase III
A Phase 3, Randomized, Multicenter, Double-blind Study to Assess Stroke and Systemic Embolism Prevention with REGN7508, a Monoclonal Antibody Against Factor XI, Versus Apixaban in Participants with Atrial Fibrillation (ROXI-EVEREST)
2025-521617-97-00Atrial Fibrillation (AF)
DrugsCenvacibart·Apixaban
Regeneron Pharmaceuticals Inc.
Cardiovascular Diseases
Germany, Italy, Czechia, Austria, Spain, Belgium, Netherlands, Poland, Sweden, Greece, Latvia, Hungary, Bulgaria, Romania
29/09/2026
Phase III
A Master Protocol for a Phase 3, Randomized, Multicenter, Double-blind Study to Assess Stroke and Systemic Embolism Prevention with REGN7508 and REGN9933, Monoclonal Antibodies Against Factor XI, versus Placebo in Participants with Atrial Fibrillation for Whom Oral Anticoagulation is Unsuitable (ROXI-INCLINE)
2025-521618-25-00Atrial Fibrillation (AF)
DrugsAmrecibart·Cenvacibart
Regeneron Pharmaceuticals Inc.
Cardiovascular Diseases
Spain, Bulgaria, Hungary, Poland, Romania, Sweden, Germany, Italy, Latvia, Netherlands, Portugal
29/09/2026
Phase II
A Randomized, Double-Blind, Placebo-controlled, Parallel Arm, 52-week Study to Assess Efficacy, Safety, Tolerability, and Pharmacokinetics of Two Doses of EXPD-101 in Participants with COPD
2026-525216-34-00Chronic Obstructive Pulmonary Disease (COPD) exacerbations
Expedition Therapeutics Inc.
Respiratory Tract Diseases
Italy, Germany, Spain, Poland, Czechia, Romania, Hungary, Denmark, Bulgaria
29/09/2026
Phase III
A Master Protocol for a Phase 3, Multicenter, Randomized Study to Evaluate the Efficacy and Safety of REGN7508 and REGN9933, Monoclonal Antibodies Against Factor XI, in Participants with Recent Lower Extremity Revascularization for Symptomatic Peripheral Artery Disease (ROXI-PALISADE)
2025-522954-37-00Peripheral Artery Disease
DrugsAmrecibart·Cenvacibart·Rivaroxaban
Regeneron Pharmaceuticals Inc.
Hemic and Lymphatic Diseases
Spain, Slovakia, Hungary, Czechia, Romania, Estonia, Austria, France, Belgium, Sweden, Italy, Latvia, Poland, Bulgaria, Greece, Germany, Denmark, Lithuania, Netherlands
29/09/2026
Phase III
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Multicenter Study to Evaluate the Effect of Mitapivat on Transfusion Burden in Subjects With Sickle Cell Disease
2026-526778-18-00Anemia in subjects with sickle cell disease (SCD)
DrugMitapivat
Agios Pharmaceuticals Inc.
Hemic and Lymphatic Diseases
Italy, France, Belgium, Ireland
28/09/2026
Phase I
A prospective, open-label, single-arm, multicenter pharmacokinetic study evaluating the placental transfer of dapirolizumab pegol to the infant(s) from pregnant study participants with active systemic lupus erythematosus who are administered dapirolizumab pegol
2025-524595-37-00Systemic lupus erythematosus (SLE)
DrugsDiphenhydramine·Epinephrine·Paracetamol
UCB Biopharma
Immune system processes
Greece, Italy, Netherlands, Austria, Belgium, Sweden, Spain, Denmark, Germany
28/09/2026
Phase III
A Multicenter, Phase 2/3, Dose Range Finding Study to Evaluate the Efficacy and Safety of Atumelnant in Adults with ACTH-Dependent Cushing’s Syndrome (ADCS) Including an Open-Label Extension for Long-Term Assessment. (EQUILIBRIUM-ADCS)
2025-522648-42-01• ACTH-Dependent Cushing’s Syndrome. • Pituitary-dependent …
DrugsAtumelnant·Hydrocortisone
Crinetics Pharmaceuticals Inc.
Not possible to specify
Sweden, Austria, Spain, Poland, Netherlands, Italy, Germany, France
28/09/2026
Phase III
An Open-label Extension Study to Assess the Long-term Safety and Efficacy of Danicamtiv in Adults with Symptomatic Genetic and Familial Dilated Cardiomyopathy (KINSHIP-OLE).
2026-526139-20-00Symptomatic genetic and familial dilated cardiomyopathy.
DrugDanicamtiv
Kardigan Inc.
Cardiovascular Diseases
Poland, Sweden, Belgium, France, Spain, Hungary, Denmark, Italy, Netherlands
28/09/2026
Phase III
A Phase 1/2/3, Open-Label, Dose Escalation, Dose Expansion, and Randomized, Controlled Study to Evaluate the Safety and Efficacy of ATSN-201 Gene Therapy in Subjects with RS1-Associated X-linked Retinoschisis (LIGHTHOUSE)
2026-525886-38-00Inherited retinal dystrophy due to dysfunction in the human…
Atsena Therapeutics Inc.
Eye Diseases
Italy, Germany, Spain, Netherlands, France, Belgium
28/09/2026
Phase III
A Phase 3 Global, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Demonstrate the Efficacy, Safety, and Tolerability of Claseprubart (DNTH103) in Patients with Generalized Myasthenia Gravis (EMERGE)
2026-525298-38-00generalized Myasthenia gravis
DrugClaseprubart
Dianthus Therapeutics Inc.
Immune System Diseases
Czechia, Portugal, Austria, Bulgaria, Germany, France, Latvia, Poland, Italy, Spain, Denmark
28/09/2026
Phase I/II
ROSETTA RCC-208: A Phase 1/2 Open-label, Multi-center, Randomized Study of Pumitamig Alone or in Combination with Ipilimumab or Cabozantinib in Participants with Advanced Renal Cell Carcinoma (RCC)
2026-527163-15-00Advanced Renal Cell Carcinoma
DrugsCabozantinib·Ipilimumab
Bristol-Myers Squibb Services Unlimited Company
Neoplasms
Ireland, Romania, Italy, Spain, Czechia, Finland, France, Germany
24/09/2026
Phase II
Use of the Checkpoint inhibitor DOstarlimab in the endOmetrial cancer fertility-Sparing trEatment: CHOOSE study.
2023-509535-11-00Newly diagnosed endometrial carcinomas of the MMR-deficient…
DrugDostarlimab
UZ Leuven
Neoplasms
Italy, Belgium
23/09/2026
Phase III
A Phase III, Open-Label, Randomised, Multicentre, Global Study of Adjuvant Datopotamab Deruxtecan in Combination With Rilvegostomig in Participants With High-risk Muscle Invasive Urothelial Carcinoma (TROPION-Urothelial04).
2025-525030-57-00High-risk muscle invasive urothelial carcinoma (MIUC) origi…
DrugsMycophenolate Mofetil·Infliximab·Rilvegostomig·Enfortumab Vedotin
AstraZeneca AB
Neoplasms
Italy, Poland, Spain, France, Germany
23/09/2026
Phase III
J2A-MC-GZGY: A Phase 3, Randomized, Open-Label Study to Investigate the Efficacy, Safety, and Pharmacokinetics of Once-Daily Oral Orforglipron Compared With Once-Weekly Dulaglutide in Pediatric Participants 10 to Less Than 18 Years of Age With Type 2 Diabetes
2025-524811-35-00Diabetes Mellitus, Type 2
DrugsDulaglutide·Orforglipron
Eli Lilly & Co.
Nutritional and Metabolic Diseases
Italy, Spain, Belgium
22/09/2026
Phase II
A Phase 2b, Randomized, Placebo-controlled, Double-blind, Dose-ranging Trial to Assess the Efficacy and Safety of Ontunisertib in Patients with Fibrostenosing Crohn’s Disease
2026-525197-19-00Fibrostenosing Crohn’s Disease
DrugOntunisertib
Agomab Spain S.L.U.
Digestive System Diseases
France, Germany, Poland, Spain, Czechia, Denmark, Austria, Italy, Belgium, Netherlands
21/09/2026
Phase III
A Phase 3, Randomized, Double-Blind Extension Trial to Evaluate the Long-term Efficacy, Safety, and Tolerability of Maridebart Cafraglutide in Participants with Obesity or Overweight
2026-525408-82-00Chronic Weight Management
DrugMaridebart cafraglutide
Amgen Inc.
Nutritional and Metabolic Diseases
Czechia, Spain, Poland, Denmark, Germany, Italy, Belgium, Finland
21/09/2026
Phase III
A Phase 3, Randomized, Double-Blind Extension Trial to Evaluate the Long-term Efficacy, Safety, and Tolerability of Maridebart Cafraglutide in Participants with Obesity or Overweight with Type 2 Diabetes Mellitus
2025-524788-19-00Chronic Weight Management
DrugMaridebart cafraglutide
Amgen Inc.
Nutritional and Metabolic Diseases
Germany, Hungary, Czechia, Italy, Poland, Bulgaria
21/09/2026
Phase III
A global phase 3 randomised, double-blind and placebo-controlled study evaluating the efficacy and safety of etavopivat in children with sickle cell disease
2025-524464-38-00Sickle cell disease
Novo Nordisk A/S
Hemic and Lymphatic Diseases
France, Netherlands, Spain, Italy
21/09/2026
Phase III
A randomized, open-label, multicenter, Phase 3 study to investigate mocertatug rezetecan compared with chemotherapy in participants with endometrial cancer after platinum-based chemotherapy and immunotherapy
2025-523362-25-00Neoplasms, Endometrial
DrugsDoxorubicin·Paclitaxel
Glaxosmithkline Research & Development Limited
Neoplasms
Denmark, Netherlands, Italy, Spain, France, Portugal, Greece, Poland, Germany, Belgium, Norway, Czechia
21/09/2026
Phase III
A randomized, open-label, multicenter, Phase 3 study to investigate mocertatug rezetecan compared with standard of care in participants with platinum- resistant ovarian cancer.
2025-523361-25-00Ovarian Neoplasms
DrugsDoxorubicin·Gemcitabine·Paclitaxel·Bevacizumab
Glaxosmithkline Research & Development Limited
Neoplasms
Denmark, Austria, France, Sweden, Finland, Netherlands, Norway, Czechia, Belgium, Greece, Italy, Germany, Spain
21/09/2026
Phase II
Randomized, double-blind, placebo-controlled, parallel-group, multicenter study to evaluate the safety and efficacy of 2 dose levels of the oral ghrelin receptor agonist AC01 over 12 weeks in patients with chronic advanced heart failure with reduced ejection fraction (HFrEF)
2025-524469-25-00chronic advanced heart failure with reduced ejection fracti…
AnaCardio AB
Cardiovascular Diseases
Czechia, Slovakia, Spain, Bulgaria, Netherlands, Italy, Poland, Germany, Sweden, Hungary
21/09/2026
Phase III
A Randomized, Double-Blind, Head-to-Head Phase 3 Trial to Evaluate the Efficacy and Safety of LYT-100 (Deupirfenidone) Compared to Pirfenidone at 52 Weeks in Adults with Idiopathic Pulmonary Fibrosis (SURPASS-IPF)
2025-524493-42-00Idiopathic Pulmonary Fibrosis
DrugsDeupirfenidone·Pirfenidone
Puretech Lyt 100 Inc.
Respiratory Tract Diseases
Greece, Italy, Czechia, France, Portugal, Denmark, Spain, Poland, Germany, Romania, Belgium, Netherlands
18/09/2026
Phase II
A Phase 2 Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability, and Preliminary Efficacy of Soquelitinib in Moderate to Severe Atopic Dermatitis (SIERRA1)
2025-524384-20-00Atopic dermatitis (AD)
DrugSoquelitinib
Corvus Pharmaceuticals Inc.
Skin and Connective Tissue Diseases
Italy, Czechia, Germany, Poland, Spain, Bulgaria
18/09/2026
Phase III
A Randomized, Open-label, Phase 3 Study of Rina-S ± Bevacizumab Versus Investigator's Choice of Platinum-Based Chemotherapy ± Bevacizumab as 2L Treatment in Participants With Recurrent Platinum-Sensitive Ovarian Cancer
2025-524202-15-00Recurrent Platinum-Sensitive Ovarian Cancer
DrugsPegfilgrastim·Doxorubicin·Paclitaxel·Bevacizumab
Genmab A/S
Neoplasms
Czechia, Netherlands, Lithuania, Ireland, Finland, Hungary, Spain, Greece, Italy, France, Germany, Poland
18/09/2026
Phase II
Prevention of venous thromboembolism in cirrhotic patients with hepatocellular carcinoma
2026-526857-33-00liver cirrhosis and hepatocellular carcinoma
DrugTinzaparin
Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Neoplasms
Italy
17/09/2026
Phase III
A Long-Term Follow-Up Study of Subjects Completing the AU-011-301 (CoMpass) Trial of Bel-sar for Early Choroidal Melanoma (Indeterminate Lesions/Small Choroidal Melanomas)
2025-524405-33-00Choroidal Melanoma
Aura Biosciences Inc.
Neoplasms
Austria, Netherlands, Belgium, Czechia, Spain, France, Germany, Italy
17/09/2026
Phase III
A Phase 3 Randomized, Open-Label Study of Atebimetinib in Combination with the Modified Gemcitabine and nab-Paclitaxel Regimen Versus the Standard Gemcitabine and nab-Paclitaxel Regimen for the Treatment of Patients with Metastatic Pancreatic Ductal Adenocarcinoma Cancer (MAPKeeper 301)
2026-525617-31-00Metastatic Pancreatic Ductal Adenocarcinoma
DrugsGemcitabine·Paclitaxel
Immuneering Corp.
Neoplasms
Spain, Czechia, Hungary, Belgium, Poland, Germany, France, Italy, Romania
17/09/2026
Phase III
A phase III, randomised, double-blind, placebo-controlled, multicentre trial comparing efficacy and safety of trilaciclib versus placebo in participants with limited-stage small cell lung cancer
2025-525026-35-00Limited-stage small cell lung cancer (LS-SCLC)
Pharmacosmos A/S
Neoplasms
Czechia, Greece, France, Belgium, Italy, Spain, Germany
17/09/2026
Phase III
Zenagamtide use for the reduction of risk of major adverse cardiovascular events in people with established atherosclerotic cardiovascular disease and either overweight or obesity (AMBIENCE)
2026-525182-53-00Atherosclerotic cardiovascular disease and either overweigh…
Novo Nordisk A/S
Cardiovascular Diseases
Denmark, Czechia, Greece, France, Italy, Germany, Spain, Poland, Netherlands, Bulgaria
16/09/2026
Phase III
A Phase 3 Randomized Study Comparing Ramantamig Plus Daratumumab Versus Investigator’s Choice of Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone (DVRd) or Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Participants With Newly Diagnosed Multiple Myeloma for Whom Hematopoietic Stem Cell Transplant is Not Planned as Initial Therapy.
2026-526654-14-01Newly Diagnosed Multiple Myeloma
DrugsRamantamig·Velcade·Bortezomib·Daratumumab
Janssen Cilag International
Neoplasms
Greece, Portugal, Italy, France, Netherlands, Czechia, Germany, Poland, Spain
16/09/2026
Phase III
A Phase 2/3, Randomized, Double-blind, Multicenter, Placebo-Controlled Study Of Inebilizumab In Participants With Autoimmune Hepatitis
2025-522393-37-00Autoimmune Hepatitis (AIH)
DrugInebilizumab
Amgen Inc.
Digestive System Diseases
Belgium, Germany, Hungary, Czechia, Bulgaria, France, Netherlands, Italy, Poland, Greece, Portugal, Spain
16/09/2026
Phase I
A clinical trial to learn about the effects of IEV407 when given alone or with endocrine therapy in people with advanced breast cancer
2025-522707-26-00Advanced HR+/HER- breast cancer
Novartis Pharma AG
Neoplasms
Germany, France, Netherlands, Spain, Italy
15/09/2026
Phase I
Clinical study to evaluate the safety and efficacy of a new targeted radioactive drug treatment for advanced prostate cancer
2026-525244-14-00Metastatic prostate cancer
Fondazione IRCCS Istituto Nazionale Dei Tumori
Neoplasms
Italy
15/09/2026
Phase II
Interventional, randomized, double-blind, parallel-group, placebo-controlled, flexible-dose trial of Lu AF28996 in adults with Parkinson’s disease experiencing motor fluctuations.
2025-524655-30-00Parkinson’s disease
H. Lundbeck A/S
Nervous System Diseases
Czechia, France, Spain, Poland, Italy, Germany, Sweden
15/09/2026
Phase II
Optimization of De-EscalatiON strategies in early breast cancer
2026-527524-27-00breast cancer
DrugsTrastuzumab emtansine·Exemestane·Anastrozole·Abemaciclib
Istituto Di Candiolo Fondazione Del Piemonte Per L'Oncologia IRCCS
Neoplasms
Italy
14/09/2026
Phase III
An Open-label, Multi-Center, Single-arm Prospective Clinical Trial to Evaluate Efficacy, Safety, and Pharmacokinetics of Gamunex®-C plus Standard Medical Treatment to Prevent Infections in Participants with Secondary Antibody Deficiency Associated with Chronic Lymphocytic Leukemia, Multiple Myeloma, or Non-Hodgkin Lymphoma (Sigma).
2026-526803-31-00Secondary Antibody Deficiency Associated with Chronic Lymph…
Grifols Therapeutics LLC
Immune System Diseases
Italy, Poland, Czechia, France, Spain
14/09/2026
Phase II
A multicenter, randomized, double-blind, placebo- controlled Phase 2 study to investigate the efficacy, safety and tolerability of remibrutinib (LOU064) in adult patients with Papulopustular Rosacea (PPR)
2025-524496-23-00Papulopustular Rosacea (PPR)
DrugRemibrutinib
Novartis Pharma AG
Skin and Connective Tissue Diseases
Bulgaria, Spain, France, Italy, Germany
14/09/2026
Phase I
A PHASE I FIRST-IN-HUMAN, OPEN-LABEL, MULTICENTER STUDYTO INVESTIGATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS AND PRELIMINARY ANTITUMOR ACTIVITY OF SIM0505 IN ADULT PARTICIPANTS WITH ADVANCED SOLID TUMORS
2026-525888-40-00Advanced solid tumors
Nextcure Inc.
Neoplasms
Italy, Poland, France, Spain
09/09/2026
Phase IV
AIRITY: A hybrid cross-sectional and prospective study to assess patient characteristics, disease burden, disease control, phenotypes, endotypes, and outcomes in a real-world setting in patients with asthma
2025-524916-13-00Asthma
Sanofi-Aventis Recherche & Developpement
Respiratory Tract Diseases
France, Spain, Germany, Italy
09/09/2026
Phase III
C6491013 - A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of Once-Monthly PF-08653944 in Adults with Overweight or Obesity (VESPER 6)
2026-525318-75-00Overweight or Obesity
DrugBerobenatide
Pfizer Inc.
Nutritional and Metabolic Diseases
Spain, France, Germany, Poland, Italy
09/09/2026
Phase II
A Multicenter, Open-Label, Long-Term Extension Study to Evaluate the Long Term Safety and Tolerability of KT-621 in Participants With Asthma Previously Enrolled in a KT-621 Asthma Study
2026-526241-98-00Uncontrolled Moderate to Severe Eosinophilic Asthma
DrugKT-621
Kymera Therapeutics Inc.
Immune System Diseases
Austria, Germany, Belgium, Romania, Italy, Slovakia, Poland, Spain
09/09/2026
Phase I
A Study of LY4584180 in Adult Participants With Previously Treated Blood Cancers
2025-523601-16-00Lymphoma, Non-Hodgkin's Lymphoma, Diffuse Large B-Cell Foll…
Eli Lilly & Co.
Hemic and Lymphatic Diseases
Spain, Poland, Italy, France, Germany
08/09/2026
Phase III
A Phase 3, Open-Label, Multicenter, Randomized Study of Subcutaneous vs Intravenous Tarlatamab in Participants with Relapsed Extensive-Stage Small Cell Lung Cancer After Platinum-based First-line chemotherapy (DeLLphi-315)
2026-525489-23-00Relapsed Extensive-Stage Small Cell Lung Cancer After Plat…
DrugsSiltuximab·Tarlatamab
Amgen Inc.
Neoplasms
Romania, Poland, Germany, Greece, Netherlands, Hungary, Portugal, France, Belgium, Italy, Spain
08/09/2026
Phase IV
A double-blind, randomised, 30-week placebo-controlled phase IV study to assess the efficacy and safety of osilodrostat in patients with hypertension caused by hypercortisolaemia due to Cushing’s Syndrome
2025-524649-28-00Cushing's syndrome
DrugOsilodrostat
Recordati AG
Hormonal diseases
Germany, Bulgaria, France, Romania, Italy, Poland, Spain
08/09/2026
Phase I
A clinical trial to learn about the effects of 225Ac-ETN029 in people with advanced solid tumors
2024-519111-34-00Small Cell Lung Cancer (SCLC), Neuroendocrine Prostate Canc…
Novartis Pharma AG
Neoplasms
France, Spain, Italy, Germany
08/09/2026
Phase III
EFC18362 - A Phase 3, multicenter, multinational, randomized, open-label, active-comparator study to evaluate the efficacy and safety of venglustat compared with Cerezyme in pediatric participants 2 to 11 years of age with Gaucher disease type 3 who have reached therapeutic goals with enzyme replacement therapy
2026-525374-19-00Immune system diseases
DrugImiglucerase
Sanofi-Aventis Recherche & Developpement
Immune System Diseases
Hungary, Italy, France, Finland, Germany, Spain
08/09/2026
Phase II
A Phase 2, Randomized, Open-label, Study Assessing the Safety, Tolerability and Efficacy of Imzokitug in Combination with Pumitamig and Platinum-Doublet Chemotherapy (PDCT) versus Pumitamig and PDCT as First-line Treatment for Participants with Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)
2026-525170-19-00Locally Advanced or Metastatic Non-Small Cell Lung Cancer (…
DrugsVedolizumab·Infliximab·Pemetrexed·Paclitaxel
Bristol-Myers Squibb Services Unlimited Company
Neoplasms
Italy, Spain, Romania, Germany, France
07/09/2026
Phase I
A Study of RO7806767 as Single Agent and in Combination with Pembrolizumab in Participants with Advanced Solid Tumors
2026-525215-13-00Advanced Solid Tumors
F. Hoffmann-La Roche AG
Neoplasms
Spain, Poland, Romania, Hungary, Germany, Italy, Belgium, Netherlands, Denmark, France
07/09/2026
Phase I
A Phase I dose escalation study of intrapleural administration of Oncofid-P-M in patients with unresectable recurrent/progressive pleural mesothelioma after first-line treatment
2026-526119-12-00unresectable recurrent/progressive pleural mesothelioma
Fidia Farmaceutici S.p.A.
Neoplasms
Italy
03/09/2026
Phase III
Sequence Strategy of Immuneoncology (IO-IO) vs IO-tyrosine kinase inhibitors (TKI) followed by TKI in metastatic renal cell carcinoma (mRCC): A randomized phase 3 study Meet uro and FICOG trial. COMBO-Seq trial.
2025-523903-31-00Metastatic renal cell carcinoma
DrugsSorafenib·Sunitinib·Axitinib·Cabozantinib
Fondazione IRCCS Istituto Nazionale Dei Tumori
Neoplasms
Italy
03/09/2026
Phase II
Hyperthermic Intraperitoneal Chemotherapy and Regional Adrenalectomy in the management of Stage II & III Adrenocortical Carcinoma
2026-525406-36-00Adrenocortical Carcinoma
DrugsSodium Thiosulfate·Doxorubicin·Cisplatin
Azienda Socio Sanitaria Territoriale Degli Spedali Civili Di Brescia
Neoplasms
Italy
02/09/2026
Phase III
A parallel group, Phase 3, randomized, open-label, 2-arm study to demonstrate the superiority of belumosudil versus best available therapy (BAT) in participants at least 12 years of age with chronic graft versus host disease (cGVHD) refractory to or recurrent after 2 to 5 prior lines of systemic therapy
2026-525913-30-00Immune system diseases
DrugsBelumosudil·Ixazomib·Imatinib·Sirolimus
Sanofi-Aventis Recherche & Developpement
Immune System Diseases
Belgium, Czechia, Hungary, Sweden, Lithuania, Croatia, Netherlands, Slovakia, Poland, Austria, Norway, France, Italy, Bulgaria, Spain, Germany, Romania, Slovenia, Estonia, Portugal, Greece, Denmark
02/09/2026
Phase III
A phase III, randomized, prospective, double-blind, parallel design, multi-arm, multicenter study to compare the efficacy and safety of alogliptin and empagliflozin combination therapy versus alogliptin alone and empagliflozin alone in metformin-treated participants with type 2 diabetes mellitus and insufficient glycemic control despite diet and exercise (ODISSEIA 2026).
2025-524606-15-00Type 2 Diabetes mellitus
Tecnimede-Sociedade Tecnico-Medicinal S.A.
Nutritional and Metabolic Diseases
Poland, Germany, Portugal, Italy, Spain
02/09/2026
Phase II
Randomized, Multicenter, Vehicle-Controlled, Double-Masked Study to Evaluate the Efficacy and Safety of Intranasal Cenegermin (Recombinant Human Nerve Growth Factor [rhNGF]) in Adult Participants with Non-Arteritic Anterior Ischemic Optic Neuropathy (NAION)
2025-524748-37-00Non-Arteritic Anterior Ischemic Optic Neuropathy (NAION)
DrugCenegermin
Dompe' Farmaceutici S.p.A.
Eye Diseases
Denmark, Italy, Germany, Hungary, Netherlands, Spain, Belgium, France, Portugal
01/09/2026
Phase III
A Phase III Open-Label, Randomised, Multicentre Study of Consolidation with a Single Administration of AZD0120, a Dual-Targeting Autologous Chimeric Antigen Receptor T-cell (CAR T) Therapy Directed Against BCMA and CD19, Compared with Continuous Standard Therapy in Participants with NDMM Who Are Ineligible to Receive ASCT as Initial Therapy (DURGA-5).
2025-524014-29-00Newly Diagnosed Multiple Myeloma
DrugsAZD0120·Isatuximab·Bortezomib·Daratumumab
AstraZeneca AB
Neoplasms
Poland, Italy, Denmark, France, Sweden, Germany, Spain
01/09/2026
Phase III
A Phase 3, Randomized, Double-blind, Placebo‑controlled Study to Assess the Efficacy and Safety of Engasertib in Subjects With Moderate to Severe Hereditary Hemorrhagic Telangiectasia (HHT)
2025-524490-17-00Hereditary Hemorrhagic Telangiectasia (HHT)
DrugEngasertib
Vaderis Therapeutics AG
Congenital, Hereditary, and Neonatal Diseases and Abnormalities
Hungary, Netherlands, Germany, Bulgaria, France, Italy, Lithuania, Spain, Belgium
31/08/2026
Phase III
A Phase 3, Randomized, Double-Blinded Study to Evaluate the Safety and Efficacy of Salanersen (BIIB115) After Onasemnogene Abeparvovec Treatment in Infants with Genetically Diagnosed Spinal Muscular Atrophy
2025-523857-32-00Spinal Muscular Atrophy
DrugSalanersen
Biogen Idec Research Limited
Nervous System Diseases
Portugal, Italy, Belgium, Croatia, Hungary, Germany, Ireland, France, Norway, Poland
31/08/2026
Phase III
Targeted versus standard peri-operative prophylaxis in patients colonized with carbapenemase-producing Enterobacterales undergoing liver transplantation: a stepped-wedge cluster randomization trial
2025-523453-34-00Patients colonized with CPE undergoing liver transplantatio…
DrugsEravacycline·Aztreonam·Tigecycline
Azienda Ospedaliero-Universitaria Di Bologna IRCCS Istituto Di Ricerca E Di Cura A Carattere Scientifico
Bacterial Infections and Mycoses
Italy
31/08/2026
Phase I/II
A Phase 1/2, Open-Label, Multicenter, Multi-cohort Study of S241656 as Monotherapy or in Combination with other Antileukemic Agents in participants with Selected Myeloid Malignancies
2025-525128-88-00Patients with Acute Myeloid Leukemia (AML), Myelodysplastic…
DrugPosaconazole
Institut De Recherches Internationales Servier IRIS
Neoplasms
Netherlands, Spain, Germany, Italy, France, Finland
27/08/2026
Phase II
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy, Safety, and Tolerability of Oral PIPE-791 in Subjects with Idiopathic Pulmonary Fibrosis
2025-521901-42-00Idiopathic Pulmonary Fibrosis (IPF)
Contineum Therapeutics Inc.
Respiratory Tract Diseases
Italy, Belgium, Denmark, Austria, Greece, Germany, France, Netherlands, Portugal, Poland, Spain
26/08/2026
Phase II
C6461010 - An Interventional, Open-Label, Phase 2 Study to Investigate the Safety and Efficacy of PF-08634404 Monotherapy or in Combination in Adult Participants with Early-Stage Resectable or Locally Advanced Unresectable Non-Small Cell Lung Cancer
2025-524825-42-00Early-Stage Resectable or Locally Advanced Unresectable Non…
DrugsPF-08634404·Pemetrexed·Paclitaxel·Carboplatin
Pfizer Inc.
Neoplasms
Spain, France, Italy, Ireland, Germany, Poland
26/08/2026
Phase II
A Phase 2, Open-label, Multicohort, Study of Rinatabart Sesutecan (Rina S) in Participants With Advanced Gastrointestinal (GI) Cancers
2025-524130-26-00Gastrointestinal Cancers
DrugPegfilgrastim
Genmab A/S
Neoplasms
Italy, Belgium, France, Spain, Denmark, Netherlands, Germany
26/08/2026
Phase III
A Phase 3, open-label extension study to evaluate the long-term safety and efficacy of rozanolixizumab in adult participants with ocular myasthenia gravis
2025-524757-14-00Ocular Myasthenia Gravis
DrugRozanolixizumab
UCB Biopharma
Immune System Diseases
Hungary, France, Greece, Poland, Spain, Italy, Germany
25/08/2026
Phase III
A Phase 3, Randomized, Double-blind, Placebo-Controlled, Efficacy and Safety Study of HBS-301 in Participants with Narcolepsy Followed by an Open-label Extension
2025-523821-17-00narcolepsy
DrugPitolisant
Harmony Biosciences Management Inc.
Nervous System Diseases
Belgium, Italy, Germany, France, Spain, Poland
25/08/2026
Phase II
Solid tumor Study for Long term Treatment of Cancer Patients Who Have Participated in BMS-Parent Studies Investigating Adagrasib (BMS-986503)
2025-524905-34-00Solid tumor
Bristol-Myers Squibb Services Unlimited Company
Neoplasms
Greece, Hungary, Poland, Belgium, Spain, Netherlands, Germany, France, Portugal, Italy, Romania
25/08/2026
Phase I
A Phase 1 Study of TT125-802 as Monotherapy and in Combination with Pomalidomide and Dexamethasone in Participants with Multiple Myeloma
2025-523536-39-00Relapsed and Refractory Multiple Myeloma
TOLREMO therapeutics AG
Neoplasms
Italy, Spain
24/08/2026
Phase III
A Phase 3, Randomized, Double-blind, Placebo-controlled Study of Investigator Choice of Chemotherapy (modified FOLFIRINOX or Gemcitabine plus Nab-paclitaxel) with or without Zoldonrasib (RMC-9805) as First-line Treatment in Patients with Metastatic KRAS G12D-mutated Pancreatic Adenocarcinoma (RASolute 305)
2025-524928-21-00Pancreatic Adenocarcinoma
DrugRMC-9805
Revolution Medicines Inc.
Neoplasms
Sweden, Spain, France, Poland, Italy, Norway, Belgium, Germany, Czechia, Austria, Netherlands, Denmark
24/08/2026
Phase III
A Phase 3 Randomized, Double-blind, Placebo-controlled Global Study of Sapablursen in Polycythemia Vera
2025-524669-25-00Polycythemia Vera
Deciphera Pharmaceuticals Inc.
Hemic and Lymphatic Diseases
Austria, Czechia, Italy, Portugal, Germany, France, Hungary, Spain, Poland
21/08/2026
Phase III
A Phase 3, Randomized, Multicenter, Open-Label Study of Velzatinib (GSK6042981) versus Imatinib in Participants with Previously Untreated Metastatic and/or Unresectable Gastrointestinal Stromal Tumors (GIST)
2025-524934-24-00Neoplasms, Gastrointestinal Stromal
DrugImatinib
Glaxosmithkline Research & Development Limited
Neoplasms
Italy, Portugal, Germany, Sweden, Poland, Romania, Finland, Greece, Norway, Spain, Netherlands, France, Hungary
21/08/2026
Phase III
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Multicenter Study Evaluating the Efficacy, Pharmacokinetics, and Safety of Mitapivat in Pediatric Subjects With α- or β-Non–Transfusion-Dependent Thalassemia (ENERGIZEKids)
2025-524706-15-00Non-Transfusion-Dependent Alpha- or Beta-Thalassemia
DrugMitapivat
Agios Pharmaceuticals Inc.
Hemic and Lymphatic Diseases
Italy, Greece
21/08/2026
Phase III
A Randomized, Open-Label Phase 3 Study of Azenosertib Versus Investigator’s Choice of Chemotherapy in Platinum-Resistant High-Grade Serous Ovarian, Primary Peritoneal, or Fallopian Tube Cancers Positive for Cyclin E1 Protein Expression
2025-524641-27-00High-Grade Serous Ovarian, Fallopian Tube, or Primary Perit…
DrugsTopotecan·Doxorubicin·Gemcitabine·Paclitaxel
K-Group Beta Inc.
Neoplasms
Germany, Spain, Italy, Belgium, Poland, France, Ireland
21/08/2026
Phase III
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Multicenter Study Evaluating the Efficacy, Pharmacokinetics, and Safety of Mitapivat in Pediatric Subjects With α- or β-Transfusion-Dependent Thalassemia (ENERGIZEKids-T)
2025-524707-71-00Transfusion-Dependent Alpha- or Beta-Thalassemia
DrugMitapivat
Agios Pharmaceuticals Inc.
Hemic and Lymphatic Diseases
Italy, Greece
20/08/2026
Phase III
A Phase 3, Randomized, Open-Label Study of Linvoseltamab Versus Daratumumab in Participants with Smoldering Multiple Myeloma at High Risk of Developing Multiple Myeloma
2025-523252-31-00High Risk Smoldering Multiple Myeloma (HR-SMM)
DrugsLinvoseltamab·Daratumumab
Regeneron Pharmaceuticals Inc.
Neoplasms
Italy, Spain, Poland, France, Norway, Greece, Germany
20/08/2026
Phase III
A Phase 3 Multicenter, Double-Masked, Randomized, Placebo-Controlled Study to Investigate the Safety, Tolerability, and Efficacy of Gildeuretinol Acetate (ALK-001) on the Progression of Stargardt Disease (STGD) - NORTHSTAR
2026-525296-60-00Stargardt Disease (STGD1)
Alkeus Pharmaceuticals Inc.
Eye Diseases
Belgium, France, Spain, Italy, Germany
20/08/2026
Phase III
A Phase 3, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of rozanolixizumab in adult participants with ocular myasthenia gravis
2025-524756-54-00Ocular Myasthenia Gravis
DrugRozanolixizumab
UCB Biopharma
Immune System Diseases
Hungary, Greece, Italy, Spain, Germany, Poland, France
18/08/2026
Phase II
A Phase II, Randomized, Open-label, Multi-center Study of AK104 in Combination with Lenvatinib versus Lenvatinib in Participants with Advanced Hepatocellular Carcinoma Who Have Progressed on Atezolizumab and Bevacizumab
2025-524591-30-00Hepatocellular Carcinoma
Akeso Biopharma Co. Ltd.
Neoplasms
Poland, France, Spain, Italy
18/08/2026
Phase I
A clinical trial to learn about the effects of INR731 alone or with an androgen receptor pathway inhibitor (ARPI) in men with prostate cancer
2025-524080-20-00Metastatic castration resistant prostate cancer
Novartis Pharma AG
Neoplasms
France, Italy, Spain, Germany
17/08/2026
Phase III
C4931007 - A PHASE 3, RANDOMIZED, DOUBLE-BLIND TRIAL TO EVALUATE THE SAFETY AND TOLERABILITY OF A MULTIVALENT PNEUMOCOCCAL CONJUGATE VACCINE IN HEALTHY INFANTS
2025-523447-35-02Pneumoccoccal Immunisation
DrugPF-07872412
Pfizer Inc.
Bacterial Infections and Mycoses
Spain, Finland, Poland, Germany, Greece, Hungary, Italy
17/08/2026
Phase I/II
A Phase 1/2 Open-label, Multi-center Study to Evaluate the Safety and Clinical Activity of GSK5926371 in Adult Participants with Relapsed or Refractory B-cell Non-Hodgkin Lymphomas (B-NHL)
2025-524915-36-00Lymphoma, Non-Hodgkin
Glaxosmithkline Research & Development Limited
Neoplasms
Italy, Germany, Spain, Finland, France
17/08/2026
Phase III
A Phase III, Randomized, Open-label Trial of BNT324 Versus Docetaxel With Prednisone/Prednisolone in Metastatic Castration-resistant Prostate Cancer
2025-524445-27-00Metastatic castration-resistant prostate cancer (mCRPC)
DrugsBNT324·Prednisone·Docetaxel
BioNTech SE
Male Urogenital Diseases
Belgium, Spain, Italy, Poland, Germany, Hungary
17/08/2026
Phase II
A phase IIa open-label dose-finding study with lead-in phase evaluating the safety, pharmacokinetics, and attenuating effects of trazodone on the consciousness-altering effects of psilocybin in individuals with Treatment-Resistant Depression
2025-523346-27-00Treatment-Resistant Depression
Universita' Degli Studi G. D'Annunzio Di Chieti
Mental Disorders
Italy
14/08/2026
Phase III
The HCC patient-journey study: a prospective, adaptive, master protocol, to assess the value of the available sequences of treatment for patients with advanced hepatocellular carcinoma. The Journey of liver cancer patient - J-LI
2026-525898-39-00Advanced hepatocellular carcinoma
DrugsSorafenib·Regorafenib·Tremelimumab·Cabozantinib
Azienda Sanitaria Locale Napoli 1 Centro
Neoplasms
Italy
14/08/2026
Phase II
Denosumab or Zoledronic acid for erosive hand osteoarthritis (EHOA) in patients with osteoporosis a randomized controlled trial (ZODIAC trial)
2026-526828-41-00Erosive hand osteoarthritis (EHOA)
DrugsZoledronic Acid·Denosumab
Azienda Ospedaliera Universitaria Integrata Verona
Musculoskeletal Diseases
Italy
14/08/2026
Phase II
A Phase 2, randomized, double-blind, placebo-controlled trial to evaluate the efficacy, safety, and tolerability of CRD-4730 in patients with heart failure with reduced ejection fraction (HFREF) (CALIBRATE-HF)
2025-525033-31-00heart failure
DrugCRD-4730
Cardurion Pharmaceuticals Inc.
Cardiovascular Diseases
Latvia, Slovakia, Lithuania, Hungary, Italy, Netherlands, Spain, Poland, Bulgaria, Czechia
14/08/2026
Phase II
A TWO-STAGE, SINGLE-ARM, PHASE II STUDY OF ZONGERTINIB PLUS FULVESTRANT IN PARTICIPANTS WITH HORMONE RECEPTOR-POSITIVE/HER2-NEGATIVE ADVANCED BREAST CANCER HARBORING HER2 MUTATIONS (AGATHA)
2026-525328-10-00HR-positive/HER2-negative advanced breast cancer
DrugsZongertinib·Goserelin·Fulvestrant
Medica Scientia Innovation Research S.L.
Neoplasms
Spain, Italy, Germany
13/08/2026
Phase III
SERAFA-1: A Single arm, Open label, Multicentre, Phase IIIb Study Of Camizestrant plus Ribociclib in 1st line Treatment of ER-positive, HER2-negative Advanced Breast Cancer Patients
2025-523444-12-00Breast Cancer
DrugsCamizestrant·Ribociclib
AstraZeneca AB
Neoplasms
Poland, Spain, France, Germany, Italy
13/08/2026
Phase IV
A randomized, double blind, placebo-controlled study comparing the efficacy of dupilumab to standard of care (SOC) treatment following hospitalization for a COPD exacerbation
2025-524392-23-00Chronic obstructive pulmonary disease (COPD)
DrugDupilumab
Regeneron Pharmaceuticals Inc.
Respiratory Tract Diseases
Belgium, Italy, Spain
13/08/2026
Phase II
AN OPEN LABEL, SINGLE ARM, EXPLORATIVE TRIAL TO EVALUATE EFFICACY AND SAFETY OF BEROTRALSTAT IN PREVENTING ANGIOEDEMA ATTACKS IN SUBJECTS WITH ACQUIRED ANGIOEDEMA DUE TO C1 INHIBITOR DEFICIENCY (AAE)
2025-524747-13-00Acquired angioedema due to C1 inhibitor deficiency
Policlinico San Donato S.p.A.
Genetic Phenomena
Italy
12/08/2026
Phase II
A RANDOMIZED, PLACEBO-CONTROLLED, MULTICENTER, CLINICAL TRIAL OF COLCHICINE IN AMYOTROPHIC LATERAL SCLEROSIS (CO-ALS II)
2026-526460-20-00AMYOTROPHIC LATERAL SCLEROSIS
Azienda Ospedaliero Universitaria Di Modena
Musculoskeletal Diseases
Italy
12/08/2026
Phase III
Premedication with dexamethasone for preventing interstitial lung disease in patients with breast cancer treated with trastuzumab deruxtecan
2025-521798-15-00Breast Cancer
DrugDexamethasone
Istituto Di Ricerche Farmacologiche Mario Negri
Neoplasms
Italy
11/08/2026
Phase I
A dose escalation and expansion study of XB010 as a single agent and combination therapy in subjects with locally advanced or metastatic solid tumors
2025-524805-34-00Locally Advanced or Metastatic Solid Tumors
Exelixis Inc.
Neoplasms
Italy, Netherlands, France, Spain
11/08/2026
Phase III
A multicentre randomised study on percutaneous stellate ganglion block as first line treatment in patients with electrical storm: the STAR 2 study
2024-520387-34-01electrical storm
Fondazione IRCCS Policlinico San Matteo
Cardiovascular Diseases
Italy
11/08/2026
Phase II
Valproic acid and lenvatinib in Recurrent and/or Metastatic Adenoid Cystic Carcinoma
2026-525733-24-00Recurrent and/or Metastatic Adenoid Cystic Carcinom
DrugsSodium valproate·Lenvatinib
Azienda Socio Sanitaria Territoriale Degli Spedali Civili Di Brescia
Neoplasms
Italy
11/08/2026
Phase I
A Phase 1, Open-Label, Multicenter Study of INCA036978 in Participants With Myeloproliferative Neoplasms
2026-525217-31-00Myeloproliferative Neoplasms
Incyte Corp.
Neoplasms
Italy, Belgium, Germany, France, Spain
10/08/2026
Phase III
A Phase 3, Randomized, Double-Masked, Placebo-Controlled, Multicenter Study Evaluating the Efficacy and Safety of Efgartigimod PH20 SC PFS in Adult Participants With Graves’ Disease Inadequately Controlled With Antithyroid Drugs
2025-523333-26-00Graves' Disease (GD)
Argenx
Hormonal diseases
Italy, Czechia, Spain, Denmark, Belgium, Romania, Latvia, France, Germany, Greece, Sweden, Poland, Lithuania, Bulgaria
07/08/2026
Phase II
[22961] A placebo-controlled, parallel-group, double blind, randomized, multi-cohort Phase 2 study to investigate efficacy, safety, tolerability, pharmacodynamics and pharmacokinetics of BAY 3670549 in adult participants with atrial fibrillation.
2025-523807-31-00Atrial fibrillation
Bayer AG
Cardiovascular Diseases
Belgium, Netherlands, Germany, Poland, Italy, Hungary, Bulgaria
06/08/2026
Phase III
ROSY-F: Roll-Over Study for Participants Who Have Completed a Previous Study with Benralizumab (Fasenra) and Are Judged by the Investigator to Clinically Benefit from Continued Treatment
2025-523307-29-00Eosinophilic Granulomatosis with Polyangiitis (EGPA), Hyper…
DrugBenralizumab
AstraZeneca AB
Respiratory Tract Diseases
Denmark, Belgium, France, Italy, Netherlands, Austria, Poland
04/08/2026
Phase II
A Phase IIb Study to Evaluate the Efficacy, Safety, and Tolerability of AZD8965 in Participants with Idiopathic Pulmonary Fibrosis (IPF)) (ARGiNAUT)
2025-525016-41-00Idiopathic Pulmonary Fibrosis
AstraZeneca AB
Respiratory Tract Diseases
Poland, Hungary, Netherlands, Germany, Spain, Greece, Bulgaria, Italy, France, Denmark
04/08/2026
Phase I
A First-in-Human Study of INCA035784 in Participants With Myeloproliferative Neoplasms
2026-525360-18-00Myeloproliferative Neoplasms
Incyte Corp.
Neoplasms
Italy, Belgium, Germany
03/08/2026
Phase III
A double-blind, randomised, placebo-controlled trial evaluating the efficacy and safety of oral nerandomilast treatment in patients with systemic sclerosis (SSc)
2025-523884-39-00Systemic sclerosis
DrugNerandomilast
Boehringer Ingelheim International GmbH, Boehringer Ingelheim Espana S.A.
Skin and Connective Tissue Diseases
Denmark, Hungary, Sweden, Netherlands, Germany, Belgium, France, Greece, Norway, Finland, Czechia, Portugal, Bulgaria, Spain, Austria, Romania, Croatia, Poland, Estonia, Italy, Lithuania
03/08/2026
Phase III
A Phase 3, Randomized, Double-blind, and Active‑controlled Multicenter Study to Evaluate the Efficacy and Safety of JNJ‑78934804 in Participants With Moderately to Severely Active Crohn’s Disease
2026-525922-39-00Moderately to Severely Active Crohn’s Disease
Janssen Cilag International
Immune System Diseases
Norway, Romania, Austria, Italy, Slovakia, Germany, Hungary, Netherlands, Belgium, France, Portugal, Czechia, Poland, Spain, Greece
03/08/2026
Phase III
A Phase 3 Randomized, Double-blind, and Active-controlled, Multicenter Study to Evaluate the Efficacy and Safety of JNJ-78934804 in Participants with Moderately to Severely Active Ulcerative Colitis
2026-525923-26-00Moderately to Severely Active Ulcerative Colitis
DrugsJNJ-78934804·Guselkumab
Janssen Cilag International
Immune System Diseases
France, Bulgaria, Romania, Slovakia, Norway, Denmark, Greece, Italy, Austria, Poland, Netherlands, Czechia, Germany, Belgium, Spain, Hungary, Portugal
03/08/2026
Phase III
A Phase III, Randomized, Double-blind, Parallel-group, Placebo controlled, Multicenter Study to Evaluate the Effect of Elecoglipron in Reducing Cardiovascular Outcomes in Participants with HFpEF and HFmrEF (Elevate-HF)
2026-526304-79-00Heart failure with preserved ejection fraction (HFpEF) and …
DrugsElecoglipron·Dapagliflozin
AstraZeneca AB
Cardiovascular Diseases
Spain, Hungary, Germany, Poland, Italy, Bulgaria, Netherlands, Austria, Romania, Sweden, France, Greece, Slovakia, Czechia
29/07/2026
Phase I
A Phase 1 Study of PRT12396 in Participants with Select Myeloproliferative Neoplasms
2026-525484-40-00Post-Essential Thrombocythemia Myelofibrosis, Post-Polycyth…
Prelude Therapeutics Inc.
Neoplasms
Italy, France, Spain
27/07/2026
Phase III
A Randomized Controlled Study Evaluating Short-Term Dual Antiplatelet Therapy with Low-Dose Ticagrelor (60 mg) Followed by Monotherapy versus Standard-Duration Dual Antiplatelet Therapy with Clopidogrel in Patients with Chronic Coronary Syndrome Undergoing Percutaneous Coronary Intervention: the STELAR trial
2026-526368-18-00Chronic Coronary Syndrome in patients undergoing percutaneo…
DrugClopidogrel
Azienda Ospedaliera Universitaria Gaetano Martino Messina
Cardiovascular Diseases
Italy
27/07/2026
Phase III
A clinical study to compare efficacy and safety of two different doses of CagriSema and semaglutide in participants with obesity with or without type 2 diabetes
2025-522488-14-00Participants with obesity with or without type 2 diabetes
Novo Nordisk A/S
Nutritional and Metabolic Diseases
Greece, Portugal, France, Slovakia, Bulgaria, Netherlands, Romania, Italy, Austria, Poland, Hungary, Spain, Czechia, Belgium
27/07/2026
Phase III
4TAZPower: A Phase 3b/4, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, Trial to Evaluate the Efficacy and Safety of Daily Subcutaneous Injections of Elamipretide in Patients with Genetically Confirmed Barth Syndrome
2025-523837-25-00Barth Syndrome
DrugElamipretide
Stealth Biotherapeutics Inc.
Congenital, Hereditary, and Neonatal Diseases and Abnormalities
Ireland, Netherlands, France, Italy
27/07/2026
Phase I/II
Phase I/II Trial to Determine Safety and Efficacy of non-Viral Allogeneic Dual CD123/33-Chimeric Antigen Receptor CIK (CARCIK-CD123/33) Cells in Adult and Pediatric Patients with Relapse/Refractory Acute Myeloid Leukemia (AML) and Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)
2025-524977-18-00Acute myeloid leukemia and Blastic plasmacytoid dendritic c…
Fondazione Tettamanti, Fondazione IRCCS San Gerardo Dei Tintori
Neoplasms
Italy
27/07/2026
Phase III
A Phase 3 Randomized, Open Label, Multicenter Study to Evaluate the Safety and Efficacy of ABBV-706 versus Standard of Care in Subjects with Relapsed/Refractory Small Cell Lung Cancer (SCLC)
2025-523819-11-00Small Cell Lung Cancer
DrugsABBV-706·Topotecan
AbbVie Deutschland GmbH & Co. KG
Neoplasms
Italy, Greece, Spain, Belgium, France, Austria, Germany
27/07/2026
Phase III
A Phase III Randomized, Double-blind, Placebo-controlled Multicenter Master Protocol to Evaluate the Efficacy and Safety of Elecoglipron in Participants with Obesity or Overweight with or without Type 2 Diabetes Mellitus (Embold)
2025-524688-19-00Participants Living with Obesity or Overweight with at leas…
AstraZeneca AB
Nutritional and Metabolic Diseases
Spain, Germany, Italy, Poland
27/07/2026
Phase III
An Open-Label, Randomized, Multicenter Phase 3 Study Investigating the Efficacy and Safety of BGB-43395 Plus Letrozole versus CDK4/6 Inhibitors (Abemaciclib, Palbociclib, Ribociclib) Plus Letrozole in Patients with Advanced or Metastatic HR+/HER2- Breast Cancer Who Have Not Received Prior Systemic Anticancer Treatment for Advanced or Metastatic Disease
2025-523960-19-00Advanced or Metastatic HR+/HER2- Breast Cancer
BeOne Medicines I GmbH
Neoplasms
Poland, Italy, Germany, France, Spain
27/07/2026
Phase III
An Open-Label, Phase 3 Study to Evaluate the Efficacy and Safety of Salanersen (BIIB115) in Participants Aged 15-60 Years With Spinal Muscular Atrophy Who Are Either Treatment-Naïve or Have Previously Been Treated With Risdiplam
2025-524054-34-00Spinal Muscular Atrophy
DrugSalanersen
Biogen Idec Research Limited
Nervous System Diseases
Finland, Spain, Italy, Poland, Ireland, Germany, France
24/07/2026
Phase III
A Phase III, Randomized, Double-blind, Parallel-group, Placebo-controlled Multicenter Study to Evaluate the Effect of Elecoglipron in Reducing Renal Outcomes and Mortality in Participants with Chronic Kidney Disease (Elevate-CKD)
2025-523994-41-00Chronic kidney disease (CKD) in adults, with specified rang…
DrugsElecoglipron·Dapagliflozin
AstraZeneca AB
Cardiovascular Diseases
Czechia, Italy, Hungary, Romania, Bulgaria, Sweden, Denmark, Poland, Spain, Norway, Finland, Greece, France, Germany
24/07/2026
Phase II
Immune dynamics and biomarkers of anti-tumor response in BMS-986340 (anti-CCR8) and nivolumab (anti-PD-1) co-treatment of metastatic tumors
2025-524125-40-01Metastatic solid tumors, with the following specific indica…
DrugNivolumab
Humanitas Mirasole S.p.A., Fondazione Humanitas Per La Ricerca Ets
Neoplasms
Italy
23/07/2026
Phase II
A Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Efficacy and Safety of SIR9900 in Patients with VEXAS Syndrome (SIVEX)
2025-524918-28-00VEXAS Syndrome
Sironax USA Inc.
Immune System Diseases
Italy
23/07/2026
Phase III
A Phase 3b, Open-Label Study of Crinecerfont to Evaluate Androgen Reduction and Related Outcomes in Adults With Classic Congenital Adrenal Hyperplasia
2025-524282-24-00Classic Congenital Adrenal Hyperplasia (CAH)
DrugCrinecerfont
Neurocrine Biosciences Inc.
Hormonal diseases
Czechia, Germany, Sweden, Portugal, Romania, Bulgaria, Italy, Austria, Spain
23/07/2026
Phase I/II
A Phase 1/2, dose escalation and expansion study of TRI-611, an oral ALK molecular glue degrader in participants with advanced ALK-positive NSCLC
2025-524418-27-00Advanced ALK-positive NSCLC
Triana Biomedicines Inc.
Respiratory Tract Diseases
France, Italy, Germany, Spain
22/07/2026
Phase I/II
A Phase 1/2a, Open-label, First-in-Human Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of BMS-986528 in Participants with Refractory Rheumatoid Arthritis
2025-520666-22-00Refractory, difficult-to-treat Rheumatoid Arthritis
DrugTocilizumab
Bristol-Myers Squibb Services Unlimited Company
Immune System Diseases
Poland, Italy, Spain, Germany
22/07/2026
Phase III
A Randomized, Open-label, Parallel-group Phase III Study to Evaluate the Efficacy, Safety, and Tolerability of Elecoglipron Compared with Oral Semaglutide in Adults with Type 2 Diabetes Mellitus (Eluminate-2)
2025-523933-24-00type 2 diabetes mellitus
AstraZeneca AB
Nutritional and Metabolic Diseases
Poland, Hungary, Italy, Bulgaria, Germany
22/07/2026
Phase II
A Phase 2, Multicenter, Randomized, Double-blind, Placebocontrolled Study, to Evaluate Efficacy, Safety, Tolerability, and Pharmacodynamics of Intrathecally Administered Mivelsiran in Adult Participants with Early-Stage Down Syndrome-Associated Alzheimer’s Disease (DS-AD)
2025-523390-42-00Early-Stage Down Syndrome-Associated Alzheimer’s Disease (D…
DrugMivelsiran
Alnylam Pharmaceuticals Inc.
Nervous System Diseases
Italy, Netherlands, Spain, Germany, Ireland
22/07/2026
Phase I
Phase 1/1b Study of BMS-986463 in Advanced Malignant Tumors
2025-523067-38-01Advanced Malignant Tumors; High-grade Serous Ovarian Carcin…
Bristol-Myers Squibb Services Unlimited Company
Neoplasms
Spain, France, Italy
21/07/2026
Phase III
A Phase III, Multicentre, Randomised, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Elafibranor in Adult Participants with Primary Sclerosing Cholangitis
2026-525242-29-00Primary Sclerosing Cholangitis
DrugElafibranor
Ipsen Bioscience Inc.
Digestive System Diseases
Spain, Sweden, Germany, Romania, Finland, Portugal, Austria, Italy, Denmark, Czechia, France, Netherlands, Poland, Belgium, Norway
21/07/2026
Phase II
A Phase 2, open-label, randomized, dose optimization study evaluating the efficacy and safety of belantamab mafodotin administered in combination with cyclophosphamide, bortezomib, and dexamethasone in adult participants with newly diagnosed amyloid light chain amyloidosis (ALANIS)
2025-522803-60-00newly diagnosed amyloid light chain amyloidosis
DrugsEndoxan·Velcade·Bortezomib
Glaxosmithkline Research & Development Limited
Immune System Diseases
Italy, Greece, Spain
21/07/2026
Phase III
A Phase 3, Randomized, Open-label Study to Evaluate the Efficacy and Safety of Switching to a Regimen of Broadly Neutralizing Antibodies Teropavimab and Zinlirvimab in Combination with Capsid Inhibitor Lenacapavir Twice Yearly in Virologically Suppressed Adults with HIV-1 Infection on Stable Oral Treatment Regimens
2025-524336-19-00HIV-1
DrugsCobicistat·Doravirine·Ritonavir·Tenofovir DF
Gilead Sciences Inc.
Virus Diseases
Poland, Italy, France, Spain, Germany, Netherlands
21/07/2026
Phase III
A Phase 3, Randomized, Open-label Study to Evaluate the Efficacy and Safety of Switching to Long-acting Antiretroviral Therapy of Broadly Neutralizing Antibodies Teropavimab and Zinlirvimab in Combination With the Capsid Inhibitor Lenacapavir Twice-Yearly Versus Cabotegravir and Rilpivirine Every 8 Weeks in Virologically Suppressed Adults With HIV-1 on Oral Daily Antiretroviral Therapy
2025-524335-39-00HIV-1
DrugsZinlirvimab·Rilpivirine·Cabotegravir·Lenacapavir
Gilead Sciences Inc.
Virus Diseases
Netherlands, Poland, Germany, France, Spain, Italy
21/07/2026
Phase III
A Phase 3, Double-blinded, Vehicle-controlled Trial to Investigate the Efficacy and Safety of Twice-daily Delgocitinib Cream in Adult Participants with Lichen Sclerosus During a 12-Week Initial Treatment Period Followed by a 40-Week Continuation Treatment Period
2025-524873-17-00Lichen Sclerosus
DrugDelgocitinib
Leo Pharma A/S
Skin and Connective Tissue Diseases
Italy, France, Spain, Poland, Germany
21/07/2026
Phase II
J2J-MC-JZLL - preEMBER: A Phase 2, Open-label Study Evaluating Imlunestrant in Premenopausal Women with Estrogen Receptor-Positive, HER2-Negative Breast Cancer.
2025-523258-15-00Breast Neoplasms
DrugsGoserelin·Tamoxifen
Eli Lilly & Co.
Neoplasms
Belgium, France, Italy, Germany
21/07/2026
Phase II
A Phase IIb, randomised, double-blind, placebo-controlled, multicentre study to evaluate the efficacy and safety of concomitant use of eplontersen and ALXN2220 compared with eplontersen and placebo in adult participants with transthyretin-mediated amyloid cardiomyopathy (ATTR-CM).
2025-523908-75-00Transthyretin-Mediated Amyloid Cardiomyopathy (ATTR-CM)
DrugEplontersen
AstraZeneca AB
Cardiovascular Diseases
Germany, Italy, Spain, France, Sweden
20/07/2026
Phase III
A randomized, placebo-controlled, double-blind Phase 3 study to evaluate the efficacy, safety and tolerability of votoplam in participants with Huntington’s Disease
2025-522227-99-00Huntington’s Disease
DrugVotoplam
Novartis Pharma AG
Nervous System Diseases
Norway, Poland, Spain, Sweden, Bulgaria, Netherlands, Finland, Portugal, Austria, Italy, Greece, Ireland, Czechia, France, Romania, Belgium, Germany, Denmark, Slovakia, Hungary
20/07/2026
Phase III
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of ALKS 2680 in Adults With Narcolepsy Type 1
2025-524711-36-00Narcolepsy Type 1
DrugALKS 2680
Alkermes Inc.
Nervous System Diseases
Sweden, Finland, Belgium, Spain, Austria, Netherlands, France, Norway, Germany, Italy, Poland
20/07/2026
Phase III
Triple oral therapy with bempedoic acid vs usual care in early lipid management of patients with acute coronary syndrome
2026-525740-15-00Acute Coronary Syndrome
Fondazione Per Il Tuo Cuore Onlus Denominabile Anche Fondazione Italiana Per La Lotta Alle Malattie Cardiovascolari Onlus Ed Anche Heart Care Foundation Hcf Onlus
Cardiovascular Diseases
Italy
17/07/2026
Phase II
A Phase 2 Randomized, Double-Blind, Placebo-Controlled Study to Confirm Efficacy and Safety of MH002 and to Assess the Effect of Dose in Patients With Mild-to-Moderate Ulcerative Colitis Insufficiently Controlled With 5-Aminosalicylic Acid
2025-524682-24-00Ulcerative Colitis
Microbial Resource Management Health
Digestive System Diseases
Czechia, Poland, Italy
16/07/2026
Phase III
The MODIFY Study: A Phase 3b/4 randomized, double-blind, placebo-controlled, multicentre study evaluating the impact of early intervention with depemokimab on exacerbation rate, clinical remission, lung function decline, and safety in adults and adolescents with at risk Type 2 asthma, conducted up to 156 weeks.
2025-524463-20-00Asthma
DrugsDopamine·Depemokimab
Glaxosmithkline Research & Development Limited
Respiratory Tract Diseases
Ireland, Spain, Germany, Czechia, Bulgaria, France, Belgium, Romania, Italy
14/07/2026
Phase III
A Randomized, Open Label, 3-arm Phase 3 Study of Precemtabart Tocentecan with or Without Bevacizumab Compared to Trifluridine/Tipiracil plus Bevacizumab in Participants with Previously Treated Metastatic Colorectal Cancer (PROCEADE-CRC-03)
2025-524648-37-00Metastatic colorectal cancer
Merck Healthcare KGaA
Neoplasms
Belgium, Germany, France, Denmark, Poland, Spain, Netherlands, Italy, Austria
14/07/2026
Phase II
A Phase II, Open-Label, Single-Arm, Multicentre Study of Immunotherapy and non-invasive response evaluation in cutaneous squamous cell carcinoma as an organ preservation strategy: a proof of concept clinical study and translational correlates - INCEPT
2025-523633-25-00cutaneous squamous cell carcinoma
DrugCemiplimab
Fondazione GONO Plus
Neoplasms
Italy
14/07/2026
Phase III
A Sequential Phase 2/3, Single-Arm, Open-Label Study in Adults Followed by a Randomized, Placebo-Controlled, Double-Blind, Multicenter Study to Evaluate the Efficacy and Safety of Pegcetacoplan in Adults and Adolescents with Focal Segmental Glomerulosclerosis
2025-524448-36-00Focal segmental glomerulosclerosis (FSGS)
DrugPegcetacoplan
Apellis Pharmaceuticals Inc.
Female Urogenital Diseases and Pregnancy Complications
France, Portugal, Spain, Slovakia, Italy, Germany, Poland
14/07/2026
Phase III
RASolute 303: A Phase 3 Global, Multicenter, Open-label, Randomized, 3-Arm Study of Daraxonrasib Monotherapy or Daraxonrasib Plus Gemcitabine and Nab-paclitaxel versus Gemcitabine and Nab-paclitaxel as a First-Line Treatment for Patients with Metastatic Pancreatic Adenocarcinoma
2025-525088-34-00Metastatic Pancreatic Adenocarcinoma
Revolution Medicines Inc.
Digestive System Diseases
Poland, Belgium, Norway, Sweden, Austria, Germany, Denmark, Netherlands, France, Italy, Spain
14/07/2026
Phase II
A Phase 2, Open-label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of Surovatamig in Adults with Antibody-mediated Kidney Disease
2025-524139-38-00Antibody-mediated Kidney Disease
DrugSurovatamig
AstraZeneca AB
Immune System Diseases
France, Germany, Italy, Belgium, Poland, Spain
13/07/2026
Phase I/II
A Phase 1/2, Open-Label, Platform Study to Evaluate Safety and Efficacy of the BCL-2 Inhibitor Surzetoclax (ABBV-453) given as Monotherapy or in Combination with Antimyeloma Regimens in Subjects with Multiple Myeloma
2025-525105-20-00Multiple Myeloma (MM), Multiple Myeloma (MM)
DrugEtentamig
AbbVie Deutschland GmbH & Co. KG
Neoplasms
Germany, Poland, Czechia, Belgium, France, Greece, Sweden, Portugal, Italy
13/07/2026
Phase II
Master Protocol Full Title- A Master Protocol for an Exploratory, Phase 2a, Proof-of-Concept Platform Study to Evaluate the Safety, Tolerability, and Efficacy of Multiple Regimens in Participants With Myasthenia Gravis. ISA 2 to Master Protocol ARGX-999-2-MG-2000 – an Exploratory, Phase 2a, Randomized, Double-Blinded, Placebo-Controlled Study to Evaluate the Safety, Tolerability, and Efficacy of Empasiprubart IV Monotherapy in Participants With AChR-Ab Seropositive Generalized Myasthenia Gravis
2025-522939-33-00AChR-Ab Seropositive Generalized Myasthenia Gravis, Myasthe…
DrugEmpasiprubart
Argenx
Immune System Diseases
Greece, Italy, Germany, Belgium, Netherlands, Spain, Poland
08/07/2026
Phase III
Fight Osteosarcoma Through European Research evolving study platform from diagnosis to relapse (FOSTER evolving study platform)
2023-505575-69-01Osteosarcoma
DrugCabozantinib
Institut Gustave Roussy
Neoplasms
Sweden, Poland, Denmark, Finland, Netherlands, Italy, France, Spain
08/07/2026
Phase II
A Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Efficacy and Safety of E2086 in Adults with Narcolepsy
2025-523503-30-00Narcolepsy
Eisai Limited
Nervous System Diseases
Belgium, Italy, Spain, Germany
08/07/2026
Phase II
A Phase 2 Open-Label, Multi-Center Study of BMS-986504 as Monotherapy and in Combination with Other Agents in Participants with Advanced and/or Metastatic Solid Tumors with Homozygous MTAP Deletion
2025-524285-18-00Advanced and/or Metastatic Solid Tumors with Homozygous MTA…
Bristol-Myers Squibb Services Unlimited Company
Neoplasms
Belgium, Ireland, Germany, Norway, Italy, France, Spain
07/07/2026
Phase III
Multicenter, randomized, double-blind, parallel-group clinical study comparing RD03/2016 (levoFloxacin and ketorolac trometAmol) eye drops vs Leviosa® (levofloxacin and dexamethaSone 21-phosphaTe) eye drops for 7 days for the prevention and treatment of inflammation and prevention of infection associated with cataract surgery in adults. (FAST 7)
2026-525594-39-00Cataract
DrugLevofloxacin
Ntc S.r.l.
Eye Diseases
Spain, Poland, Greece, Sweden, Italy
07/07/2026
Phase III
C6461016 - A PHASE 2/3 INTERVENTIONAL STUDY OF PF-08634404 IN COMBINATION WITH CHEMOTHERAPY IN TREATMENT-NAÏVE PARTICIPANTS WITH LOCALLY ADVANCED OR METASTATIC GASTRIC, GASTROESOPHAGEAL JUNCTION, OR ESOPHAGEAL ADENOCARCINOMA
2025-524717-86-00LOCALLY ADVANCED OR METASTATIC GASTRIC, GASTROESOPHAGEAL JU…
Pfizer Inc.
Neoplasms
France, Spain, Italy
07/07/2026
Phase III
A study to evaluate the dose-exposure, safety, and exploratory efficacy of nerandomilast in children and adolescents from 2 years to less than 18 years of age with fibrosing interstitial lung disease (Part A: double-blind, placebo-controlled in children from 6 to less than 18 years of age and open-label active treatment in children from 2 to less than 6 years of age), followed by an open-label phase with active treatment (Part B)
2025-523369-32-00Fibrosing interstitial lung disease
DrugNerandomilast
Boehringer Ingelheim International GmbH, Boehringer Ingelheim Espana S.A.
Respiratory Tract Diseases
Belgium, Greece, Germany, France, Finland, Spain, Czechia, Poland, Italy, Netherlands, Denmark, Portugal
07/07/2026
Phase III
A Phase III, Randomized, Open-Label, Multicenter Study Evaluating the Efficacy and Safety of Cevostamab in Combination with Pomalidomide and Dexamethasone Versus Standard of Care in Patients with Multiple Myeloma who Have Received One to Three Prior Lines of Therapy
2025-524028-23-00Multiple Myeloma
DrugsCevostamab·Elotuzumab·Carfilzomib·Pomalidomide
F. Hoffmann-La Roche AG
Neoplasms
France, Germany, Italy, Greece, Denmark, Czechia, Spain, Poland
07/07/2026
Phase III
Phase 2/3 Open Label Randomized Study of Telisotuzumab Adizutecan in Combination with FOLFOX Compared to Standard of Care in Subjects with First-Line Metastatic Pancreatic Ductal Adenocarcinoma - AndroMETa-PDAC-288
2025-522563-15-00Metastatic Pancreatic Ductal Adenocarcinoma; PDAC
DrugsTelisotuzumab Adizutecan·Calcium folinate·Fluorouracil·Irinotecan
AbbVie Deutschland GmbH & Co. KG
Neoplasms
Portugal, Spain, France, Italy, Germany, Austria
06/07/2026
Phase III
A Phase 2b/Phase 3, randomized, double-blind, placebo-controlled, multicenter study, to investigate the efficacy and safety of lunsekimig in adult participants with inadequately controlled chronic obstructive pulmonary disease (COPD) characterized by an eosinophilic phenotype
2024-518016-39-00Respiratory tract diseases
Sanofi-Aventis Recherche & Developpement
Respiratory Tract Diseases
Denmark, Sweden, Poland, Estonia, Portugal, Latvia, Spain, Hungary, Germany, Finland, Italy, Belgium, France
06/07/2026
Phase II
A multicenter open-label phase II study of Cemiplimab plus chemotherapy, selected on the basis of baseline cytidine deaminase activity, in advanced squamous non-small cell lung cancer - CECYDE trial - GOIRC-04-2024
2024-517799-40-00Advanced squamous non-small cell lung cancer
DrugCemiplimab
G.O.I.R.C. Gruppo Oncologico Italiano Di Ricerca Clinica
Neoplasms
Italy
03/07/2026
Phase III
AugmENtation witH cAnnabidiol iN first episode psyChosis: a doublE blind randomised controlled trial (STEP-ENHANCE Trial)
2025-521929-32-01First Episode Psychosis (FEP)
DrugCannabidiol
University Of Oxford
Mental Disorders
Netherlands, Greece, Germany, Italy, Austria, Spain
01/07/2026
Phase III
"A Phase 3 Randomized Study Comparing JNJ-79635322 versus Teclistamab in Participants with Relapsed or Refractory Multiple Myeloma after 1 to 3 Prior Lines of Therapy, Including an Anti-CD38 Antibody and Lenalidomide"
2025-523815-12-00Relapsed or Refractory Multiple Myeloma
Janssen Cilag International
Neoplasms
Poland, Spain, Czechia, France, Italy, Germany, Greece
01/07/2026
Phase I
A Study to Evaluate Targeted Therapies for Patients with Rheumatoid Arthritis
2025-523127-21-00Rheumatoid Arthritis
AbbVie Deutschland GmbH & Co. KG
Immune System Diseases
Belgium, Netherlands, Spain, Germany, Italy
01/07/2026
Phase III
A Randomized, Open-Label, Phase 3 Study of Rinatabart Sesutecan (Rina-S) Plus Standard of Care Versus Standard of Care as Maintenance Treatment After 2L PlatinumBased Doublet Chemotherapy in Participants With Recurrent Platinum-Sensitive Ovarian Cancer (PSOC)
2025-522167-15-00Ovarian Cancer Platinum-Sensitive Ovarian Cancer (PSOC)
Genmab A/S
Neoplasms
Finland, Belgium, Hungary, France, Denmark, Austria, Germany, Italy, Spain, Czechia, Norway, Poland
01/07/2026
Phase III
A Phase 3 Multicenter Double-blind Randomized Study of Taletrectinib Versus Placebo in Patients With ROS1-Fusion Positive Stage IB-IIIA Non-Small Cell Lung Cancer Who Have Undergone Complete Tumor Resection
2025-521971-29-00Non Small Cell Lung Cancer (NSCLC)
DrugTaletrectinib
Nuvation Bio Inc.
Respiratory Tract Diseases
Spain, Belgium, France, Italy, Germany
30/06/2026
Phase III
A Long-term Open-Label Extension Study of Treprostinil Palmitil Inhalation Powder for Treatment of Pulmonary Hypertension Associated with Interstitial Lung Disease
2025-521769-29-00Pulmonary Hypertension Associated with Interstitial Lung Di…
DrugTreprostinil Palmitil
Insmed Inc.
Respiratory Tract Diseases
Greece, France, Italy, Belgium, Denmark, Germany, Poland, Czechia, Portugal, Austria, Spain, Romania
30/06/2026
Phase III
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Parallel Study to Evaluate the Efficacy and Safety of Enpatoran in Participants with Active Cutaneous Manifestations of Lupus Erythematosus With or Without Systemic Disease Receiving Standard of Care
2025-524855-30-00Cutaneous Manifestations of Lupus Erythematosus With or Wit…
DrugEnpatoran
Merck Healthcare KGaA
Skin and Connective Tissue Diseases
Germany, Romania, France, Bulgaria, Belgium, Spain, Poland, Greece, Italy, Czechia
29/06/2026
Phase III
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Parallel Study to Evaluate the Efficacy and Safety of Enpatoran in Participants with Active Cutaneous Manifestations of Lupus Erythematosus With or Without Systemic Disease Receiving Standard of Care
2025-523871-44-00Cutaneous Manifestations of Lupus Erythematosus With or Wit…
DrugEnpatoran
Merck Healthcare KGaA
Immune System Diseases
Spain, Belgium, France, Germany, Slovakia, Romania, Bulgaria, Italy, Poland, Greece
29/06/2026
Phase II
C6461014 - A Phase 2 Interventional Study of PF-08634404 in Combination with Chemotherapy in Participants with Previously Untreated Transformed Small Cell Lung Cancer
2025-524686-24-00Small Cell Lung Cancer
DrugsPF-08634404·Etoposide·Carboplatin
Pfizer Inc.
Neoplasms
France, Italy, Spain
29/06/2026
Phase I/II
A Phase 1/2 Open-Label, Multicenter Study of RAS(ON) inhibitors in Combination with Ivonescimab with or without Other Anti-Cancer Agents in Patients with Solid Tumors
2025-524623-50-00Solid Tumors
DrugsElironrasib·RMC-9805·Erbitux·Ivonescimab
Revolution Medicines Inc.
Neoplasms
France, Poland, Ireland, Spain, Greece, Germany, Italy, Sweden, Belgium
29/06/2026
Phase II
A Phase 2 Randomized, Double-blind, Placebo-Controlled Study to Assess the Safety and Efficacy of MTX-474 in the Treatment of Participants with Diffuse Cutaneous Systemic Sclerosis (dcSSc)
2025-523288-39-00Diffuse Cutaneous Systemic Sclerosis (dcSSc)
Mediar Therapeutics Inc.
Immune System Diseases
Netherlands, Romania, Poland, France, Italy, Spain
29/06/2026
Phase III
A Randomized, Double-Blind, Phase 3 Study of Chemotherapy With or Without INCB161734 in Previously Untreated, KRAS G12D-Mutated Metastatic Pancreatic Ductal Adenocarcinoma (DAWN-303)
2025-525009-18-00Pancreatic Ductal Adenocarcinoma
DrugsINCB161734·Fluorouracil·Irinotecan·Oxaliplatin
Incyte Corp.
Neoplasms
Poland, Italy, Netherlands, Sweden, Denmark, Finland, Spain, France, Germany, Belgium, Norway, Austria
26/06/2026
Phase IV
Prospective, multicenter, randomized study on combined LT4 + LT3 therapy versus LT4 in the control of TSH in patients with advanced thyroid cancer treated with tyrosine kinase inhibitors.
2026-526113-28-00Advanced thyroid carcinoma. Post-thyroidectomy hypothyroidi…
Ceinge Biotecnologie Avanzate Franco Salvatore S.c.a.r.l.
Hormonal diseases
Italy
26/06/2026
Phase III
A PHASE III, OPEN-LABEL, SINGLE-ARM, MULTI-CENTER STUDY TO EVALUATE THE SAFETY AND USE OF AN ON-BODY DELIVERY SYSTEM FOR THE SUBCUTANEOUS HOME ADMINISTRATION OF OCRELIZUMAB IN PATIENTS WITH MULTIPLE SCLEROSIS
2025-523726-40-00Multiple Sclerosis
F. Hoffmann-La Roche AG
Immune System Diseases
Spain, France, Poland, Italy
24/06/2026
Phase III
SERENDIPITY: phase III multicentric randomized study assessing the reduction of chronic prostate inflammation with Permixon®
2025-525123-27-00Benign prostatic hypertrophy
Azienda Ospedaliero Universitaria Careggi, University Of Florence
Male Urogenital Diseases
Italy
23/06/2026
Phase III
A Phase 3 Extension Study of siRNA Targeting of Prekallikrein With ADX-324 in Participants With Hereditary Angioedema
2025-521353-16-00Hereditary Angioedema
DrugDopamine
Adarx Pharmaceuticals Inc.
Immune System Diseases
Poland, Italy, Hungary, France, Austria, Czechia, Belgium, Spain, Bulgaria, Germany, Croatia
22/06/2026
Phase III
A Phase 3, Randomized, Double-blind, Efficacy and Safety Study Comparing Orelabrutinib to Placebo in Patients With Non-Active Secondary Progressive Multiple Sclerosis
2025-524322-18-00Non-active Secondary Progressive Multiple Sclerosis (SPMS)
DrugOrelabrutinib
Zenas Biopharma (USA) LLC
Nervous System Diseases
Germany, Bulgaria, Netherlands, Sweden, Portugal, Croatia, Italy, Austria, Spain, Poland, France, Denmark, Hungary, Romania, Estonia, Slovakia, Belgium, Czechia, Norway, Lithuania, Greece, Slovenia
22/06/2026
Phase II
An Open-label, Single-Arm, Phase 2 Study to Evaluate Enfortumab Vedotin plus Pembrolizumab for Bladder Preservation in Participants with Muscle-invasive Bladder Cancer (EV-209).
2025-524488-18-00Muscle-invasive Bladder Cancer
Astellas Pharma Global Development Inc.
Neoplasms
Germany, France, Poland, Italy, Spain
22/06/2026
Phase II
A Phase 2a Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of MK-8690 in Adult Participants with Moderately to Severely Active Ulcerative Colitis
2025-523479-49-00Colitis ulcerative
Merck Sharp & Dohme LLC
Digestive System Diseases
Italy, Greece, Netherlands, Poland, Germany, France
22/06/2026
Phase IV
Sample Collection Study to Monitor the Risk of Malignancy Due to Insertional Oncogenesis in Early Onset Patients with Metachromatic Leukodystrophy Treated with OTL-200 in the Clinical Development Program
2025-522275-28-00Metachromatic leukodystrophy
Orchard Therapeutics (Europe) Limited
Musculoskeletal Diseases
Netherlands, Germany, Italy, Sweden, France
22/06/2026
Phase II
A Randomized, Double-blind, Placebo-controlled Trial to Evaluate the Safety, Tolerability, and Efficacy of TAK-360 for the Treatment of Narcolepsy with Cataplexy (Narcolepsy Type 1)
2025-522587-33-00Narcolepsy with Cataplexy (NT1)
Takeda Development Center Americas Inc.
Nervous System Diseases
Spain, Italy, France
22/06/2026
Phase III
Effects of bempedoic acid/ezetimibe/high-intensity statin on plaque regression and stabilisation of coronary atherosclerosis among patients without cardiovascular events
2025-524625-41-00Coronary atherosclerosis
DrugsRosuvastatin·Atorvastatin
Daiichi Sankyo Europe GmbH
Cardiovascular Diseases
Italy, Spain, Germany
22/06/2026
Phase III
A Phase 3, Randomized, Open-label, Multicenter Study to Compare the Efficacy and Safety of BMS-986353, CD19-targeted NEX-T CAR T Cells, Versus Standard of Care in Participants with Active Systemic Sclerosis (Breakfree-SSc)
2025-524337-11-00Systemic Sclerosis
DrugsNintedanib·Tocilizumab·Fludarabine·Rituximab
Celgene Corp.
Immune System Diseases
Spain, Germany, France, Italy, Belgium
19/06/2026
Phase III
Paclitaxel plus ramucirumab and tislelizumab as switch maintenance versus continuation of chemotherapy and tislelizumab in patients with advanced HER2-negative and PD-L1 positive gastroesophageal adenocarcinoma: the ARMANI-2/ENGIC08 trial by GONO
2025-524048-36-00Advanced HER2-negative and PD-L1 positive gastroesophageal …
DrugsCalcium folinate·Ramucirumab·Fluorouracil·Tislelizumab
Fondazione GONO G.I.
Neoplasms
Spain, Germany, Italy
18/06/2026
Phase II
A randomized, double-blind, placebo-controlled, 104-week proof-of-concept study to evaluate the efficacy of intravenous prasinezumab in participants with Parkinson's disease carrying a severe mutation in the GBA gene (prevent cognitive decline in GBA-associated PD)
2024-513496-40-00PARKINSON’S DISEASE
DrugPrasinezumab
Universitaetsklinikum Tuebingen AöR
Nervous System Diseases
Spain, Germany, Italy, Sweden, France, Luxembourg
18/06/2026
Phase III
IM0271016: An Open-label, Multi-center, Long-term Extension Study to Evaluate the Long-term Safety and Tolerability of Admilparant in Participants with Pulmonary Fibrosis
2025-522373-10-00Progressive pulmonary fibrosis and Idiopathic pulmonary fib…
DrugAdmilparant
Bristol-Myers Squibb Services Unlimited Company
Respiratory Tract Diseases
Finland, Portugal, Hungary, Ireland, Poland, Greece, France, Belgium, Denmark, Italy, Spain, Netherlands, Austria, Germany
17/06/2026
Phase II
A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Study of Nemolizumab in Adult Patients with Systemic Sclerosis, including a 52-Week Main Treatment Period and a 156-Week Extension Treatment Period
2025-522294-11-00Systemic sclerosis
Galderma S.A.
Skin and Connective Tissue Diseases
Poland, Italy, Bulgaria, France, Greece, Spain, Croatia
17/06/2026
Phase I
Open-label study of BBO-11818 in adult subjects with KRAS mutant cancer
2025-524690-16-00Solid Tumors
Theras Inc.
Neoplasms
Spain, Italy, France
16/06/2026
Phase II
A Phase 2, Open-Label Long-Term Extension Study in Participants With Duchenne Muscular Dystrophy Amenable to Exon Skipping to Assess the Long-Term Safety, Tolerability, Pharmacokinetics, and Efficacy of Endosomal Escape Vehicle Phosphorodiamidate Morpholino Oligomer Platform Products (ELEVATE-LTE)
2025-525124-10-00Duchenne Muscular Dystrophy
DrugsENTR-601-44·ENTR-601-45
Entrada Therapeutics Inc.
Musculoskeletal Diseases
Belgium, Italy, Netherlands, Spain
16/06/2026
Phase I
A Phase 1, Open-Label, Multicenter Study of INCA036873 in Participants With Advanced Solid Tumors and Hematological Malignancies
2025-523130-11-00Advanced solid tumors, Hematological malignancies
Incyte Corp.
Neoplasms
Italy, Belgium, Denmark
16/06/2026
Phase III
A Phase III, Multicentre, Randomised Controlled Study of Sonesitatug vedotin in Combination with Capecitabine with or without Rilvegostomig in First-line Claudin18.2-positive, HER2-negative, Advanced/Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma (CLARITY-Gastric 02)
2024-519787-40-00Gastric Cancer, Gastroesophageal Junction Adenocarcinoma, E…
AstraZeneca AB
Neoplasms
France, Italy, Spain, Hungary, Poland, Belgium, Germany, Netherlands
16/06/2026
Phase I/II
A Phase I/II Open-label, Dose Escalation and Dose Expansion Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of AZD6621, a T Cell-engaging Antibody That Targets STEAP2, CD3, and CD8 in Adult Participants With Metastatic Prostate Cancer (ACTIVATED-4-PC)
2025-520626-37-00Metastatic Prostate Cancer
AstraZeneca AB
Neoplasms
Belgium, Spain, Poland, Italy, Netherlands
16/06/2026
Phase III
A Phase 3, Randomized, Placebo-Controlled Study of Adjuvant Intismeran Autogene Plus Subcutaneous Pembrolizumab and Berahyaluronidase Alfa (MK-3475A) or Intismeran Autogene Monotherapy Versus Placebo in Participants With Completely Resected High-Risk Stage I Non-Small Cell Lung Cancer (INTerpath-014)
2025-522643-18-00Stage I NSCLC
DrugsPembrolizumab Formulated with Berahyaluronidase Alfa·Intismeran autogene
Merck Sharp & Dohme LLC
Neoplasms
Greece, Poland, Italy, Hungary, Germany, Netherlands, France, Spain
16/06/2026
Phase II
A Study to Evaluate the Long-term Safety and Efficacy of Long-acting Antibodies as Single Agents and in Combinations in Participants with Inflammatory Bowel Disease
2025-524640-35-00Ulcerative colitis (Inflammatory Bowel Disease)
DrugsSPYPBO-101·SPY001·SPY002·SPY003
Spyre Therapeutics Inc.
Digestive System Diseases
Croatia, Poland, Austria, Czechia, Italy, Slovakia, Bulgaria, Greece, Belgium, Spain, Hungary, Germany, Lithuania, France, Romania
16/06/2026
Phase III
An Open-Label Extension Study to Evaluate the Long-Term Safety and Efficacy of BBP-418 (Ribitol) in Participants with Limb-Girdle Muscular Dystrophy 2I/R9 (LGMD2I/R9)
2025-524371-23-00Limb Girdle Muscular Dystrophy (LGMD) Type 2I
DrugRibitol
ML Bio Solutions Inc.
Musculoskeletal Diseases
Germany, Denmark, Netherlands, Italy, Norway
15/06/2026
Phase IV
Real-World Effectiveness and Safety of Pegcetacoplan in Patients with C3 Glomerulopathy (C3G) or Primary Immune Complex Membranoproliferative Glomerulonephritis (IC-MPGN): A Multi-Country Study (PRISMC3)
2025-524487-37-00C3 Glomerulopathy (C3G), Primary Immune Complex Membranopro…
DrugPegcetacoplan
Swedish Orphan Biovitrum AB (publ)
Immune System Diseases
France, Italy, Spain, Germany, Austria, Belgium, Czechia
15/06/2026
Phase III
A Phase 3, Randomized, Double-blind, Placebo- and Active-Comparator-Controlled Study of MK-1084 Plus Durvalumab Versus Placebo Plus Durvalumab in Participants With Locally Advanced, Unresected KRAS G12C-Mutant Non-Small Cell Lung Cancer Without Disease Progression Following Definitive Platinum-Based Chemoradiotherapy (KANDLELIT-015)
2025-522038-29-00Locally advanced, unresected (unresectable or medically ino…
DrugsCalderasib·Durvalumab
Merck Sharp & Dohme LLC
Neoplasms
Italy, Netherlands, France, Germany, Spain, Poland, Greece
12/06/2026
Phase III
A Phase 2/3, Randomized, Open-Label, Comparison Study of MK-1045 Versus Blinatumomab in Participants With Relapsed or Refractory CD19+ B-Cell Acute Lymphoblastic Leukemia (B-ALL)
2025-522267-15-00​Relapsed/refractory B-cell Acute Lymphoblastic Leukemia​
DrugsMK-1045·Blinatumomab·Tocilizumab
Merck Sharp & Dohme LLC
Neoplasms
Greece, Netherlands, Sweden, France, Italy, Spain, Denmark
12/06/2026
Phase III
A Phase 3, Randomized, Double-Blind, Placebo-Controlled, 3-Arm Study to Investigate the Safety and Tolerability of Efimosfermin Alfa in Participants With Known or Suspected F2- or F3-Stage Metabolic Dysfunction-Associated Steatohepatitis (MASH) (ZENITH-2)
2025-523674-16-00Metabolic Dysfunction-Associated Steatohepatitis (MASH)
Glaxosmithkline Research & Development Limited
Nutritional and Metabolic Diseases
Greece, Germany, Belgium, Netherlands, Poland, Italy, France, Spain, Bulgaria, Austria
12/06/2026
Phase II
A PHASE 2 STUDY OF STRIDE (durvalumab + tremelimumab) With Lenvatinib Versus STRIDE Alone in Patients With Unresectable Hepatocellular Carcinoma (SLIDE-HCC) - HE.2
2025-521608-23-00patients with unrestectable hepatocellular carcinoma (SLIDE…
DrugsTremelimumab·Lenvatinib·Durvalumab
IRCCS Istituto Nazionale Tumori Fondazione Pascale
Neoplasms
Italy
12/06/2026
Phase II
J6Z-MC-IIBD - A Master Protocol for Phase 2, Randomized, Controlled Studies of Multiple Interventions for the Treatment of Adults With Moderately to Severely Active Ulcerative Colitis or Crohn’s Disease J6Z-MC-CD01 - A Phase 2, Multicenter, Randomized, Open-Label, Active-Controlled Study to Investigate LY4395089/Mirikizumab Co-administration Compared with Mirikizumab in Adults with Moderately to Severely Active Crohn’s Disease
2025-524112-11-00J6Z-MC-IIBD - Colitis, Ulcerative Crohn Disease J6Z-MC-CD…
DrugMirikizumab
Eli Lilly & Co.
Digestive System Diseases
Italy, Germany, Hungary, Poland, Belgium
11/06/2026
Phase II
J6E-MC-KWAM: A Randomized, Multicenter, Double-Blind, Placebo-Controlled Development Program to Evaluate the Efficacy and Safety of LY4268989 (MORF-057) for the Treatment of Adults with Moderately to Severely Active Ulcerative Colitis (EMERALD-3)
2025-524404-29-00Ulcerative Colitis, Active Severe, Ulcerative Colitis (UC),…
Eli Lilly & Co.
Digestive System Diseases
Latvia, Portugal, Greece, France, Czechia, Italy, Poland, Slovakia, Hungary, Croatia, Lithuania
10/06/2026
Phase III
A Phase 2/3 randomized, open-label study of MK-1045 in combination with rituximab in patients with 1L follicular lymphoma.
2025-522777-10-00Follicular Lymphoma
Merck Sharp & Dohme LLC
Neoplasms
France, Spain, Germany, Greece, Italy, Poland
09/06/2026
Phase I/II
A Phase 1/2, Open-label Study of VS-7375, a KRAS G12D (ON/OFF) Inhibitor, as Monotherapy and in Combination, in Patients with Advanced KRAS G12D-Mutant Solid Tumors
2025-523432-39-01Advanced KRAS G12D-Mutant Solid Tumors
Verastem Inc.
Neoplasms
Italy, France, Germany, Belgium, Spain, Netherlands
09/06/2026
Phase I/II
A Phase 1b/2 Open-label Study Evaluating different MK-6070 and Ifinatamab Deruxtecan (MK-2400)-based regimens in First-line Extensive Stage Small Cell Lung Cancer
2025-521032-11-00Small cell lung cancer extensive stage
Merck Sharp & Dohme LLC
Neoplasms
Germany, Poland, Greece, Italy, France, Spain
08/06/2026
Phase II
A multicenter, randomized, double-blind, placebo-controlled, dose-ranging Phase IIb study to assess the efficacy and safety of GIA632 in adult participants with non-segmental vitiligo followed by an extension period
2025-522301-37-00Nonsegmental vitiligo
Novartis Pharma AG
Skin and Connective Tissue Diseases
Germany, Spain, Netherlands, France, Italy
08/06/2026
Phase II
A Phase 2, Open Label, Multicenter, Randomized Study, to Evaluate the Efficacy and Safety of Denikitug Monotherapy and Denikitug-based Combinations in Participants With Advanced Microsatellite Stable (MSS) Colorectal Cancer (CRC).
2025-523984-39-00Advanced Microsatellite Stable (MSS) Colorectal Cancer (CRC)
DrugsDenikitug·Lonsurf·Nivolumab·Bevacizumab
Gilead Sciences Inc.
Neoplasms
Spain, Italy, France
08/06/2026
Phase III
A Randomized, Open-Label, Phase 3 Study of ZL-1310, a DLL3 Antibody Drug Conjugate (ADC), Compared to Investigator’s Choice Therapy in Participants with Relapsed Small Cell Lung Cancer
2025-522818-23-00Small Cell Lung Cancer (SCLC)
DrugsZL-1310·Topotecan
Zai Lab (US) LLC
Neoplasms
Belgium, Czechia, Germany, Denmark, Greece, Netherlands, Poland, Spain, Austria, Italy, France
08/06/2026
Phase II
Radium223 dichloride (223RaCl) in the treatment of symptomatic bone metastases from breast cancer.
2025-524208-31-00Symptomatic bone metastases from breast cancer
DrugsExemestane·Anastrozole·Letrozole
Azienda Ospedaliera Universitaria Policlinico Paolo Giaccone
Neoplasms
Italy
08/06/2026
Phase II
C4531031 - AN INTERVENTIONAL PHASE 2/3, RANDOMIZED, DOUBLE-BLIND, THIRD PARTY-UNBLINDED, PLACEBO-CONTROLLED, PARALLEL-GROUP STUDY TO INVESTIGATE EFFICACY AND SAFETY OF PF-07275315 IN ADULT PARTICIPANTS WITH MODERATE-TO-SEVERE CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD)
2024-518587-12-00MODERATE-TO-SEVERE CHRONIC OBSTRUCTIVE PULMONARY DISEASE (C…
DrugTilrekimig
Pfizer Inc.
Respiratory Tract Diseases
Spain, Germany, Poland, Czechia, Greece, Italy, Bulgaria, France, Hungary
08/06/2026
Phase IV
OCTAGON:A Phase 4, Single Arm Study to Investigate Oral Corticosteroid Tapering in Adult Patients with Generalized Myasthenia Gravis Treated with Ravulizumab
2025-522555-26-00Generalized Myasthenia Gravis
DrugsRavulizumab·Prednisolone·Prednisone
Alexion Pharmaceuticals Inc.
Nervous System Diseases
Italy, Germany
08/06/2026
Phase I
A study to learn more about how safe BAY 3771249 is and how well it works in people with advanced or metastatic colorectal cancer that has a KRAS G12D mutation
2025-523648-11-00adenocarcinoma of the colon or rectum
Bayer Consumer Care AG
Neoplasms
Finland, Spain, Sweden, Italy, Denmark, Netherlands, Belgium
08/06/2026
Phase I/II
KontRASt-R: An open-label, multi-center, rollover study for participants who have been previously enrolled into a Novartis-sponsored opnurasib (JDQ443) study and are continuing to benefit from opnurasib as a single agent or in combination with other study treatments
2025-523537-26-00Locally advanced or metastatic KRAS G12C-mutated non-small …
Novartis Pharma AG
Neoplasms
Spain, Italy, France, Denmark, Belgium
08/06/2026
Phase III
A Phase 3, Randomized, Double-Blind, Placebo-Controlled, 3-Arm Study to Investigate the Safety and Efficacy of Efimosfermin Alfa in Participants With Biopsy-Confirmed F2- or F3-Stage Metabolic Dysfunction-Associated Steatohepatitis (MASH) (ZENITH-1)
2025-523675-39-00Metabolic Dysfunction-Associated Steatohepatitis (MASH)
Glaxosmithkline Research & Development Limited
Nutritional and Metabolic Diseases
Belgium, Greece, Poland, France, Spain, Bulgaria, Italy, Germany, Austria, Netherlands
08/06/2026
Phase III
A randomized double-masked, multicenter, 3-arm, pivotal Phase 2/3 study to evaluate the efficacy and safety of intravitreal (IVT) EYE201/MK-8748 compared to aflibercept (2 mg) in participants with neovascular age-related macular degeneration (NVAMD)
2025-524894-17-00Neovascular age-related macular degeneration (NVAMD)
Eyebiotech Limited
Eye Diseases
Austria, Slovakia, Portugal, Czechia, Hungary, Spain, France, Denmark, Italy, Croatia
05/06/2026
Phase III
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of ALKS 2680 in Adults With Narcolepsy Type 2
2025-523912-35-00Narcolepsy Type 2
Alkermes Inc.
Nervous System Diseases
Spain, Netherlands, Belgium, Italy, France, Austria, Czechia, Germany, Sweden, Poland
04/06/2026
Phase I/II
A Phase 1b/2 Study to Evaluate NB-4746 in Participants with Amyotrophic Lateral Sclerosis.
2025-523939-18-00Amyotrofic Lateral Sclerosis (ALS)
DrugRiluzole
Nura Bio Inc.
Nervous System Diseases
Poland, Netherlands, Italy, Spain
03/06/2026
Phase I/II
A Phase 1/2, Multicenter, Open-label, Dose-escalation, and Dose-expansion Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamic, and Antitumor Activity of CR-001 in Adult Participants with Locally Advanced or Metastatic Solid Tumors.
2025-523590-42-00Locally Advanced or Metastatic Solid Tumors
Crescent Biopharma Inc.
Neoplasms
Spain, Ireland, Italy, France, Romania
02/06/2026
Phase III
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of ALKS 2680 in Adults With Narcolepsy Type 1
2025-523911-13-00Narcolepsy Type 1
Alkermes Inc.
Nervous System Diseases
Italy, France, Netherlands, Spain, Belgium, Austria, Czechia, Finland, Germany, Sweden, Norway, Poland
02/06/2026
Phase III
Multinational, Interventional, 52-week, Open-label, Single-arm Study to Evaluate the Treatment Outcomes of Anifrolumab 120 mg Subcutaneous Once Weekly in Immunosuppressant-naïve and Biologic-naïve Systemic Lupus Erythematosus (SUNFLOWER)
2025-523670-17-00Systemic lupus erythematosus
DrugAnifrolumab
AstraZeneca AB
Immune System Diseases
Poland, Germany, Italy, France, Spain
02/06/2026
Phase III
A MULTICENTER, RANDOMIZED, OPEN-LABEL, PHASE III CLINICAL TRIAL TO EVALUATE THE EFFICACY, SAFETY, PHARMACOKINETICS AND PHARMACODYNAMICS OF NXT007 PROPHYLAXIS VERSUS FACTOR VIII PROPHYLAXIS IN PEOPLE WITH HEMOPHILIA A WITHOUT INHIBITORS
2025-522434-32-00Hemophilia A Without Inhibitors
F. Hoffmann-La Roche AG
Congenital, Hereditary, and Neonatal Diseases and Abnormalities
France, Austria, Poland, Netherlands, Spain, Denmark, Italy, Germany, Hungary
01/06/2026
Phase III
A MULTICENTER, RANDOMIZED, OPEN-LABEL, PHASE III CLINICAL TRIAL TO EVALUATE THE EFFICACY, SAFETY, PHARMACOKINETICS AND PHARMACODYNAMICS OF NXT007 PROPHYLAXIS VERSUS EMICIZUMAB PROPHYLAXIS IN PEOPLE WITH HEMOPHILIA A
2025-522435-33-00Hemophilia A
F. Hoffmann-La Roche AG
Hemic and Lymphatic Diseases
Hungary, Spain, Ireland, Poland, Austria, Germany, Denmark, Belgium, Netherlands, Italy, France
01/06/2026
Phase II
Leveraging the neural mechanisms of social reward for drug relapse prevention
2023-504518-31-01substance use disorder
DrugOxytocin
Fondazione Santa Lucia IRCCS
Mental Disorders
Italy
29/05/2026
Phase III
A Phase 3, Randomized, Double-Blind, Active-Control Study of Pelabresib (DAK539) and Ruxolitinib vs. Placebo and Ruxolitinib in Adult Patients with Myelofibrosis who are JAK inhibitor naive
2025-523555-66-00Myelofibrosis
DrugsPelabresib·Ruxolitinib
Novartis Pharma AG
Neoplasms
Belgium, Germany, Austria, Poland, Spain, Italy, Netherlands, Czechia, France
29/05/2026
Phase II
A Phase 2, Randomized, Double-blind, Controlled Study to Evaluate the Safety and Efficacy of VX‑828/Deutivacaftor With and Without Tezacaftor in Subjects Aged 18 Years and Older With Cystic Fibrosis
2025-523400-72-00Cystic fibrosis
Vertex Pharmaceuticals Inc.
Congenital, Hereditary, and Neonatal Diseases and Abnormalities
Spain, Sweden, Germany, Italy, Belgium, Czechia, Ireland, Portugal, Netherlands, France, Denmark
29/05/2026
Phase I/II
A Phase 1b/2 Study to Evaluate the Safety and Efficacy of MK‑1045 Monotherapy or in Combination with Other Anticancer Agents in Participants with Non-Hodgkin Lymphoma
2025-523005-15-00Non-Hodgkin Lymphoma
Merck Sharp & Dohme LLC
Neoplasms
Poland, Italy, France, Germany, Spain
28/05/2026
Phase II
An Extension Study to Evaluate the Long-Term Safety and Efficacy of Afimkibart (RO7790121) in Patients with Rheumatoid Arthritis who Participated in Previous Afimkibart Clinical Trials
2025-523579-47-00moderate to severe rheumatoid arthritis (RA)
DrugAfimkibart
F. Hoffmann-La Roche AG
Immune System Phenomena
Italy, Spain, Germany, France, Denmark, Poland, Belgium
27/05/2026
Phase III
A Phase 3b, Multicenter, Randomized, Open-Label, Active-Controlled Study to Compare the Efficacy and Safety of Guselkumab versus Risankizumab in the Treatment of Participants with Moderately to Severely Active Crohn’s Disease
2025-521590-13-00Moderately to Severely Active Crohn’s Disease
Janssen Cilag International
Immune System Diseases
Slovakia, Germany, Denmark, France, Spain, Italy, Netherlands, Belgium, Poland, Sweden, Austria, Czechia, Hungary
27/05/2026
Phase II
An Open-Label Study to Assess the Long-Term Safety and Tolerability of ML-007C-MA in Adult Participants with Hallucinations and Delusions Associated with Alzheimer’s Disease Psychosis
2025-521757-16-00Hallucinations and Delusions Associated with Alzheimer’s Di…
Maplight Therapeutics Inc.
Mental Disorders
Italy, Poland, Czechia, Portugal, Bulgaria, France, Slovakia, Romania, Hungary
27/05/2026
Phase III
A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Efficacy of a Single Intravenous Dose of SGT-003 in Ambulant Males With Duchenne Muscular Dystrophy
2025-522949-22-00Duchenne muscular dystrophy
Solid Biosciences Inc.
Musculoskeletal Diseases
Spain, Netherlands, France, Italy, Belgium, Germany
26/05/2026
Phase I/II
LIGHTBEAM-U01 Substudy 01D: A Phase 1b/2 Substudy to Evaluate the Safety and Efficacy of Ifinatamab Deruxtecan in Pediatric Participants With Relapsed or Refractory Solid Tumors
2025-522339-32-00Neoplasm malignant
DrugIfinatamab Deruxtecan
Merck Sharp & Dohme LLC
Neoplasms
France, Spain, Sweden, Germany, Italy, Belgium, Denmark, Czechia, Hungary, Netherlands, Slovakia
26/05/2026
Phase III
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of GB-0895 Adjunctive Therapy in Adults and Adolescents with Severe Uncontrolled Asthma
2025-524040-35-00Severe uncontrolled asthma
Generate Biomedicines Inc.
Respiratory Tract Diseases
Italy, Slovakia, Spain, Ireland, Belgium, France, Estonia
26/05/2026
Phase II
A Phase 2, Open-Label, Single-Arm, Multicenter Study to Evaluate the Efficacy of Cemsidomide + Dexamethasone in Subjects With Relapsed/Refractory Multiple Myeloma (r/r MM)
2025-524181-26-00relapsed/refractory multiple myeloma
DrugCemsidomide
C4 Therapeutics Inc.
Hemic and Lymphatic Diseases
Italy, France, Spain, Poland
25/05/2026
Phase III
ROSETTA Lung-201: A Randomized, Multicenter, Open-label Phase 3 study of Pumitamig Monotherapy Compared to Durvalumab in Participants with Unresectable Stage III NSCLC Without Progression After Platinum-based Concurrent Chemoradiation Therapy
2025-523576-23-00Unresectable Stage III non-small cell lung cancer without p…
Bristol-Myers Squibb Services Unlimited Company
Neoplasms
France, Ireland, Germany, Greece, Bulgaria, Spain, Netherlands, Italy, Sweden, Romania, Hungary, Belgium, Austria, Poland
22/05/2026
Phase II
A Global, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase 2/3 Study of EIK1001 in Combination with Pembrolizumab and Chemotherapy in Participants with Stage 4 Non-Small Cell Lung Cancer (TeLuRide-008).
2025-525013-23-00Stage 4 (IV) Non-Small Cell Lung Cancer (NSCLC)
DrugPembrolizumab
Eikon Therapeutics Inc.
Neoplasms
Germany, Spain, Netherlands, Romania, Greece, Italy, Austria, Belgium, Bulgaria, France, Hungary, Poland
21/05/2026
Phase II
An open-label, single-arm extension study to evaluate the long-term safety, tolerability, and efficacy of KL1333 (napazimone) in patients with primary mitochondrial disease
2025-524367-20-00Adult patients with primary mitochondrial disease
Pharming Technologies B.V.
Metabolism
Belgium, Germany, Czechia, Spain, Denmark, Italy, France
21/05/2026
Phase IV
Intensified Monitoring of PhArmacology of Cabozantinib as a tool for Toxicity management in patients with renal cell carcinoma
2026-525267-40-00Renal cell carcinoma
Centro Di Riferimento Oncologico Di Aviano
Neoplasms
Italy
21/05/2026
Phase II
An Open-Label, Rollover Study for Participants With Thyroid Eye Disease Previously Enrolled in Amgen-Sponsored AMG 732 Studies and are Primary Proptosis Non-responders or who Relapsed During the Safety Follow-up
2025-523280-38-00Thyroid Eye Disease
Amgen Inc.
Eye Diseases
Spain, Poland, France, Italy, Greece
20/05/2026
Phase I/II
An Open Label, Single Arm, Phase I/II Clinical Study of Autologous CD4+ T-Cells Edited Ex-Vivo at the CD40LG Locus by CRISPR/Cas9 and IDLV-based vector in Patients with X-linked Hyper IgM Syndrome Type 1 (HIGM1)
2025-524635-39-00X-linked immunodeficiency with hyper-IgM type 1 (HIGM1)
Fondazione Telethon Ets, San Raffaele Hospital
Immune System Diseases
Italy
20/05/2026
Phase III
A double-blind, double-dummy, parallel group, multicenter Phase 3 extension study evaluating the long-term safety and efficacy of 2 doses of remibrutinib in adult participants with moderate to severe hidradenitis suppurativa
2025-523259-72-00Hidradenitis Suppurativa (HS)
DrugRemibrutinib
Novartis Pharma AG
Immune System Diseases
Portugal, Greece, Germany, Hungary, France, Spain, Bulgaria, Slovakia, Poland, Czechia, Belgium, Italy
20/05/2026
Phase III
A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Global Study with an Open-Label Extension to Evaluate the Efficacy and Safety of Intravenous AOC 1044 (delpacibart zotadirsen) for the Treatment of DMD with Gene Mutations Amenable to Exon 44 Skipping
2025-523087-20-00Duchenne muscular dystrophy
DrugAOC 1044
Avidity Biosciences Inc.
Musculoskeletal Diseases
Italy, Germany, France, Spain, Belgium, Poland, Netherlands
20/05/2026
Phase IV
Erdosteine effect on oxidative stress, inflammatory response and immune modulation in patients with COPD. A single center, open label, double arm, controlled, 4-week, explorative, ex vivo study.
2025-524821-42-00COPD
ASST Fatebenefratelli Sacco
Respiratory Tract Diseases
Italy
20/05/2026
Phase III
Phase III Randomized, International, Open-Label Clinical Trial of Treatment Intensification with Docetaxel plus Apalutamide in Patients with Metastatic Hormone-Sensitive Prostate Cancer Who Did Not Achieve a Deep PSA Response After Initial Treatment with Apalutamide: REINFORCE Trial
2025-524408-30-01Metastatic hormone-sensitive prostate cancer
DrugApalutamide
Alianza Multidisciplinar Para La Investigacion De Los Tumores Genitourinarios Guard
Neoplasms
Spain, Germany, France, Portugal, Italy
19/05/2026
Phase III
A Phase 3 prospective randomised clinical trial of VMX-C001 vs usual pharmacological care in patients receiving a FXa direct oral anticoagulant (FXa DOAC) who require urgent surgery or other invasive procedure that is associated with a high risk of bleeding, with or without planned administration of heparin (EQUILIBRIX-S)
2025-521632-12-00Patients on Factor Xa inhibitor treatment needing an urgent…
VarmX B.V.
Hemic and Lymphatic Diseases
Belgium, Germany, Italy, France, Czechia, Bulgaria, Hungary, Spain, Netherlands, Poland, Austria, Estonia, Romania, Portugal, Lithuania
19/05/2026
Phase II
PODOMOUNT-Basket, a Phase II, multicentre, randomised, 2-arm parallel-group, double-blind, placebo-controlled basket trial to assess safety, tolerability, PK, and efficacy of BI 764198 in four proteinuric kidney diseases
2025-523425-17-00Proteinuric kidney diseases
Boehringer Ingelheim International GmbH, Boehringer Ingelheim Espana S.A.
Nutritional and Metabolic Diseases
Portugal, Greece, Italy, Poland, Estonia, Slovakia, Sweden, Denmark, Belgium, Norway, Romania, France, Spain, Germany, Netherlands, Croatia
19/05/2026
Phase II
An Open-label, Single-arm, Global Study of Perioperative Durvalumab With Cisplatin-based Neoadjuvant Chemotherapy in Patients With Muscle-Invasive Bladder Cancer (NIAGARA-2)
2024-519246-75-01Patients With Muscle-Invasive Bladder Cancer
AstraZeneca AB
Neoplasms
Italy, Spain, France, Netherlands
19/05/2026
Phase II
A Phase II, Open-Label Randomized Study of Intravenous Tambiciclib in Combination with the Standard of care Venetoclax and Azacitidine in Patients with Newly Diagnosed AML Who Failed to Achieve at Least MLFS After the First Two Cycles of Treatment with Venetoclax and Azacitidine Alone
2025-524308-31-00Acute myeloid leukemia
DrugsAzacitidine·Venetoclax
Istituto Romagnolo Per Lo Studio Dei Tumori Dino Amadori IRST S.r.l., IIS La Fe
Neoplasms
Italy, Spain
19/05/2026
Phase III
A Randomized, Double-Blind, Phase 3 Study of Standard-of-Care Chemotherapy and Bevacizumab With or Without INCA33890 in the First-Line Treatment of Metastatic Microsatellite Stable Colorectal Cancer
2025-523735-19-00Metastatic Microsatellite Stable Colorectal Cancer
DrugsINCA33890·Calcium folinate·Fluorouracil·Oxaliplatin
Incyte Corp.
Neoplasms
Poland, France, Denmark, Norway, Spain, Germany, Belgium, Netherlands, Austria, Italy
19/05/2026
Phase IV
A Multicenter Randomized Controlled Trial Assessing the Efficacy and Safety of Recombinant Human Follicle Stimulating Hormone (r-hFSH-alfa originator) and Human Chorionic Gonadotropin (hCG) in Enhancing Sperm Concentration in Men with Oligozoospermia, Low Testosterone, and Normal FSH Serum Levels (APHRODITE Group 3): A Collaborative Research Initiative
2025-525005-20-00Male Infertility
DrugGonal-F
Martin-Luther-Universitaet Halle-Wittenberg
Reproductive and Urinary Physiological Phenomena
Italy, Spain, Germany
18/05/2026
Phase II
A Phase 2a, Randomized, Open-Label, Active-Controlled, Crossover Study to Evaluate Safety and Explore Efficacy of Different Doses of New Lipase NHS7108 Administered Orally in Participants with Exocrine Pancreatic Insufficiency.
2025-521816-20-00​​Exocrine Pancreatic Insufficiency​
DrugZenpep
Aimmune Nestle Health Science US R&D LLC
Nutritional and Metabolic Diseases
Poland, Hungary, Spain, Bulgaria, Italy
18/05/2026
Phase I/II
A Phase 1/2 Study of BMS-986525 as Monotherapy and in Combination with Nivolumab in Participants with Relapsed/Refractory Small Cell Lung Cancer
2025-524090-16-00Relapsed/Refractory Small Cell Lung Cancer
Bristol-Myers Squibb Services Unlimited Company
Neoplasms
Italy, Spain, Romania
18/05/2026
Phase III
A Phase 3, Randomized, Double-blind, Efficacy and Safety Study Comparing Orelabrutinib to Placebo in Patients With Primary Progressive Multiple Sclerosis
2025-524316-11-00Primary Progressive Multiple Sclerosis (PPMS)
DrugOrelabrutinib
Zenas Biopharma (USA) LLC
Nervous System Diseases
Italy, Finland, Bulgaria, Greece, Belgium, Estonia, Portugal, Spain, Germany, France, Czechia, Slovakia, Romania, Croatia, Poland, Austria, Netherlands, Denmark, Sweden, Hungary
18/05/2026
Phase II
A phase II, multicenter, open-label, single arm study to evaluate the safety and efficacy of asciminib in pediatric participants newly diagnosed or previously treated with Philadelphia positive Chronic Myelogenous Leukemia in Chronic Phase (Ph+ CML-CP) with or without known T315I mutation
2025-522138-29-00Philadelphia positive Chronic Myeloid leukemia in Chronic P…
Novartis Pharma AG
Neoplasms
Spain, France, Germany, Poland, Italy, Netherlands, Greece, Hungary
18/05/2026
Phase IV
A pragmatic, phase IV, randomized, open-label, multinational, multicentre, 2-arm parallel group, prospective study comparing efficacy and safety of Single Inhaler ICS/LABA/LAMA (beclometasone/formoterol fumarate/glycopyrronium bromide [87/5/9 pMDI {BD/FF/GB - 100/6/12.5 µg}]) vs Single Inhaler ICS/LABA (beclometasone dipropionate plus formoterol fumarate [200/6 pMDI {BD/FF - 200/6 µg}]) in asthma subjects.
2025-524289-56-00Asthma
Chiesi Farmaceutici S.p.A.
Respiratory Tract Diseases
Germany, Romania, Italy, Bulgaria, Poland, Slovakia, Spain, France
18/05/2026
Phase III
A Phase 3 Randomized Study Comparing JNJ-79635322 and an Anti-BCMAxCD3 Bispecific Antibody in Participants With Relapsed or Refractory Multiple Myeloma who Have Received at Least 3 Prior Lines of Therapy Including a PI, an IMiD, and an Anti-CD38 Antibody
2025-522007-18-00Relapsed or Refractory Multiple Myeloma
Janssen Cilag International
Neoplasms
Spain, Norway, Germany, Greece, France, Italy, Netherlands
18/05/2026
Phase III
ROSETTA Lung-202: A Randomized, Double-Blind, Phase 3 Study of Pumitamig Monotherapy Compared to Pembrolizumab as First-line Treatment in Participants with Locally Advanced or Metastatic Non-Small Cell Lung Cancer with PD-L1 ≥ 50%
2025-523586-18-00Non-Small Cell Lung Cancer
DrugPembrolizumab
Bristol-Myers Squibb Services Unlimited Company
Neoplasms
Portugal, Norway, Sweden, Bulgaria, France, Belgium, Austria, Germany, Finland, Poland, Romania, Netherlands, Spain, Italy, Hungary, Czechia
15/05/2026
Phase I/II
A Multicenter, Multi-Part, Phase 1/2 Study of EIK1005 as Monotherapy and in Combination with Pembrolizumab in Participants with Advanced Solid Tumors, including Checkpoint Inhibitor Naïve Participants with Microsatellite Instability High (MSI-H) or Mismatch Repair Deficient (dMMR) Tumors
2026-525248-13-00Advanced Solid Tumors
Eikon Therapeutics Inc.
Neoplasms
France, Spain, Norway, Italy, Germany, Austria, Poland, Finland, Belgium, Denmark, Portugal
15/05/2026
Phase II
A Phase 2, Open-label Study of JNJ-79635322 in Participants with Relapsed or Refractory Multiple Myeloma (RRMM) who Have Received at least 3 Prior Lines of Therapy Including a PI, an IMiD, and an Anti-CD38 Antibody
2025-521976-80-00Relapsed or Refractory Multiple Myeloma (RRMM)
Janssen Cilag International
Neoplasms
Poland, Italy
14/05/2026
Phase III
A Phase 3, Multi-regional, Open-label, Randomized Study of Tirabrutinib vs Rituximab and Temozolomide in Participants with Relapsed/Refractory Primary Central Nervous System Lymphoma
2025-523389-26-00Relapsed/refractory primary central nervous system lymphoma
DrugsTirabrutinib·Temozolomide·Rituximab
Deciphera Pharmaceuticals Inc.
Nervous System Diseases
Czechia, Germany, Italy, Belgium, Spain, Poland, Austria, France, Hungary
14/05/2026
Phase III
A Pivotal Open-label Phase 3 Clinical Study Evaluating the Efficacy and Safety of QTX-2101 in Combination With All-trans Retinoic Acid in Newly Diagnosed, Low-risk Acute Promyelocytic Leukemia
2025-524810-28-00Acute Promyelocytic Leukemia
DrugArsenic Trioxide
Quetzal Therapeutics LLC
Neoplasms
Germany, Poland, Spain, Romania, Italy, France
13/05/2026
Phase III
A Phase III, multi-center, open-label, randomised, controlled trial of intravenous obrixtamig in combination with carboplatin and etoposide vs. carboplatin and etoposide as first-line therapy in DLL3-positive patients with unresectable locally advanced or metastatic extrapulmonary neuroendocrine carcinomas.
2025-523869-22-00advanced or metastatic extrapulmonary neuroendocrine carcin…
DrugsObrixtamig·Tocilizumab·Carboplatin
Boehringer Ingelheim International GmbH, Boehringer Ingelheim Espana S.A.
Neoplasms
Portugal, Spain, Poland, Sweden, Italy, Czechia, France, Netherlands, Finland, Denmark, Austria, Germany, Belgium, Norway
13/05/2026
Phase III
A Phase III, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Once-Weekly RO7795068 Administered to Participants With Obesity or Overweight and Type 2 Diabetes
2025-523106-32-00Obesity or Overweight and Type 2 Diabetes
F. Hoffmann-La Roche AG
Nutritional and Metabolic Diseases
Germany, Romania, Czechia, Poland, Hungary, France, Spain, Italy
13/05/2026
Phase III
DAREON®-Lung-1: A Phase III multi-center, open-label, randomised trial of intravenous obrixtamig in combination with atezolizumab, carboplatin, and etoposide vs. atezolizumab, carboplatin, and etoposide as first-line treatment in patients with extensive-stage small cell lung cancer.
2025-520565-51-00small cell lung cancer
DrugsObrixtamig·Tocilizumab·Atezolizumab·Carboplatin
Boehringer Ingelheim International GmbH, Boehringer Ingelheim Espana S.A.
Neoplasms
Czechia, Sweden, Poland, Netherlands, Greece, Latvia, Finland, Norway, Belgium, Austria, Portugal, Romania, Italy, Estonia, France, Ireland, Germany, Spain, Bulgaria, Hungary
12/05/2026
Phase III
A Phase 3, Multicenter, Long-Term Extension Study to Evaluate the Long-Term Safety, Tolerability, and Efficacy of Zasocitinib (TAK-279) in Subjects With Active Psoriatic Arthritis Who are Either Biologic DMARD-Naïve or Biologic DMARD-Experienced, Including Those With Inadequate Response to Biologic DMARDs
2025-522586-30-00Psoriatic Arthritis
DrugZasocitinib
Takeda Development Center Americas Inc.
Musculoskeletal Diseases
Germany, Belgium, Spain, Czechia, Croatia, Portugal, Poland, Latvia, Bulgaria, France, Estonia, Hungary, Italy
12/05/2026
Phase II
Maintenance AVElumab after SECond line platinum-based chemotherapy for metastatic urothelial carcinoma: AVESEC trial - GOIRC-02-2025
2025-524077-16-00metastatic urothelial carcinoma
DrugAvelumab
G.O.I.R.C. Gruppo Oncologico Italiano Di Ricerca Clinica
Neoplasms
Italy
12/05/2026
Phase II
A Phase II, Multicenter, Open-Label Trial of DB-1311 in combination with BNT327 or DB-1305 in Participants with Advanced/Metastatic Solid Tumors
2025-523895-22-00Non-small cell lung cancer (NSCLC), Cervical cancer (CC), M…
DrugsBNT324·Pumitamig
Dualitybio Inc.
Neoplasms
Italy, Poland, France, Spain, Germany
12/05/2026
Phase I
A Study to Assess the Safety of RG6496 in Huntington’s Disease Gene Expansion Carriers with the Selected Genetic Variant (POINT-HD)
2025-520631-17-00Huntington’s Disease Gene Expansion Carriers
F. Hoffmann-La Roche AG
Nervous System Diseases
Italy, Poland, Denmark, Germany, Portugal, Spain
11/05/2026
Phase III
A Double-Blind, Randomized, Comparative Study of Obicetrapib and Bempedoic Acid on top of Maximally Tolerated Lipid-Lowering Therapy in Patients With Dyslipidemia at High to Very High Cardiovascular Risk (MEDICI Study)
2025-524265-24-00Dyslipidemia at High to Very High Cardiovascular Risk
A. Menarini International Licensing S.A.
Hemic and Lymphatic Diseases
Spain, Poland, Netherlands, Italy, Slovakia, Czechia, Germany
11/05/2026
Phase III
A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Assess the Efficacy and Safety of Panzyga for Prevention of Major Infections in Patients with Hypogammaglobulinemia and Autoimmune or Rheumatic Conditions Receiving Treatment with B-cell Depletion Therapy ("PROTECT")
2025-522854-37-00Prevention of a Major infection in patients with Hypogammag…
Octapharma Pharmazeutika Produktionsgesellschaft mbH
Immune System Diseases
Czechia, Lithuania, Greece, Poland, Germany, Latvia, Bulgaria, Italy
11/05/2026
Phase III
J5E-MC-JZXB - FRAmework-01: A Two-Part Phase 3 Study of Sofetabart Mipitecan (LY4170156) versus Chemotherapy or Mirvetuximab Soravtansine in Platinum-Resistant Ovarian Cancer, and Sofetabart Mipitecan plus Bevacizumab versus Platinum-Based Chemotherapy plus Bevacizumab in Platinum-Sensitive Ovarian Cancer
2025-522255-25-00Fallopian Tube Neoplasms, Neoplasm Metastasis, Ovarian Neop…
Eli Lilly & Co.
Neoplasms
Netherlands, Hungary, France, Austria, Poland, Italy, Denmark, Romania, Greece, Norway, Czechia, Belgium, Spain, Ireland, Germany
11/05/2026
Phase III
A double-blinded extension study to evaluate the long-term safety and tolerability of itepekimab in adult participants with inadequately controlled chronic rhinosinusitis with nasal polyps (CRSwNP) who participated in either EFC18418 or EFC18419 clinical studies
2025-522983-33-00Chronic rhinosinusitis with nasal polyps
DrugItepekimab
Sanofi-Aventis Recherche & Developpement
Respiratory Tract Diseases
Germany, Netherlands, Portugal, Denmark, Sweden, Finland, France, Spain, Austria, Italy, Hungary, Romania, Belgium, Czechia, Poland
11/05/2026
Phase I/II
A Phase 1/2a, Open-Label, Dose-Escalation and Dose-Expansion First-In-Human Study of the Safety, Tolerability, Activity, and Pharmacokinetics of REGN10597 (Anti PD-1-IL2RA-IL2 Fusion Protein) Alone or in Combination with Cemiplimab in Patients with Advanced Solid Organ Malignancies
2025-523399-22-00Advanced Solid Tumours, Melanoma, Clear-Cell Renal-Cell Car…
DrugsREGN10597·Cemiplimab
Regeneron Pharmaceuticals Inc.
Neoplasms
Italy, Spain, Germany, France
08/05/2026
Phase III
A Phase III, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Once-Weekly RO7795068 Administered to Participants With Obesity or Overweight Without Type 2 Diabetes
2025-523104-71-00Obesity or Overweight Without Type 2 Diabetes
F. Hoffmann-La Roche AG
Nutritional and Metabolic Diseases
Poland, Hungary, France, Belgium, Italy, Netherlands, Czechia, Germany, Spain
07/05/2026
Phase II
A prospective, multinational, multicenter, randomized, sequential, double-blind, placebo-controlled, phase 2a clinical study to assess the safety and pharmacokinetics (PK) of OMN6 in hospital-acquired bacterial pneumonia (HABP) or ventilated-associated bacterial pneumonia (VABP) caused by Acinetobacter baumannii complex (ABC).
2025-524200-29-00Hospital-acquired bacterial pneumonia or ventilated-associa…
Omnix Medical Ltd.
Respiratory Tract Diseases
Italy, Hungary, Greece
06/05/2026
Phase II
A Master Protocol of an Open-Label, Multi-Drug, Multi-Centre, Phase II Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Immunogenicity, and Antitumour Activity of Novel Combinations in Participants with Locally Advanced or Metastatic Non-Small Cell Lung Cancer (LIBRA)
2025-524843-11-00Non-Small Cell Lung Cancer
DrugsMycophenolate Mofetil·Infliximab·Ramucirumab·Rilvegostomig
AstraZeneca AB
Neoplasms
France, Italy, Spain
06/05/2026
Phase II
A Phase II, Multi-Center, Master Protocol to Evaluate the Efficacy and Safety of Volrustomig as Monotherapy or in Combination with Anti-cancer Agents in Participants with Advanced/Metastatic Solid Tumors (eVOLVE-02)
2025-523947-36-00Sub-study 5: Unresectable Pleural Mesothelioma (Volrustomig…
AstraZeneca AB
Neoplasms
Italy, Germany
05/05/2026
Phase III
Phase 3, Multicenter, Randomized, Double-Masked, Vehicle-Controlled, Parallel Group Study to Evaluate the Safety and Efficacy of Recombinant Human Nerve Growth Factor Eye Drop Solution in Participants With Persistent Corneal Epithelial Defect (PCED)
2025-523443-35-00Persistent Corneal Epithelial Defect (PCED)
Dompe' Farmaceutici S.p.A.
Eye Diseases
Czechia, Italy, Netherlands, Poland, Germany, Spain, Hungary, France
05/05/2026
Phase II
A Long-Term Extension Study to Assess the Efficacy, Safety, and Tolerability of IMVT-1402 in Adult Patients With Graves' Disease
2025-524001-33-00Graves’ Disease
Immunovant Sciences GmbH
Immune System Diseases
Italy, Greece, Germany, Hungary, Poland, Czechia, Netherlands, Spain, Belgium, Bulgaria, Latvia
05/05/2026
Phase III
A Multicenter, Randomized, Operationally Seamless Phase 2/3 Study to Evaluate the Efficacy and Safety of BMN 333 versus Vosoritide in Children with Achondroplasia
2025-523811-12-00Achondroplasia
DrugVosoritide
Biomarin Pharmaceutical Inc.
Congenital, Hereditary, and Neonatal Diseases and Abnormalities
Poland, Italy, Romania
05/05/2026
Phase III
A Phase 3, Randomized, Double-blind, Placebo-controlled, Multicenter Study of Nipocalimab in Adults with Moderate to Severe Systemic Lupus Erythematosus
2025-523552-31-00Systemic Lupus Erythematosus
Janssen Cilag International
Immune System Diseases
Denmark, Hungary, Portugal, Italy, Norway, Greece, Slovakia, Czechia, France, Poland, Bulgaria, Germany, Spain, Romania, Finland
05/05/2026
Phase II
A randomized, double masked, placebo-controlled, multicenter, dose-range finding study to assess the efficacy and safety of FWY003 in patients with geographic atrophy secondary to age-related macular degeneration
2025-523704-77-00Geographic atrophy secondary to age-related macular degener…
Novartis Pharma AG
Eye Diseases
Bulgaria, Romania, Germany, Czechia, Spain, Poland, Italy, Hungary, France
04/05/2026
Phase III
Efficacy and safety of NNC0487-0111 s.c. once-weekly in participants with overweight or obesity, and type 2 diabetes (AMAZE 2)
2024-520441-23-00Overweight or obesity, and type 2 diabetes
Novo Nordisk A/S
Nutritional and Metabolic Diseases
Italy, Croatia, Hungary, Slovakia, Romania
04/05/2026
Phase III
A multicenter open-label extension study to evaluate the long-term safety and tolerability of zigakibart in adults with primary IgA nephropathy
2024-519638-22-00IgA nephropathy
Novartis Pharma AG
Immune System Diseases
Belgium, France, Czechia, Croatia, Greece, Germany, Italy, Spain
04/05/2026
Phase III
A Phase 3, Randomized, Double-blind, Study of Belzutifan + Zanzalintinib Versus Belzutifan + Placebo in Participants with Advanced RCC who have progressed on or after both PD-1/L1 and VEGF-TKI therapies in sequence or in combination (LITESPARK-034)
2024-516993-31-00Renal Cell Carcinoma
Merck Sharp & Dohme LLC
Neoplasms
Denmark, Spain, Netherlands, Germany, France, Czechia, Poland, Italy, Greece
04/05/2026
Phase IV
PHASE IV, PROSPECTIVE, OPEN-LABEL, SINGLE ARM STUDY ON THE PAIN-RELIEF EFFECT OF BENZYDAMINE HYDROCHLORIDE LOZENGES 3 MG MINT TASTE (TANTUM VERDE) IN NON STREPTOCOCCAL PHARYNGOTONSILLITIS IN PEDIATRIC AGE (6-11 YEARS OLD).
2025-521526-15-00NON STREPTOCOCCAL PHARYNGOTONSILLITIS
Angelini Pharma Italia Aziende Chimiche Riunite Angelini Francesc O A.C.R.A.F. S.p.A. Enunciabile Anche Angelini Pharma Italia S.p.A. Angelini Pharma S.p.A. A.C.R.A.F. S.p.A. Acraf S.p.A. Angelini S.p.A. Aziende Chimiche Riunite Angelini Francesco A.C.R.A.F. S.p.A.
Respiratory Tract Diseases
Italy
30/04/2026
Phase III
A phase III randomised, double-blind, placebo-controlled, multicentre efficacy and safety clinical trial of angiotensin II in paediatric patients of 0 to 17 years of age with refractory hypotension in distributive shock receiving fluid resuscitation and standard-of-care vasopressors
2025-523750-14-00refractory hypotension in distributive shock
Paion Pharma GmbH
Cardiovascular Diseases
Italy, Germany, France, Spain
30/04/2026
Phase III
A Phase III Open-label, Randomised, Multicentre Study Comparing AZD0120, a Dual-Targeting Autologous Chimeric Antigen Receptor T-cell (CAR-T) Therapy Directed Against BCMA and CD19, versus Standard Regimens in Participants with Relapsed Refractory Multiple Myeloma (DURGA-4)
2025-523285-25-00Relapsed or Refractory Multiple Myeloma
DrugsAZD0120·Carfilzomib·Pomalidomide·Bortezomib
AstraZeneca AB
Neoplasms
Norway, Poland, Spain, Germany, France, Italy
30/04/2026
Phase IV
EaRly impAct theraPy with ceftazidime-avibactam via rapID diagnostics versus standard of care antibiotics and diagnostics in patients with bloodstream infection, hospital-acquired pneumonia or ventilator-associated pneumonia due to Pseudomonas aeruginosa or carbapenemase producing Enterobacterales ("RAPID")
2024-520067-13-00Bloodstream Infection, Ventilator Associated Pneumonia and …
National University Of Singapore
Bacterial Infections and Mycoses
Italy, Greece
29/04/2026
Phase I/II
A Phase 1/2, Open-Label Study to Evaluate the Safety and Efficacy of Autologous CD19-specific Chimeric Antigen Receptor T cells (CABA-201) in Subjects with Active Idiopathic Inflammatory Myopathy or Active Juvenile Idiopathic Inflammatory Myopathy
2025-521145-24-01Active Idiopathic Inflammatory Myopathy including dermatomy…
DrugEndoxan
Cabaletta Bio Inc.
Immune System Diseases
Italy, Spain, Germany
28/04/2026
Phase II
Efficacy of cell therapy with allo-MSCs in patients with gvhd resistant to ruxolitinib second line therapy: a Phase IIB Clinical Trial - MSC-GRR2 Study
2025-523448-10-00Gvhd Resistant to ruxolitinib and steroids
DrugMC0518
Azienda Socio Sanitaria Territoriale Degli Spedali Civili Di Brescia
Hemic and Lymphatic Diseases
Italy
28/04/2026
Phase III
An Adaptive, 2-Part, Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Efficacy and Safety of IKT-001 in Pulmonary Arterial Hypertension.
2024-520218-23-00Pulmonary Arterial Hypertension
Inhibikase Therapeutics Inc.
Cardiovascular Diseases
Spain, Poland, Italy, Belgium, Latvia, Denmark, Czechia, Germany, France, Netherlands, Portugal, Ireland, Austria, Greece, Lithuania
28/04/2026
Phase II
A Phase 2 Study of [68Ga]BED003 for PET Imaging of Fibroblast Activation Protein in Selected Oncology Indications
2025-521983-36-00Colorectal cancer (CRC), gastric cancer (GC), pancreatic du…
Blue Earth Diagnostics Ireland Limited
Neoplasms
Netherlands, Italy
28/04/2026
Phase II
Phase 2a, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Assess the Safety of Anumigilimab (CSL324) in Adults with Sickle Cell Disease
2025-521154-42-00Sickle Cell Disease
CSL Behring LLC
Hemic and Lymphatic Diseases
Belgium, Netherlands, France, Italy
28/04/2026
Phase III
A two-part, seamless, multicenter, RANDOMIZED, open-label, ADAPTIVE Phase ii/III STUDY OF THE BLOOD-BRAIN barrier PENETRANT RO7771950 versus Tucatinib, both in combination with trastuzumab and capecitabine, in patients with Pretreated unresectable locally advanced or metastatic HER2-positive breast cancer, with or without central nervous system metastases
2025-524498-17-00Pretreated Unresectable Locally Advanced or Metastatic huma…
F. Hoffmann-La Roche AG
Neoplasms
Belgium, France, Italy, Austria, Romania, Poland, Portugal, Czechia, Germany, Spain, Hungary
28/04/2026
Phase III
A Phase 3, Randomized, Double-Blind, 48-Week Placebo-Controlled Study to Assess the Efficacy, Safety, and Tolerability of DYNE-101 Administered to Participants with Myotonic Dystrophy Type 1
2025-522957-20-00Myotonic Dystrophy Type 1
Dyne Therapeutics Inc.
Musculoskeletal Diseases
Netherlands, Spain, Italy, Denmark, Germany, Belgium, France
28/04/2026
Phase III
Efficacy, safety and pharmacokinetics of cagrilintide s.c. 2.4 mg as monotherapy and in combination with semaglutide s.c. 2.4 mg (CagriSema) once weekly for weight management in children and adolescents with overweight or obesity
2023-509176-42-00Obesity and T2D
DrugsCagrilintide·Semaglutide
Novo Nordisk A/S
Nutritional and Metabolic Diseases
Slovakia, Austria, Spain, Romania, Portugal, Italy, Denmark, Belgium, Sweden, Poland, Netherlands, Croatia, Hungary, Bulgaria
28/04/2026
Phase III
A Phase 3, Randomized, Open-label, Multicenter Study of Sacituzumab Tirumotecan (sac-TMT, MK-2870) Maintenance Treatment With or Without Bevacizumab Versus Standard of Care in Participants With Newly Diagnosed Advanced HRD-Negative Ovarian Cancer Following First-line Platinum-based Chemotherapy (TroFuse-021/ENGOTov85/ GOG-3102)
2023-508047-40-00Ovarian cancer
Merck Sharp & Dohme LLC
Neoplasms
Norway, Ireland, Spain, Greece, France, Poland, Denmark, Austria, Hungary, Belgium, Czechia, Finland, Germany, Italy, Sweden
28/04/2026
Phase III
Multicenter, Randomized, Double-blind, Placebo-controlled Trial of Clemizole HCl as Adjunctive Therapy in Patients with Lennox-Gastaut Syndrome
2025-522552-20-00Lennox-Gastaut Syndrome
Epygenix Therapeutics Inc.
Nervous System Diseases
Italy, Spain, Hungary, Romania, Czechia, Poland
28/04/2026
Phase III
Phase 2/3, Double-blind, Placebo-controlled Study to Evaluate the Safety and Efficacy of EXV-802 and EXV-801 in the Treatment of Agitation in Participants with Alzheimer’s Disease Dementia
2024-517388-22-00Agitation in Alzheimer's Disease Dementia
Exciva GmbH
Nervous System Diseases
Italy, Slovakia, Spain, Poland, Czechia, Germany
28/04/2026
Phase III
A Phase 3, Parallel-group Treatment, Blinded, Randomized, Placebo-controlled Study to Assess the Efficacy and Safety of Pegtibatinase Administered Subcutaneously in Addition to Standard of Care in Participants with Classical Homocystinuria due to Cystathionine Beta Synthase Deficiency (HARMONY)
2023-504135-40-00Classical Homocystinuria
Travere Therapeutics Inc.
Nutritional and Metabolic Diseases
Belgium, Ireland, Spain, Italy, Germany, France, Portugal, Poland
27/04/2026
Phase II
A Phase IIb, multicentre, randomised, doubleblind, placebocontrolled, three-arm parallel-group study to evaluate the efficacy, safety, and tolerability at Week 24 of 2 doses of CHF10067 (zampilimab) in participants with idiopathic pulmonary fibrosis
2024-514246-37-00Idiopathic pulmonary fibrosis (IPF)
Chiesi Farmaceutici S.p.A.
Respiratory Tract Diseases
Belgium, Germany, Italy, Czechia, Bulgaria, Netherlands, France, Portugal, Poland, Spain, Romania
27/04/2026
Phase III
Efficacy and safety of NNC0487-0111s.c once weekly in participants with obesity who have reached target dose during run-in period (AMAZE12).
2025-523804-62-00Obesity
Novo Nordisk A/S
Nutritional and Metabolic Diseases
Belgium, Germany, Bulgaria, France, Spain, Denmark, Italy, Netherlands
27/04/2026
Phase III
RASolute 304: A Phase 3 Multicenter, Open-label, Randomized, 2‑Arm Study of Adjuvant Daraxonrasib Versus Standard of Care Observation Following Completion of Neoadjuvant and/or Adjuvant Chemotherapy in Patients with Resected Pancreatic Ductal Adenocarcinoma (PDAC)
2025-523495-23-00Resected Pancreatic Ductal Adenocarcinoma (PDAC)
Revolution Medicines Inc.
Digestive System Diseases
France, Spain, Italy, Germany
27/04/2026
Phase IV
A Study to Evaluate Mirikizumab Concentrations in Breast Milk Following Administration of Mirikizumab by Subcutaneous Injection in Lactating Participants Receiving Mirikizumab Therapeutically for an Approved Indication
2025-522362-78-00severely active ulcerative colitis (US) and CD (Crohn’s dis…
DrugMirikizumab
Eli Lilly & Co.
Immune System Diseases
Spain, Denmark, Germany, Italy, Poland
27/04/2026
Phase II
The MAVRiC Study: A Phase II Study of Disease Risk Mutation-guided Finite Duration Acalabrutinib plus Venetoclax for Relapse in CLL/SLL after First-line Finite covalent BTKi plus BCL2i combination, with or without Obinutuzumab
2024-518858-17-00Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CL…
DrugsAcalabrutinib·Venetoclax
AstraZeneca AB
Neoplasms
Italy, Austria, Spain, Ireland, Czechia, Poland
27/04/2026
Phase I/II
A multi-center, open-label, phase I/II study to evaluate the safety and efficacy of asciminib with chemotherapy followed by blinatumomab in pediatric, adolescent, and young adult patients with relapsed or refractory BCR::ABL1-positive (Ph+) or ABL-class Ph-like Acute Lymphoblastic Leukemia (ALL)
2025-522019-40-00relapsed or refractory BCR::ABL1-positive (Philadelphia pos…
DrugsAsciminib·Hydrocortisone·Blinatumomab·Cytarabine
Novartis Pharma AG
Neoplasms
Italy, Spain, Germany, Netherlands, France, Denmark, Czechia
27/04/2026
Phase I/II
A Multicenter, Open-label, Phase 1/2 Safety Run-in and Expansion Study of PM54 in Combination With Immunotherapy Evaluating Safety and Efficacy in Adult Participants who were Previously Treated for Advanced Malignancies
2025-523774-16-00Advanced malignancies
DrugsPM54·Pembrolizumab
Pharma Mar S.A.
Neoplasms
Spain, France, Italy
24/04/2026
Phase II
Colchicine to Quench the Inflammatory Response after Deep Vein Thrombosis: The CONQUER-DVT Randomized Controlled Trial
2025-521836-12-00deep vein thrombosis
Universita' Degli Studi G. D'Annunzio Di Chieti
Hemic and Lymphatic Diseases
Italy
23/04/2026
Phase III
Impact of Oral Semaglutide on Platelet Reactivity in Patients with Diabetes Mellitus or Overweight with High Risk or established Cardiovascular Disease: the SEMA-PLAT Study
2025-522486-29-01Diabetes Mellitus, Cardiovascular disease, Overweight (BMI …
DrugSemaglutide
Casa Di Cura Accreditata Istituto Chirurgico Ortopedico Traumatologico Marco Pasquali
Cardiovascular Diseases
Italy
23/04/2026
Phase I/II
ROSETTA HCC-206: An Open-Label, Multi-Center, Randomized Phase 1/2 Study of Pumitamig Alone or In Combination with Ipilimumab in Participants with First-Line Advanced or Unresectable Hepatocellular Carcinoma (HCC)
2025-523602-33-00Advanced or unresectable Hepatocellular Carcinoma (HCC)
DrugIpilimumab
Bristol-Myers Squibb Services Unlimited Company
Neoplasms
Poland, Spain, Germany, France, Italy
22/04/2026
Phase I
Clinical Study to Evaluate the Effects of Cevostamab in Patients with Lupus with or without Active Lupus Nephritis
2025-522904-26-00Systemic Lupus Erythematosus (SLE) With or Without Active L…
Genentech Inc.
Immune System Diseases
Italy, Spain, France, Germany
22/04/2026
Phase I
A Phase I study to evaluate the safety and dosimetry of imaging with 68Ga-OncoACP3 in prostate cancer.
2025-524594-16-00Patients with prostate cancer with: - suspected metastasis …
Philogen S.p.A.
Neoplasms
Italy
22/04/2026
Phase III
A Phase III, randomized, placebo-controlled, parallel group, double-blind study to evaluate the efficacy and safety of NIO752 in participants with Progressive Supranuclear Palsy followed by an Open Label Extension
2025-523481-24-00Participants with Progressive Supranuclear Palsy Richardson…
Novartis Pharma AG
Nervous System Diseases
Netherlands, Germany, Spain, Italy, France, Belgium
21/04/2026
Phase I/II
A Phase 1/2, Open-label Study of Oral S241656 (BDTX-4933) as Monotherapy and in Combination with Other Anti-Cancer Therapies in Patients with KRAS, BRAF and Other Selected RAS/MAPK Mutation-Positive Malignancies
2025-523474-16-00Malignancies with Documented KRAS, BRAF and Other Selected …
Institut De Recherches Internationales Servier IRIS
Neoplasms
France, Spain, Denmark, Italy
21/04/2026
Phase III
A Phase 3, Open-Label, Randomized Study of Sonrotoclax (BGB-11417) plus Zanubrutinib (BGB-3111) Compared with Venetoclax plus Acalabrutinib in Patients with Previously Untreated Chronic Lymphocytic Leukemia
2025-524366-21-00treatment-naive Chronic Lymphocytic Leukemia
BeOne Medicines I GmbH
Neoplasms
Netherlands, Poland, Italy, Germany, Spain, Romania, Czechia, France, Sweden
20/04/2026
Phase II
A Phase 2, Multicenter, Randomized, Placebo-controlled, Double-blind Study of the Efficacy and Safety of Vamifeport in Adult Subjects with HFE-related Hereditary Hemochromatosis (FERROCLEAR Study)
2025-523793-16-00Homeostatic iron regulator gene-related hereditary hemochro…
CSL Behring LLC
Congenital, Hereditary, and Neonatal Diseases and Abnormalities
Austria, Poland, Spain, Germany, France, Ireland, Romania, Belgium, Italy, Czechia, Netherlands
20/04/2026
Phase I
A Phase 1b Study of the Safety and Pharmacokinetics of Pivekimab Sunirine in Pediatric Subjects with Relapsed or Refractory Acute Myeloid Leukemia (AML).
2024-520125-36-00Relapsed or Refractory Acute Myeloid Leukemia; Acute Myelo…
DrugPivekimab Sunirine
AbbVie Deutschland GmbH & Co. KG
Neoplasms
Spain, Hungary, Czechia, France, Italy, Belgium
20/04/2026
Phase III
A Phase 3, Randomized, Open-label Study of Sacituzumab Tirumotecan (MK-2870) Versus Investigator’s Choice of Non-platinum Chemotherapy in Participants with Pretreated Locally Advanced/Metastatic Urothelial Carcinoma
2024-520014-22-00Locally advanced/metastatic urothelial carcinoma
Merck Sharp & Dohme LLC
Neoplasms
Netherlands, Greece, Italy, Germany, Spain, Belgium, Sweden, France
20/04/2026
Phase III
C0371017 - A PHASE 3, NON-INVESTIGATIONAL PRODUCT, MULTI COUNTRY COHORT STUDY TO DESCRIBE THE LONG-TERM SAFETY AND EFFECTIVENESS OF A PRIOR SINGLE-DOSE TREATMENT WITH INVESTIGATIVE GIROCTOCOGENE FITELPARVOVEC OR FIDANACOGENE ELAPARVOVEC IN PARTICIPANTS WITH HEMOPHILIA A OR HEMOPHILIA B, RESPECTIVELY
2025-523660-21-00severe to moderately severe hemophilia B (FIX:C ≤ 2%), hemo…
Pfizer Inc.
Hemic and Lymphatic Diseases
Italy, Germany, France, Spain, Sweden, Greece
20/04/2026
Phase III
A Phase 3, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Pridopidine in Participants with Amyotrophic Lateral Sclerosis
2025-524002-16-00Amyotrophic Lateral Sclerosis
Ferrer Internacional S.A., Prilenia Therapeutics B.V.
Nervous System Diseases
Belgium, Netherlands, Poland, France, Germany, Ireland, Italy, Sweden, Spain
20/04/2026
Phase III
J4G-MC-JZVD - FORAGER-2: A Phase 3, Randomized, Double-blind, Placebo-controlled Study Evaluating the Efficacy and Safety of Vepugratinib Combined with Enfortumab Vedotin and Pembrolizumab in Adults with Untreated Locally Advanced or Metastatic Urothelial Carcinoma with an FGFR3 Genetic Alteration.
2025-522855-25-00Carcinoma, Transitional Cell, Urinary Bladder Neoplasms, Ne…
DrugsEnfortumab Vedotin·Pembrolizumab
Eli Lilly & Co.
Neoplasms
Italy, Poland, Denmark, Czechia, France, Hungary, Germany, Netherlands, Spain
20/04/2026
Phase II
A Multicentre, Open-Label Study Evaluating the Safety, Tolerability and Efficacy of MaaT013 in Ruxolitinib-Refractory or Intolerant Paediatric and Adolescent participants with Gastrointestinal Acute Graft-versus-Host Disease
2025-524302-15-00Gastrointestinal Acute Graft-versus-Host Disease (GI-aGvHD)
DrugVancomycin
MaaT PHARMA
Digestive System Diseases
Netherlands, Italy, France, Spain
17/04/2026
Phase III
A Phase 3, Randomized, Open-Label Study of INCB123667 Versus Investigator's Choice of Chemotherapy in Participants With Platinum Resistant Ovarian Cancer With Cyclin E1 Overexpression (MAESTRA 2)
2025-522748-42-00Ovarian cancer
DrugsTopotecan·Doxorubicin·Gemcitabine·Paclitaxel
Incyte Corp.
Neoplasms
Ireland, Poland, France, Netherlands, Spain, Italy, Germany, Belgium
17/04/2026
Phase III
Efficacy and safety of NNC0487-0111 compared to placebo on morbidity and mortality in people with heart failure with preserved or mildly reduced ejection fraction and obesity (HF-POLARIS).
2025-523717-29-00HFpEF or HFmrEF and obesity
Novo Nordisk A/S
Cardiovascular Diseases
Denmark, Greece, Bulgaria, Italy, Netherlands, Spain, Poland, Czechia, Germany, France
17/04/2026
Phase III
A Phase 3, Multicenter, Open-Label, Randomized Trial to Compare the Efficacy and Safety of Elritercept versus Epoetin Alfa for the Treatment of Anemia Due to IPSS-R Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes in ESA-naïve Adult Participants Who Require Red Blood Cell Transfusions
2025-523544-12-00Myelodysplastic neoplasms/syndromes (MDS)
Takeda Development Center Americas Inc.
Hemic and Lymphatic Diseases
France, Belgium, Germany, Italy, Bulgaria, Ireland, Lithuania, Norway, Romania, Hungary, Spain, Greece, Poland, Netherlands
17/04/2026
Phase I/II
An open-label, multi-center, phase I/II study of GVV858 as a single agent and in combination with endocrine therapy in patients with advanced hormone receptor positive, HER2-negative breast cancer and other advanced solid tumors
2025-521911-38-00Advanced HR+/HER- breast cancer
DrugsLeuprorelin Acetate·Goserelin·Letrozole·Fulvestrant
Novartis Pharma AG
Neoplasms
Italy, Germany, France, Czechia, Denmark, Spain
16/04/2026
Phase III
A Prospective, Multi-National, Randomized, Double-Blind, Crossover Study to Evaluate the Efficacy and Safety of Gadopiclenol-enhanced MRA Compared to Gadoterate Meglumine-enhanced MRA in the Assessment of Steno-occlusive Disease in Adult Patients with Suspected Vascular Disease
2024-518835-13-00Suspected Vascular Disease of supra-aortic (carotid/vertebr…
Guerbet, Bracco Imaging S.p.A.
Cardiovascular Diseases
Italy, France, Czechia, Hungary, Spain, Germany, Poland
15/04/2026
Phase I
A Phase 1 Study Investigating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Antitumor Activity of BGB-B2033, Alone or in Combination With Tislelizumab With or Without Bevacizumab, in Participants With Selected Advanced or Metastatic Solid Tumors
2025-524136-19-00Selected Advanced or Metastatic Solid Tumors
BeOne Medicines AG
Neoplasms
Italy, France
15/04/2026
Phase I/II
A two-part study: open label, dose escalation phase aimed to evaluate the safety and tolerability of two different doses of allogeneic fibroblasts for the treatment of chronic refractory wounds and identifying the best dose for subsequent cohort expansion phase aimed to assess efficacy and confirm safety and tolerability
2025-522647-17-00Refractory wounds
Hmg Biologics S.r.l.
Skin and Connective Tissue Diseases
Italy
15/04/2026
Phase III
A Phase 3 randomized, double-blind, placebo-controlled, parallel group, multicenter study with open-label extension to evaluate the efficacy and safety of fenfluramine hydrochloride in study participants with Rett syndrome
2025-523157-34-00Rett syndrome
UCB Biosciences Inc.
Congenital, Hereditary, and Neonatal Diseases and Abnormalities
Spain, Poland, France, Hungary, Belgium, Italy, Germany
15/04/2026
Phase I/II
A Phase 1/2 open-label, multicenter study of oral GSK5460025 alone or in combination with other anti-cancer agents in adult participants with Mismatch Repair-deficient (dMMR) or Microsatellite Instability-High (MSI-H) solid tumors.
2025-522318-21-00Neoplasms, Colorectal
Glaxosmithkline Research & Development Limited
Neoplasms
Italy, Denmark, Spain, Sweden, Netherlands, France
14/04/2026
Phase I
A clinical trial to learn about the effects of DAK539 on the blood levels of repaglinide, midazolam, drospirenone, and ethinyl estradiol in people with advanced cancer
2025-521000-22-00Patients with advanced malignancies
Novartis Pharma AG
Neoplasms
Spain, Italy, France
14/04/2026
Phase II
Randomized, Double-Blinded, Vehicle-Controlled, Parallel Group, Adaptive Proof-of-concept, Dose-selecting Phase 2a Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Efficacy of Intranasal Cenegermin (recombinant human Nerve Growth Factor [rhNGF]) in Adult Participants with subacute moderate to severe Traumatic Brain Injury (TBI).
2025-522692-29-00Subacute Moderate to Severe Traumatic Brain Injury (TBI)
DrugCenegermin
Dompe' Farmaceutici S.p.A.
Nervous System Diseases
Italy, Denmark, Finland, France, Germany, Spain, Sweden, Poland
14/04/2026
Phase II
A Phase 2, Open-label, Multicohort, Study of Rinatabart Sesutecan (Rina-S) in Participants with Non-Small Cell Lung Cancer
2025-522107-18-00Locally advanced or metastatic Non-Small Cell Lung Cancer
DrugPegfilgrastim
Genmab A/S
Neoplasms
Germany, Hungary, Netherlands, France, Italy, Belgium, Spain, Poland
14/04/2026
Phase II
Teclistamab plus autologous lymphocytes infusion for the treatment of relapsed/refractory Multiple Myeloma (TALIM). MM0125
2025-521827-61-00refractory/relapsed multiple myeloma
DrugTeclistamab
Fondazione Gimema Franco Mandelli Onlus
Hemic and Lymphatic Diseases
Italy
14/04/2026
Phase II
A phase II, multicenter study of GlOfitamab in patients with mantle cell Lymphoma and inaDequate response or relapse following CAR T-cell therapy (GOLD)
2025-523428-39-00Mantle Cell Lymphoma
Fondazione Italiana Linfomi Ets
Hemic and Lymphatic Diseases
Italy
14/04/2026
Phase III
A Double-blind, Randomized Clinical Trial Evaluating the Efficacy and Safety of Vormatrigine in Adults with Focal Seizures
2025-524038-24-00Focal Epilepsy
Praxis Precision Medicines Inc.
Nervous System Diseases
Poland, Germany, Czechia, Italy, Spain
10/04/2026
Phase I/II
An Open-label, Multicenter, Two Part, Ascending Dose Followed by a Controlled Trial to Assess the Safety and Efficacy of a Subretinal Administration of AAVB-039 in Participants with Stargardt Disease (STGD1) (CELESTE)
2025-522207-15-01Stargardt Disease (STGD1)
Aavantgarde Bio S.r.l.
Eye Diseases
Belgium, Italy, Netherlands, Norway
10/04/2026
Phase II
A Phase 2b, Randomized, Double blind, Placebo controlled, Parallel group, Multicenter, Dose ranging Study Investigating the Efficacy and Safety Profile of KT-621 Administered Orally to Adult Participants with Uncontrolled Moderate to Severe Eosinophilic Asthma
2025-523180-38-00Uncontrolled Moderate to Severe Eosinophilic Asthma
Kymera Therapeutics Inc.
Immune System Diseases
Spain, Romania, Slovakia, Poland, Germany, Italy, Belgium, Austria
10/04/2026
Phase I
A clinical trial to learn how liver function affects the blood levels of DAK539 in people with advanced cancer
2025-521001-40-00Advanced Malignancies and Hepatic Impairment
Novartis Pharma AG
Neoplasms
Spain, France, Italy
09/04/2026
Phase II
A Phase 2 Study to Investigate the Safety and Efficacy of Petosemtamab in Adults with Non-Small Cell Lung Cancer in Combination with Pembrolizumab.
2025-522867-13-00Non Small Cell Lung Cancer
Merus B.V.
Not possible to specify
Spain, Belgium, Netherlands, Poland, Italy, France
09/04/2026
Phase I/II
C6461020 - An Interventional Open-Label Phase 1b/2 Study to Evaluate the Safety, Pharmacokinetics, and Preliminary Efficacy of PF-08634404 in combination with Different Anticancer Agents in Participants with Advanced Solid Tumors
2025-523526-40-00Advanced Solid Tumors
DrugsSigvotatug vedotin·PF-08634404
Pfizer Inc.
Neoplasms
Italy, Spain, France, Germany
09/04/2026
Phase I/II
C6461013 - An Interventional Open-label Phase 1b/2 Study to Evaluate Safety, Pharmacokinetics, and Preliminary Efficacy of PF-08634404 as Monotherapy and Combination Therapy in Adult Participants With Unresectable Locally Advanced or Metastatic Hepatocellular Carcinoma
2025-523525-17-00Unresectable Locally Advanced or Metastatic Hepatocellular …
DrugsPF-08634404·Ipilimumab
Pfizer Inc.
Neoplasms
Spain, Italy, Germany, France
09/04/2026
Phase III
A randomized, Phase 3, open-label study to investigate pharmacokinetics, safety, and efficacy of subcutaneous compared to intravenous frexalimab in adult participants with multiple sclerosis.
2024-519304-28-00Multiple Sclerosis
Sanofi-Aventis Recherche & Developpement
Nervous System Diseases
Belgium, Spain, Italy
08/04/2026
Phase II
ETOP 29-25 START-lung: A multicentre phase II trial of tarlatamab in patients with pretreated extensive-stage small cell lung cancer (ES-SCLC) and ECOG PS 2.
2025-522288-13-00Patients with pretreated extensive-stage small cell lung ca…
ETOP IBCSG Partners Foundation
Neoplasms
France, Greece, Spain, Italy
08/04/2026
Phase III
C6461004 - A GLOBAL PHASE 2/3 INTERVENTIONAL STUDY OF PF-08634404 IN COMBINATION WITH CHEMOTHERAPY IN PARTICIPANTS WITH EXTENSIVE-STAGE SMALL CELL LUNG CANCER
2025-523522-41-00Extensive-Stage Small Cell Lung Cancer
DrugsPF-08634404·Etoposide·Atezolizumab·Carboplatin
Pfizer Inc.
Neoplasms
France, Italy, Germany, Spain
07/04/2026
Phase III
A multicenter, randomized, double-blind, parallel group, placebo-controlled study of the efficacy and safety of early depemokimab initiation as add-on treatment in COPD patients with type 2 inflammation.
2025-521108-23-00Chronic Obstructive Pulmonary Disease
Glaxosmithkline Research & Development Limited
Respiratory Tract Diseases
Germany, Belgium, Netherlands, Denmark, Spain, Greece, Poland, Hungary, France, Italy, Bulgaria, Romania
07/04/2026
Phase III
Efficacy and safety of NNC0487-0111 s.c. once-weekly in participants with overweight or obesity, and knee osteoarthritis (AMAZE 5)
2024-520444-42-00Overweight or obesity, and knee osteoarthritis
Novo Nordisk A/S
Nutritional and Metabolic Diseases
Italy, Greece, Spain, Bulgaria, Denmark, Poland
07/04/2026
Phase III
Efficacy and safety of NNC0487-0111 s.c. once-weekly in participants with overweight or obesity, and knee osteoarthritis (AMAZE 6)
2024-520445-23-00Overweight or obesity, and knee osteoarthritis
Novo Nordisk A/S
Nutritional and Metabolic Diseases
Greece, Poland, Spain, Bulgaria, Italy, Denmark
07/04/2026
Phase III
Multicenter, open-label study to evaluate the safety, tolerability, pharmacokinetics, and efficacy of filgotinib in children and adolescents from 8 years to less than 18 years of age with polyarticular-course juvenile idiopathic arthritis
2024-511593-70-00Polyarticular-course juvenile idiopathic arthritis
Alfasigma S.p.A.
Musculoskeletal Diseases
Spain, Bulgaria, France, Belgium, Germany, Greece, Italy, Poland, Hungary, Czechia
07/04/2026
Phase II
Efficacy and safety of a novel dual pH-dependent delayed-release ColeseveLam for the trEatment of bile Acid diarrhoea: a Randomized, double-blind, parallel-group, placebo-controlled clinical trial - CLEAR
2025-523868-20-00Bile acid diarrhoea
Monteresearch S.r.l.
Digestive System Diseases
Italy
02/04/2026
Phase III
A Phase 3, Multicenter, Double-Blinded, Randomized Study to Evaluate REGN7508, a Factor XI Monoclonal Antibody, Versus Acetylsalicylic Acid for Prophylaxis of Symptomatic Venous Thromboembolism After Elective Total Knee Arthroplasty (ROXI-ASPEN)
2025-520479-25-00Symptomatic Venous Thromboembolism (VTE)
DrugsCenvacibart·Acetylsalicylic acid
Regeneron Pharmaceuticals Inc.
Hemic and Lymphatic Diseases
Greece, Italy, Spain
01/04/2026
Phase III
A Phase 3, Randomized, Multicenter, Double-Blind, Placebo-Controlled Trial to Evaluate the Efficacy, Safety, Tolerability, and Pharmacokinetics of Zasocitinib in Pediatric Participants Aged 4 to Less Than 18 Years With Moderate-to-Severe Plaque Psoriasis
2025-522567-15-00Plaque Psoriasis
Takeda Development Center Americas Inc.
Skin and Connective Tissue Diseases
Spain, Poland, Germany, Italy
01/04/2026
Phase I
A First-in-Human Study of KK2223 in Participants with T-cell Non-Hodgkin Lymphoma
2025-522523-96-00T-cell Non-Hodgkin Lymphoma, Cutaneous T-cell lymphoma (CTC…
Kyowa Kirin Inc.
Neoplasms
Spain, Italy
01/04/2026
Phase II
A multicenter, multicohort, phase 2 platform trial to personalize second-line treatment intensity and targeting in HR-positive, HER2-negative metastatic breast cancer through an integrated liquid biopsy algorithm.
2025-523460-21-00Metastatic breast cancer
DrugsCapivasertib·Elacestrant·Trastuzumab deruxtecan·Fulvestrant
Centro Di Riferimento Oncologico Di Aviano
Neoplasms
Italy
31/03/2026
Phase I/II
A Phase Ib/II Open-Label, Multicentre Platform Study Evaluating Novel Combinations in Participants with Advanced or Metastatic Non-Small Cell Lung Cancer (ALTAIR)
2024-519786-22-01metastatic non-small cell lung cancer (NSCLC)
DrugsRamucirumab·Rilvegostomig
AstraZeneca AB
Neoplasms
Germany, Spain, France, Poland, Belgium, Netherlands, Italy
30/03/2026
Phase III
Randomised, Open-label, Phase III Study of AZD5335 Versus Mirvetuximab Soravtansine in FRα-high and AZD5335 Versus Investigator’s Choice Chemotherapy in FRα-low Expressing High-grade Platinum-resistant Epithelial Ovarian Cancer Patients (TREVI-OC-01)
2025-520466-22-00Advanced Platinum-resistant Epithelial Ovarian Cancer
AstraZeneca AB
Pathological Conditions, Signs and Symptoms
Ireland, Greece, Czechia, France, Sweden, Belgium, Denmark, Spain, Italy, Germany
27/03/2026
Phase III
A Phase 3 Randomized, Open-label Study of Rinatabart Sesutecan (Rina-S) Versus Treatment of Investigator’s Choice (IC) in Patients With Endometrial Cancer After Platinum-Based Chemotherapy and PD(L)-1 Therapy
2024-519818-31-01Endometrial Cancer Advanced, Recurrent, Metastatic, or Prim…
DrugsDoxorubicin·Paclitaxel
Genmab A/S
Neoplasms
Poland, Denmark, Finland, Lithuania, France, Germany, Spain, Belgium, Greece, Norway, Italy
26/03/2026
Phase II
A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Proof of Concept (POC) Study Evaluating the Safety, Tolerability, and Efficacy of Nintedanib Solution for Inhalation (AP02) in Participants with Idiopathic Pulmonary Fibrosis (IPF) (AURA-IPF)
2025-523431-19-00Idiopathic Pulmonary Fibrosis (IPF)
Avalyn Pharma Inc.
Respiratory Tract Diseases
Germany, Italy, Spain, Ireland
26/03/2026
Phase III
IB1001-304: Effects of N-Acetyl-L-Leucine on CACNA1A Disorders: A Phase III, randomized, placebo-controlled, double-blind, crossover study
2025-523828-51-00CACNA1A Disorders
Intrabio Limited, IntraBio Inc
Nervous System Diseases
Italy, Germany, Austria, Greece
25/03/2026
Phase II
An Open-label, Multi-center, Global Phase II Clinical Study to Evaluate the Efficacy and Safety of HLX43 (Anti-PD-L1 ADC) in Subjects with Advanced Non-small Cell Lung Cancer (NSCLC)
2025-523803-31-00Advanced non-small cell lung cancer (NSCLC)
Shanghai Henlius Biotech Inc.
Therapeutics
Italy, Romania, Poland, Spain, France
25/03/2026
Phase III
A Phase 3, Double-Blind, Randomized, Placebo-Controlled Study of Levosimendan in Pulmonary Hypertension Patients with Heart Failure with Preserved Left Ventricular Ejection Fraction
2025-522475-28-00Pulmonary Hypertension (PH) with Heart Failure with preserv…
Tenax Therapeutics Inc.
Cardiovascular Diseases
France, Italy, Germany, Czechia, Austria, Poland, Hungary, Bulgaria, Spain
24/03/2026
Phase III
AN INTERVENTIONAL PHASE 3, DOUBLE-BLIND, RANDOMIZED STUDY TO EVALUATE EFFICACY AND SAFETY OF PF-08634404 IN COMBINATION WITH CHEMOTHERAPY VERSUS PEMBROLIZUMAB IN COMBINATION WITH CHEMOTHERAPY IN ADULT PARTICIPANTS WITH LOCALLY ADVANCED OR METASTATIC NON-SMALL CELL LUNG CANCER
2025-523461-17-01LOCALLY ADVANCED OR METASTATIC NON-SMALL CELL LUNG CANCER
Pfizer Inc.
Neoplasms
France, Italy, Hungary, Greece, Czechia, Spain, Poland, Germany
24/03/2026
Phase I
A study to investigate the safety, pharmacokinetics, pharmacodynamics, and immunogenicity of a CD19/CD20 T-cell engager in participants with B-cell driven ARD.
2025-522932-15-00Systemic Lupus Erythematosus
Glaxosmithkline Research & Development Limited
Immune System Diseases
Germany, France, Italy, Spain, Poland
23/03/2026
Phase II
A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study of V940 in Combination With Pembrolizumab and Chemotherapy as First-Line Treatment for Participants With Metastatic Squamous NSCLC (INTerpath-013)
2025-520902-37-00Non-small cell lung cancer stage IV
Merck Sharp & Dohme LLC
Neoplasms
Italy, Spain, Poland, France
23/03/2026
Phase III
Phase III, Randomized, Open-label, Global, Multicenter Study of Rilvegostomig or Durvalumab in Combination With Chemotherapy as a First-line Treatment for Patients With Advanced Biliary Tract Cancer (ARTEMIDE-Biliary02).
2025-523085-24-00Biliary Tract Cancer
AstraZeneca AB
Neoplasms
Germany, Poland, Italy, Belgium, France, Netherlands, Spain
23/03/2026
Phase III
A Phase 3, Randomised, Double-Blind, Placebo-Controlled, Parallel Group, Multicentre Study With a Double-Blind Extension Evaluating Efficacy and Safety of Lebrikizumab Administered to Adult Patients With Nummular Eczema who are not Adequately Controlled With Topical Corticosteroids or When This Treatment is not Medically Advisable (LUMINE)
2025-522403-17-00Nummular Dermatitis
Almirall S.A.
Skin and Connective Tissue Diseases
Italy, Bulgaria, Spain, Germany, Poland, France
23/03/2026
Phase II
A Phase II, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of Inavolisib plus Ribociclib plus Fulvestrant Versus Placebo plus Ribociclib plus Fulvestrant in Patients with Endocrine-Resistant Hormone-Receptor-Positive, HER2-Negative Advanced Breast Cancer with Chromosome 8P Loss and Without a PIK3CA Mutation
2025-523013-28-00Endocrine-Resistant Hormone-Receptor-Positive, HER2-Negativ…
F. Hoffmann-La Roche AG
Neoplasms
France, Italy, Poland, Germany, Spain
23/03/2026
Phase II
A Phase 2 Study of ACR-368 Therapy in Subjects with Endometrial Cancer
2025-524542-10-00Endometrial cancer
Acrivon Therapeutics Inc.
Neoplasms
Italy, Germany, Spain, France
23/03/2026
Phase III
C6461003 - AN INTERVENTIONAL, PHASE 3, DOUBLE-BLIND, RANDOMIZED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF PF-08634404 IN COMBINATION WITH CHEMOTHERAPY VERSUS BEVACIZUMAB IN COMBINATION WITH CHEMOTHERAPY IN TREATMENT-NAÏVE PARTICIPANTS WITH METASTATIC COLORECTAL CANCER
2025-523521-18-00Metastatic Colorectal Cancer
DrugsPF-08634404·Calcium folinate·Fluorouracil·Oxaliplatin
Pfizer Inc.
Neoplasms
Spain, Belgium, France, Italy, Netherlands, Germany, Poland, Denmark
23/03/2026
Phase II
A Phase 2 Posology Study with Long-Term Extension in Participants with Well‑Controlled Recurrent Pericarditis to Evaluate the Efficacy and Safety of Transition Regimens to KPL-387 Monotherapy from Standard Therapies
2025-523234-66-00Well-Controlled Recurrent Pericarditis
Kiniksa Pharmaceuticals GmbH
Therapeutics
Spain, Greece, Germany, France, Italy, Poland
19/03/2026
Phase II
SEZanne: A Phase 2 Randomized, Open label, Multicenter Study to Evaluate the Optimal Dose, Safety, and Efficacy of ABBV-706 in Combination with Atezolizumab versus Standard of Care as First-Line Treatment in Subjects with Previously Untreated Extensive Stage Small Cell Lung Cancer (ES-SCLC)
2024-517490-24-00Small Cell Lung Cancer
AbbVie Deutschland GmbH & Co. KG
Neoplasms
Spain, Germany, Italy, Poland, Belgium
18/03/2026
Phase II
J6E-MC-KWAN: A Phase 2, Multicenter, Randomized, Double-Blind, Active-Controlled Study of LY4268989 (MORF-057) Co-Administered with Mirikizumab in Adults with Moderately to Severely Active Ulcerative Colitis
2025-522338-30-00Ulcerative Colitis
Eli Lilly & Co.
Digestive System Diseases
Hungary, Spain, Denmark, Netherlands, Poland, Romania, Germany, Italy, Austria
18/03/2026
Phase III
A prospective, open-label, randomized, multicenter phase-III trial to evaluate the efficacy of pirtobrutinib and epcoritamab compared with R-(mini)-CHOP for treatment of patients with Richter Transformation - CLLRT2
2024-513445-37-00previously untreated RT, irrespective of risk factors and d…
DrugsEpcoritamab·Pirtobrutinib·Prednisolone·Vincristine
University Of Cologne
Neoplasms
Austria, Germany, Denmark, Ireland, Netherlands, Italy
18/03/2026
Phase III
A Phase 3, Randomized, Double-blind, Placebo-controlled, 3-Part Study to Evaluate the Efficacy and Safety of Orally Administered Deucrictibant XR Tablet for Prophylaxis and Deucrictibant Soft Capsule for On-demand Treatment of Angioedema Attacks in Adults with Acquired Angioedema due to C1 Inhibitor Deficiency
2025-522051-26-00Acquired Angioedema due to C1 Inhibitor Deficiency
DrugDeucrictibant
Pharvaris Netherlands B.V.
Immune System Diseases
Hungary, Spain, Austria, Germany, Poland, Netherlands, France, Italy, Bulgaria
17/03/2026
Phase II
An open-label, uncontrolled, multicenter study to assess the effect of zigakibart treatment on histologic, circulating, and excreted markers of kidney disease and dysfunction in adult patients with IgA nephropathy
2024-519699-24-00IgA nephropathy
Novartis Pharma AG
Immune System Diseases
Czechia, Germany, Spain, Italy, Poland
17/03/2026
Phase II
A Phase 2, Randomized, Masked, Placebo-Controlled Study of Subcutaneously Administered ADX-038 in Participants With Geographic Atrophy (GA) Secondary to Age-Related Macular Degeneration (AMD)
2025-521779-30-00Geographic atrophy secondary to age-related macular degener…
Adarx Pharmaceuticals Inc.
Eye Diseases
Germany, Portugal, Italy, Spain
17/03/2026
Phase I/II
A Phase Ib/II, Multicenter, Open-Label Study to Evaluate Safety, Efficacy, and Pharmacokinetics of YL201 in Combination with Other Anti-Cancer Therapies in Patients with Advanced Solid Tumors
2025-523742-27-00Advanced solid tumors
Medilink Therapeutics (Suzhou) Co. Ltd.
Neoplasms
Poland, Spain, France, Romania, Italy, Belgium, Hungary, Germany
17/03/2026
Phase III
A multicentre, randomised, double-blind, parallel group, placebo-controlled trial to assess the effects of oral TRPC6 inhibitor BI 764198 taken over a 104 week treatment period in adult and adolescent participants with primary focal segmental glomerulosclerosis (pFSGS) or genetic FSGS related to TRPC6 gene variants
2025-522191-86-00Focal segmental glomerulosclerosis
Boehringer Ingelheim International GmbH, Boehringer Ingelheim Espana S.A.
Female Urogenital Diseases and Pregnancy Complications
Germany, Croatia, Poland, Sweden, Portugal, Netherlands, Italy, Denmark, Slovakia, Spain, Norway, Romania, Belgium, Greece, France
17/03/2026
Phase III
A Phase 3b Long-term Efficacy and Safety Extension Study of Barzolvolimab in Participants with Chronic Spontaneous Urticaria Who Have Completed CDX0159-12 or CDX0159-13 (EMBARQ-CSU LTE)
2025-522878-36-00Chronic Spontaneous Urticaria
DrugBarzolvolimab
Celldex Therapeutics Inc.
Skin and Connective Tissue Diseases
Croatia, France, Netherlands, Bulgaria, Portugal, Slovakia, Hungary, Italy, Greece, Germany, Czechia, Lithuania, Spain, Belgium, Denmark, Poland
16/03/2026
Phase II
An Open-Label Extension Study to Evaluate the Long-term Safety and Efficacy of Weekly Intravenous Infusions of BMN 351 in Participants with Duchenne Muscular Dystrophy Amenable to Exon 51 Skipping
2024-511656-41-00Duchenne Muscular Dystrophy
Biomarin Pharmaceutical Inc.
Musculoskeletal Diseases
Spain, Italy, Netherlands
16/03/2026
Phase II
A Phase 2 Study of Emavusertib in Combination with an Approved Bruton Tyrosine Kinase Inhibitor in Patients with Chronic Lymphocytic Leukemia and Other B-cell Malignancies
2025-523600-68-00Chronic Lymphocytic Leukemia and Other B-cell Malignancies
Curis Inc.
Neoplasms
Spain, Italy
16/03/2026
Phase II
A phase 2b, randomized, double-blind, placebo-controlled, parallel-group, multicenter study to evaluate the efficacy, safety, pharmacokinetics, and pharmacodynamics of Usnoflast administered to adult subjects with Amyotrophic Lateral Sclerosis (ALS)
2025-522580-15-00Amyotrophic Lateral Sclerosis (ALS)
Zydus Therapeutics Inc.
Nervous System Diseases
Spain, Germany, Sweden, Ireland, Poland, Italy, Belgium, France, Netherlands
12/03/2026
Phase I
A Phase 1a/1b Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Preliminary Antitumor Activity of BG-75202, Alone and in Combination with Other Agents in Patients with Advanced Solid Tumors
2025-523553-34-00Advanced and Metastatic Solid tumors
BeOne Medicines I GmbH
Neoplasms
Italy, Spain
12/03/2026
Phase I
A Study to Evaluate the Safety and Tolerability of ARV-806 in Adults with Advanced Cancer that has the KRAS G12D Mutation
2025-521062-10-00KRAS G12D Mutated Advanced Solid Tumors
Arvinas Operations Inc.
Neoplasms
Spain, Italy
12/03/2026
Phase I
Safety and Preliminary Efficacy of CTX112 in Adult Participants with Relapsed/Refractory Hematologic Autoimmune Disease
2025-523845-90-00Relapsed/Refractory Hematologic Autoimmune Disease
CRISPR Therapeutics AG
Hemic and Lymphatic Diseases
Spain, Germany, France, Denmark, Italy, Netherlands
12/03/2026
Phase III
A Phase 3, Multicenter, Randomized, Double-Blinded, Placebo-Controlled Study to Evaluate the Safety and Efficacy of L606 (Treprostinil Liposome Inhalation Suspension) in Participants with Pulmonary Hypertension Associated with Interstitial Lung Disease (WHO Group 3)
2024-517943-29-00Pulmonary Hypertension associated with interstitial lung di…
DrugTreprostinil
Liquidia Technologies Inc.
Respiratory Tract Diseases
Latvia, Germany, Italy, Czechia, France, Belgium, Portugal, Poland, Austria, Spain
11/03/2026
Phase III
ROSETTA Gastric-204: A Blinded, Randomized, Phase 2/3 Study of Pumitamig in Combination with Chemotherapy Versus Nivolumab in Combination with Chemotherapy in Participants with Previously Untreated Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma
2025-523263-37-00Previously Untreated Advanced or Metastatic Gastric, Gastro…
Bristol-Myers Squibb Services Unlimited Company
Neoplasms
Germany, Spain, Poland, France, Italy, Romania
10/03/2026
Phase III
ROSETTA CRC-203: A Blinded, Randomized Phase 2/3 Study of Pumitamig in Combination with Chemotherapy Versus Bevacizumab in Combination with Chemotherapy in Participants with Previously Untreated, Unresectable, or Metastatic Colorectal Cancer
2025-523224-45-00Untreated, Unresectable or Metastatic Colorectal Cancer
DrugsCalcium folinate·Fluorouracil·Irinotecan·Capecitabine
Bristol-Myers Squibb Services Unlimited Company
Neoplasms
Sweden, Czechia, Belgium, Romania, Netherlands, Italy, France, Spain, Germany, Poland, Austria
10/03/2026
Phase II
A Phase 2a Multicenter Platform Study of Investigational Products for the Treatment of Adult Subjects with Idiopathic Pulmonary Fibrosis
2024-518013-25-00Idiopathic Pulmonary Fibrosis
AbbVie Deutschland GmbH & Co. KG
Respiratory Tract Diseases
Greece, Italy, Sweden, Germany, Portugal, Spain, France, Hungary, Poland, Bulgaria, Romania
10/03/2026
Phase III
REVEAL Study: Phase 3 Study of the Efficacy and Safety of ION582 in Children and Adults with Angelman Syndrome
2024-519711-33-01Angelman syndrome
Ionis Pharmaceuticals Inc.
Congenital, Hereditary, and Neonatal Diseases and Abnormalities
Italy, Germany, Poland, Spain
09/03/2026
Phase III
A Phase 3 Randomized, Open-label Study of Pasritamig (JNJ-78278343), a T-cell-redirecting Agent Targeting Human Kallikrein 2, With Docetaxel Versus Docetaxel for Metastatic Castration-resistant Prostate Cancer
2025-522713-29-00Metastatic Castration-resistant Prostate Cancer (mCRPC)
Janssen Cilag International
Neoplasms
Belgium, Italy, Spain, Germany, France
09/03/2026
Phase II
A Phase II, Randomized, Multicenter, Open-Label Study Evaluating the Efficacy and Safety of the Combination of Inavolisib Plus Enzalutamide Versus Physician's Choice of ARPI or Docetaxel in Patients With Metastatic Castration-Resistant Prostate Cancer
2025-521327-67-00Metastatic Castration-Resistant Prostate Cancer
F. Hoffmann-La Roche AG
Neoplasms
Germany, France, Italy, Spain
06/03/2026
Phase I/II
An Adaptive Dose Escalation and Expansion Basket Trial to Explore the Safety, Pharmacology, and Clinical Activity of TGD001 in Immune-Mediated Thrombotic Thrombocytopenic Purpura (iTTP) and Other Thrombotic Microangiopathies
2025-523802-34-00Immune-Mediated Thrombotic Thrombocytopenic Purpura, Thromb…
TargED Biopharmaceuticals B.V.
Hemic and Lymphatic Diseases
Germany, France, Italy, Spain
06/03/2026
Phase II
A multinational, multicenter extension study to investigate the long-term safety, tolerability and efficacy of balinatunfib in adults with Crohn’s disease or ulcerative colitis
2025-522511-42-00Crohn's disease, Colitis Ulcerative
DrugBalinatunfib
Sanofi-Aventis Recherche & Developpement
Digestive System Diseases
Belgium, Germany, Czechia, Netherlands, Spain, Austria, Italy, Greece, Croatia, Bulgaria, Poland, France, Romania, Hungary
06/03/2026
Phase I/II
A phase Ib/II open-label, multi-center study of the DNA protein kinase inhibitor AMO959 with lutetium (177Lu) vipivotide tetraxetan (AAA617) in combination with an androgen receptor pathway inhibitor (ARPI) in adult participants with PSMA-positive metastatic castration resistant prostate cancer (mCRPC)
2025-521859-23-00PSMA-positive mCRPC with prior exposure to at least one pri…
Novartis Pharma AG
Neoplasms
Germany, France, Spain, Italy
05/03/2026
Phase III
A Phase III, multisite, randomized, double-blind trial of BNT327 in combination with chemotherapy versus placebo with chemotherapy in patients with previously untreated locally recurrent inoperable or metastatic TNBC determined ineligible for PD(L)1 therapy based on PD-L1 negative disease
2025-521884-12-00First line triple-negative breast cancer (TNBC)
DrugsEribulin·Gemcitabine·Paclitaxel·Carboplatin
BioNTech SE
Neoplasms
Czechia, Poland, Italy, France, Belgium, Netherlands, Germany, Spain
04/03/2026
Phase II
A Phase 2, Multi-center, Randomized, Dose-Ranging, Placebo-Controlled, Double-blind Study of the Relaxin Agonist R2R01 in Patients at High Risk for Cardiac Surgery Associated - Acute Kidney Injury.
2025-523037-25-00Patients at high risk for Cardiac Surgery Associated – Acut…
River 2 Renal Corp.
Pathological Conditions, Signs and Symptoms
Italy, Germany
04/03/2026
Phase I/II
Protocol Title: KEYMAKER-U01 Substudy 01F: A Phase 1b/2 Umbrella Study With Rolling Arms of Investigational Agents for Previously Treated of Participants With Advanced or Metastatic Nonsquamous Non-small Cell Lung Cancer (NSCLC) With KRAS G12C Mutations
2024-512248-47-00Non-small Cell Lung Cancer (NSCLC)
DrugsCalderasib·Patritumab deruxtecan·Sacituzumab tirumotecan·Cetuximab
Merck Sharp & Dohme LLC
Neoplasms
Italy, Germany, Greece, Poland, Hungary, Spain
04/03/2026
Phase III
A randomized, double-blind, placebo-controlled Phase III study to evaluate the efficacy and safety of remibrutinib in patients with secondary progressive multiple sclerosis
2025-521546-23-00Secondary progressive multiple sclerosis
Novartis Pharma AG
Nervous System Diseases
Denmark, Slovenia, Netherlands, Portugal, Ireland, Sweden, Croatia, Greece, Germany, Latvia, Czechia, Spain, Romania, Belgium, Austria, Lithuania, Slovakia, Poland, Estonia, Bulgaria, France, Italy, Hungary, Finland, Norway
03/03/2026
Phase III
A double blind, randomized, placebo-controlled exploratory trial to investigate the efficacy and safety of nerandomilast over 24 months when administered in individuals with interstitial lung abnormalities and a family history of pulmonary fibrosis to reduce the risk of worsening (DROP-FPF)
2025-522383-33-00Pulmonary fibrosis, Interstitial lung diseases, Familial pu…
Boehringer Ingelheim International GmbH
Respiratory Tract Diseases
Belgium, Spain, Netherlands, Italy, Germany, France
03/03/2026
Phase II
A Phase 2 Study to Assess ADX-038 in Participants With Complement-Mediated Kidney Disease
2025-521752-26-00Complement-Mediated Kidney Disease
Adarx Pharmaceuticals Inc.
Male Urogenital Diseases
Spain, Italy
02/03/2026
Phase II
An open label extension study to evaluate the long-term safety and efficacy of subcutaneous lunsekimig in adult participants with asthma who participated in study DRI16762 or ACT18301
2025-522896-27-00Asthma
Sanofi-Aventis Recherche & Developpement
Respiratory Tract Diseases
Poland, Italy, Belgium, Sweden, Hungary, France, Germany, Spain, Denmark
02/03/2026
Phase II
A randomized, double-blind, placebo-controlled, Phase 2, dose-finding study to investigate the efficacy and safety of SAR445399 in participants with moderate to severe hidradenitis suppurativa
2025-522695-83-00Hidradenitis suppurativa
Sanofi-Aventis Recherche & Developpement
Immune System Diseases
Hungary, Spain, France, Belgium, Sweden, Germany, Italy
02/03/2026
Phase III
Effect of nepafenac/dexamethasone fixed dose combination vs. its individual components (nepafenac and dexamethasone monotherapies) on postoperative inflammation after cataract surgery: a randomized, multicentre, blinded-assessor, parallel-group clinical study – NE.DE.F. STUDY
2025-523367-38-00Postoperative inflammation after cataract surgery
Medivis S.r.l.
Eye Diseases
Italy
27/02/2026
Phase II
C5041018 - A Phase 2 Open-Label, Single Arm Study to Evaluate the Efficacy, Pharmacokinetics, and Safety of Etrasimod in Pediatric Participants with Moderately to Severely Active Ulcerative Colitis
2025-523100-77-00Ulcerative Colitis
Pfizer Inc.
Digestive System Diseases
Finland, Poland, France, Germany, Italy, Slovakia
27/02/2026
Phase III
HighLiGHts - A Pivotal, Parallel-Arm, Phase 3, Open-Label, Active-controlled, Global, Multicenter, Randomized Basket Trial Investigating the Efficacy and Safety of Once-weekly Lonapegsomatropin Compared to Daily Somatropin in Prepubertal Children and Adolescents with Growth Failure or Short Stature due to Growth Hormone Sufficient Disorders – Turner Syndrome, SHOX Deficiency, Small for Gestational Age, and Idiopathic Short Stature
2025-523079-44-00Turner Syndrome (TS), idiopathic short stature (ISS), short…
Ascendis Pharma Endocrinology Division A/S
Musculoskeletal Diseases
Germany, Spain, Italy, France, Romania
27/02/2026
Phase II
PirtobrUtinib as frontline Therapy for elderly unfit/frail patient with MAntle cell lymphoma: a phase II study of the Fondazione Italiana Linfomi (FIL)
2025-521666-10-01Mantle Cell Lymphoma
Fondazione Italiana Linfomi Ets
Hemic and Lymphatic Diseases
Italy
26/02/2026
Phase III
A Phase III, Randomised, Open-Label, Multicentre Study of Datopotamab Deruxtecan or Docetaxel in Previously Treated TROP2-positive Advanced or Metastatic Non-squamous Non-Small Cell Lung Cancer Without Actionable Genomic Alterations (TROPION-Lung17)
2024-520101-39-00TROP2 NMR-positive advanced or metastatic non-squamous non-…
AstraZeneca AB
Neoplasms
Spain, Poland, Hungary, Italy, Germany, France, Belgium, Austria
26/02/2026
Phase II
A Phase 2, Multicenter, Randomized, Double-blind Study of Safety and Efficacy of EL219 (Turletricin) versus Liposomal Amphotericin B or Voriconazole for Early Antifungal Therapy of Invasive Mould Infections (TREAT-1)
2025-522835-32-00Suspected Invasive Mould Infection
Elion Therapeutics Inc.
Bacterial Infections and Mycoses
Belgium, France, Spain, Italy
26/02/2026
Phase III
An Open-Label Study of Donidalorsen in Pediatric Patients Age 2 to Less than 12 Years Old with Hereditary Angioedema [Donidalorsen Treatment in Children with Hereditary Angioedema]
2025-523499-22-00Hereditary Angioedema (HAE)
Ionis Pharmaceuticals Inc.
Genetic Phenomena
Italy, Spain, Poland
25/02/2026
Phase II
Open-label, Uncontrolled, Multicenter Trial to Evaluate the Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability of Inebilizumab in Children From 2 Years to Less Than 18 Years of Age with Immunoglobulin G4 related Disease (IgG4-RD)
2025-520988-41-00Immunoglobulin G4 related Disease (IgG4-RD)
DrugInebilizumab
Amgen Inc.
Immune System Diseases
Greece, Poland, Italy, Spain
25/02/2026
Phase I/II
A Phase Ib/II, multi-site, open-label, two-part trial to evaluate the efficacy, safety, pharmacokinetics, and recommended combination dose of BNT324 with BNT327 in participants with advanced lung cancer
2024-520238-31-01Advanced Lung Cancer
BioNTech SE
Neoplasms
Spain, France, Italy, Poland
24/02/2026
Phase III
J2A-MC-GZPW: A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Event-Driven Study to Investigate the Effect of Orforglipron on the Incidence of Major Adverse Cardiovascular Events in Participants With Established Atherosclerotic Cardiovascular Disease and/or Chronic Kidney Disease
2025-523123-22-00Atherosclerosis Cardiovascular Disease, Chronic Kidney Dise…
Eli Lilly & Co.
Cardiovascular Diseases
Germany, Czechia, Lithuania, Spain, Austria, France, Hungary, Greece, Estonia, Netherlands, Slovakia, Poland, Romania, Bulgaria, Italy, Belgium
24/02/2026
Phase II
KEYMAKER-U01 Substudy 01J: A Randomized Phase 2 Umbrella Study With Rolling Arms of Investigational Agents for First-line Treatment of Participants With Advanced or Metastatic Nonsquamous Non-small Cell Lung Cancer (NSCLC) With KRAS G12C Mutations
2025-521939-36-00Participants with KRAS G12C-Mutant, Advanced or Metastatic …
Merck Sharp & Dohme LLC
Neoplasms
Italy, Poland, Spain, Finland, Netherlands, Greece
24/02/2026
Phase III
A multicenter, multinational, randomized, double-blind, placebo-controlled Phase 3, maintenance study to evaluate the efficacy and safety of duvakitug in participants with moderately to severely active Crohn’s disease
2025-521037-86-00Immune system diseases
Sanofi-Aventis Recherche & Developpement
Immune System Diseases
Spain, Czechia, Lithuania, Hungary, Greece, Bulgaria, Poland, Belgium, France, Germany, Norway, Austria, Netherlands, Italy, Slovakia
24/02/2026
Phase III
A multicenter, multinational, randomized, double-blind, placebo-controlled Phase 3, induction study to evaluate the efficacy and safety of duvakitug in participants with moderately to severely active Crohn’s Disease
2025-521036-11-00Immune system disseases
Sanofi-Aventis Recherche & Developpement
Immune System Diseases
Slovakia, Netherlands, Poland, Greece, Czechia, Italy, Bulgaria, Belgium, Germany, Lithuania, Austria, Spain, Hungary, Norway, France
24/02/2026
Phase IV
Effect of Romosozumab vs. Denosumab on Coronary Atherosclerotic Damage in Postmenopausal Osteoporotic Women: A Phase IV, Low-Risk, Pharmacological Intervention Study. ATRIO Study.
2025-522592-29-00Coronary atherosclerotic status in women with postmenopausa…
DrugsRomosozumab·Denosumab
Ospedale Galeazzi S.p.A.
Musculoskeletal Diseases
Italy
23/02/2026
Phase II
J2R-MC-YAAD: A Phase 2, Double-blind, Placebo-Controlled Study to Evaluate LY3537021 for the Treatment of Chemotherapy-Induced Nausea and Vomiting in Adult Participants With Malignant Disease
2025-522204-24-00Neoplasms, Vomiting, Drug-Related Side Effects and Adverse …
Eli Lilly & Co.
Neoplasms
Romania, Spain, France, Italy
23/02/2026
Phase III
INCA000585-201 - A PHASE 2A, OPEN-LABEL, MULTI-CENTER STUDY OF TAFASITAMAB IN ADULT PARTICIPANTS WITH AUTOIMMUNE BLOOD CELL DISORDERS
2025-521286-27-00Immune-mediated thrombocytopenia, Autoimmune thrombocytopen…
Incyte Corp.
Hemic and Lymphatic Diseases
Netherlands, Italy, Spain, France
23/02/2026
Phase II
Obinutuzumab Treatment in Frequently Relapsing and Rituximab-Dependent Idiopathic Nephrotic Syndrome in Adults: a fully academic, single-arm, open, prospective, intervention trial
2025-523306-33-00Idiopathic Nephrotic Syndrome
Istituto Di Ricerche Farmacologiche Mario Negri
Immune System Diseases
Italy
23/02/2026
Phase III
A seamless Phase 2/3 randomized, open-label study to investigate efficacy and safety of frexalimab versus tacrolimus in adult kidney transplant recipients
2025-521521-33-00Kidney transplant rejection
DrugsFrexalimab·Tacrolimus
Sanofi-Aventis Recherche & Developpement
Immune System Diseases
Germany, Hungary, Italy, Belgium, Czechia, Finland, Spain, Austria, Sweden, France, Denmark, Netherlands
23/02/2026
Phase III
Multicenter, Safety Follow-up Study to Assess Safety of Prior Treatment with Romosozumab in Children and Adolescents with Osteogenesis Imperfecta
2023-503293-21-00Osteogenesis Imperfecta
DrugRomosozumab
Amgen Inc.
Congenital, Hereditary, and Neonatal Diseases and Abnormalities
Germany, Hungary, Italy, Belgium, Austria, Slovakia, Spain
23/02/2026
Phase III
Phase 3 Randomized, Double-blind, Placebo-controlled Studies Assessing Ziftomenib in Combination with Either Standard of Care Nonintensive (Venetoclax+Azacitidine) or Intensive (7+3) Therapy in Patients with Untreated NPM1 Mutated or KMT2A Rearranged Acute Myeloid Leukemia
2025-521314-25-00NPM1-m and KMT2A-r Acute Myeloid Leukemia
DrugsZiftomenib·Cytarabine·Azacitidine·Venetoclax
Kura Oncology Inc.
Neoplasms
Belgium, Spain, Italy, Czechia, Hungary, Poland, France, Portugal, Germany, Greece
20/02/2026
Phase III
TRITON-PN: A Phase 3, Global, Randomized, Open-Label Study to Evaluate the Efficacy and Safety of Nucresiran in Patients with Hereditary Transthyretin-Mediated Amyloidosis with Polyneuropathy (hATTR-PN)
2025-522544-40-00Hereditary transthyretin-mediated amyloidosis with polyneur…
Alnylam Pharmaceuticals Inc.
Nervous System Diseases
France, Italy, Greece, Spain, Sweden, Ireland, Cyprus, Portugal, Germany
20/02/2026
Phase II
Master Protocol Full Title: A Master Protocol for an Exploratory, Phase 2a, Proof-of-Concept Platform Study to Evaluate the Safety, Tolerability, and Efficacy of Multiple Regimens in Participants With Myasthenia Gravis. ISA 1 Full Title: An ISA to Master Protocol ARGX-999-2-MG-2000 for an Exploratory, Phase 2a, Proof-of-Concept Study to Evaluate the Safety, Tolerability, and Efficacy of Empasiprubart IV as Add-On Therapy to Efgartigimod IV in Participants With AChR-Ab Seropositive Generalized Myasthenia Gravis With a Partial Clinical Response to Efgartigimod.
2025-522492-28-00AChR-Ab Seropositive Generalized Myasthenia Gravis, Myasthe…
Argenx
Immune System Diseases
Spain, Poland, Germany, Netherlands, Greece, Italy, Belgium
18/02/2026
Phase I/II
A Phase 1b/2, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Investigate A) the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Multiple Ascending Doses of IM-101 in Adult Participants with Generalized Myasthenia Gravis, and B) the Efficacy and Safety of Treatment of IM-101 in Adult Participants with Generalized Myasthenia Gravis and Ocular Myasthenia Gravis
2025-522406-20-00Generalized Myasthenia Gravis and Ocular Myasthenia Gravis
Immunabs Inc.
Nervous System Diseases
Bulgaria, Poland, Spain, Italy
18/02/2026
Phase II
Prevention of Ribociclib-related hepatotoxicity in breast cancer patients: a phase II, multicentre, open label, single arm trial of Silimarin.
2025-521651-22-00hormone receptor positive, HER2-negative breast cancer
DrugRibociclib
Fondazione Oncotech Impresa Sociale
Not possible to specify
Italy
17/02/2026
Phase III
A phase 3 randomized, double-blind, active-controlled study of palazestrant with ribociclib versus letrozole with ribociclib for the first-line treatment of ER+, HER2- advanced breast cancer (OPERA-02)
2025-522873-12-00ER+, HER2- Advanced Breast Cancer
Olema Pharmaceuticals Inc.
Neoplasms
Hungary, Portugal, Italy, France, Poland, Czechia, Germany, Spain, Belgium, Austria, Romania, Greece, Netherlands
17/02/2026
Phase I/II
A Phase 1/2, Multicenter, Open-Label, Multi-Cohort, First-in Human Trial of DS3790a, a DXd-ADC targeting CD37, for Hematological Malignancies.
2025-522595-87-00Hematological Malignancies
DrugsEpcoritamab·Rituximab
Daiichi Sankyo Inc.
Neoplasms
France, Italy
16/02/2026
Phase I
A Phase 1 Study of IM-1021 in Participants with Advanced Cancer
2025-523160-20-00Advanced B-cell lymphomas, Advanced solid tumors
Immunome Inc.
Neoplasms
France, Spain, Denmark, Italy
16/02/2026
Phase II
Revumenib Treatment in Combination with FLA Chemotherapy in Paediatric Refractory/Relapsed KMT2A-r, NUP98-r or NPM1-mut Acute Myeloid Leukemia (AML)
2025-521390-14-00Acute Myeloid Leukemia
DrugsRevumenib·Cytarabine·Fludarabine
Pediatric Research International GmbH
Neoplasms
Denmark, Italy, Czechia, Sweden, Poland, Netherlands, Germany, Austria
16/02/2026
Phase II
A Phase IIb, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of AZD5148 for Prevention of Recurrence of Clostridioides difficile Infection in Individuals 18 Years of Age and Above
2025-521416-19-00Recurrence of Clostridioides difficile Infection
AstraZeneca AB
Bacterial Infections and Mycoses
Greece, Spain, France, Germany, Italy, Hungary, Denmark, Sweden
16/02/2026
Phase III
Adaptive, Phase 2/3, Randomized, Double-Blind Trial Investigating the Efficacy and Safety of Visugromab versus Placebo in Patients with Cancer-associated Cachexia
2025-523533-25-00Cancer-associated Cachexia
CatalYm GmbH
Nutritional and Metabolic Diseases
France, Czechia, Romania, Italy, Germany, Poland, Spain, Bulgaria, Norway, Ireland, Netherlands
13/02/2026
Phase I/II
A Phase 1b/2 Study to Investigate the Safety, Efficacy and Pharmacokinetics of Administration of Subcutaneous (SC) Blinatumomab in Pediatric Participants with Relapsed/Refractory (R/R) and Minimal Residual Disease Positive (MRD+) B Cell Precursor Acute Lymphoblastic Leukemia (B-ALL)
2025-521671-31-00Relapsed/Refractory (R/R) and Minimal Residual Disease Posi…
Amgen Inc.
Neoplasms
France, Netherlands, Italy
13/02/2026
Phase III
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Revumenib in Combination with Intensive Chemotherapy in Participants with Newly Diagnosed AML with an NPM1 mutation (REVEAL-ND NPM1)
2025-522279-27-00Newly Diagnosed AML with an NPM1 mutation
Syndax Pharmaceuticals Inc.
Neoplasms
Greece, Poland, Spain, Austria, Italy, Romania, Belgium, France, Lithuania, Germany, Hungary, Czechia, Portugal
13/02/2026
Phase II
Inavolisib for PIK3CA mutated advanced endometrial cancer:a multicentric, phase II, MITO END-4 trial
2025-522981-61-00endometrial cancer
IRCCS Istituto Nazionale Tumori Fondazione Pascale
Female Urogenital Diseases and Pregnancy Complications
Italy
12/02/2026
Phase III
Personalized antibiotic TREATment for febrile Urinary Tract Infections in children (TREAT-UTI study): multicenter randomized controlled trial
2025-520622-38-00Urinary Tract Infections
Istituto Di Ricovero E Cura A Carattere Scientifico Materno Infantile Burlo Garofolo
Bacterial Infections and Mycoses
Italy
12/02/2026
Phase III
HELIOS: An Open-Label, Long-Term Study to Investigate the Safety, Tolerability, and Efficacy of DISC-1459 (Bitopertin) in Participants with Erythropoietic Protoporphyria (EPP) or X-Linked Protoporphyria (XLP).
2025-523275-27-00Erythropoietic Protoporphyria (EPP), X-Linked Protoporphyri…
Disc Medicine Inc.
Nutritional and Metabolic Diseases
Italy, France, Ireland, Belgium, Sweden, Germany, Netherlands, Norway, Spain
12/02/2026
Phase III
A Randomized, Active-Controlled, Double-blind, Multicenter, Phase 3 Clinical Study of Ivonescimab in Combination with FOLFOX versus Bevacizumab in Combination with FOLFOX for the First-line Treatment of Metastatic Colorectal Cancer (HARMONi-GI3)
2025-521587-35-00Metastatic colorectal cancer
Summit Therapeutics Inc.
Neoplasms
Belgium, Italy, Spain, Germany, France, Poland, Czechia, Hungary
12/02/2026
Phase III
A Long-term Extension Study of the Safety and Efficacy of Cleminorexton in Participants with Narcolepsy and Idiopathic Hypersomnia Who Completed a Sponsored Cleminorexton Clinical Trial
2025-522987-34-00Narcolepsy and Idiopathic Hypersomnia
Centessa Pharmaceuticals UK Limited
Nervous System Diseases
France, Spain, Italy
12/02/2026
Phase II
A Phase 2 study of intratumoral administration of L19IL2/L19TNF in locally advanced Cutaneous Squamous Cell Carcinoma patients progressing on or intolerant to systemic treatment.
2025-523231-19-00Cutaneous Squamous Cell Carcinoma
Philogen S.p.A.
Neoplasms
Italy, Germany, Greece, Spain, Austria, France, Netherlands
10/02/2026
Phase II
A Phase 2 controlled randomized study of the efficacy of L19IL2 or L19TNF or L19IL2/L19TNF intralesional injections for the treatment of locally advanced basal cell carcinoma patients.
2025-523229-16-00locally advanced basal cell carcinoma patients
Philogen S.p.A.
Skin and Connective Tissue Diseases
Greece, Italy, Germany, Spain, Netherlands
10/02/2026
Phase III
An Open-label, Randomized Phase 3 Study of Linvoseltamab Monotherapy and Linvoseltamab plus Carfilzomib versus Standard of Care Combination Regimens in Patients with Relapsed/Refractory Multiple Myeloma
2024-519504-27-00Relapsed Refractory Multiple Myeloma
DrugsDiphenhydramine hydrochloride·Linvoseltamab·Paracetamol·Velcade
Regeneron Pharmaceuticals Inc.
Neoplasms
Greece, Spain, Poland, Italy, Austria, Czechia, Belgium, Germany, Netherlands, France
10/02/2026
Phase II
A Phase 2 study of intratumoral administration of L19IL2/L19TNF in locally advanced Basal Cell Carcinoma patients progressed on or intolerant to systemic treatment.
2025-523230-77-00Patients with locally advanced Basal Cell Carcinoma (LaBCC)…
Philogen S.p.A.
Neoplasms
Germany, Italy, Greece, Spain, France
10/02/2026
Phase III
Trial of Sequential Medications AfteR TNFi Failure in Juvenile Idiopathic Arthritis (SMART-JIA)
2025-520923-25-00Juvenile Idiopathic Arthritis
Duke Clinical Research Institute
Immune System Diseases
Italy, Netherlands, Germany
10/02/2026
Phase II
Hyperprogression upon cemiplimab alone or with chemotherapy in PD-L1 ≥ 50% NSCLC: a biomarker guided phase 2 trial – HYPERBOLIC study
2025-521583-35-00non-small cell lung cancer (NSCLC)
DrugsCemiplimab·Pemetrexed·Paclitaxel·Cisplatin
Universita' Vita-salute S. Raffaele
Neoplasms
Italy
10/02/2026
Phase III
A Phase 3, Randomized, Double-Blinded, Placebo-Controlled Study Evaluating the Efficacy and Safety of Empasiprubart IV in Adults With Chronic Inflammatory Demyelinating Polyneuropathy
2025-520805-10-00Chronic inflammatory demyelinating polyneuropathy (CIDP)
DrugEmpasiprubart
Argenx
Nervous System Diseases
Czechia, Denmark, Poland, Slovenia, Netherlands, Austria, Estonia, Slovakia, Hungary, Finland, Bulgaria, France, Italy, Greece, Romania
10/02/2026
Phase II
A Phase 2 Open-label Multicenter Study to Evaluate the Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of Inebilizumab in Children From 2 Years to less than 18 Years of age With Generalized Myasthenia Gravis (gMG)
2025-520993-20-00Generalized Myasthenia Gravis
DrugInebilizumab
Amgen Inc.
Nervous System Diseases
Spain, Italy, Poland, France
09/02/2026
Phase I
A Phase 1 Study of AJ1-11095 in Adults with Myelofibrosis Failed by a JAK2 Inhibitor
2025-522033-64-00Myelofibrosis
Ajax Therapeutics Inc.
Neoplasms
Italy, France, Spain
09/02/2026
Phase I/II
Phase 1/2 Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antiviral Activity of GS-4321 in Healthy Participants and Participants With Chronic Hepatitis Delta.
2025-522729-36-00Chronic Hepatitis Delta.
Gilead Sciences Inc.
Virus Diseases
Italy, Romania, Germany, Bulgaria
09/02/2026
Phase III
Phase 2/3 Open Label Randomized Study of Telisotuzumab Adizutecan, Monotherapy or in Combination with Osimertinib, Compared to Standard of Care in Subjects with Locally Advanced or Metastatic EGFR-Mutated Non-Squamous Non-Small Cell Lung Cancer After Progression on a Third-Generation EGFR TKI - AndroMETa-Lung-713
2025-521124-29-00Non-Small Cell Lung Cancer
AbbVie Deutschland GmbH & Co. KG
Neoplasms
Portugal, Italy, Spain, Poland, Netherlands, Germany, Belgium, Austria, France
09/02/2026
Phase III
A Phase 3 Trial to Evaluate the Long-Term Safety and Efficacy of Navenibart in Participants with Hereditary Angioedema – ORBIT-EXPANSE
2025-521142-22-00Hereditary Angioedema
Astria Therapeutics Inc.
Congenital, Hereditary, and Neonatal Diseases and Abnormalities
Netherlands, Spain, Poland, Germany, Czechia, Austria, Portugal, Hungary, France, Italy, Bulgaria
09/02/2026
Phase III
A Multicenter, Multinational, Randomized, Double-blind, Placebo-Controlled, Phase 3 Maintenance Study to Evaluate the Efficacy and Safety of Duvakitug in Participants with Moderately to Severely Active Ulcerative Colitis
2025-521038-27-00Immune system diseases
Sanofi-Aventis Recherche & Developpement
Immune System Diseases
Slovakia, Germany, Austria, Italy, Czechia, Netherlands, Poland, Belgium, Hungary, Lithuania, Greece, France, Bulgaria, Spain, Norway
09/02/2026
Phase III
A multicenter, multinational, randomized, double-blind, placebo-controlled Phase 3, induction study to evaluate the efficacy and safety of duvakitug in participants with moderately to severely active Ulcerative Colitis.
2025-521035-37-00Immune system diseases
Sanofi-Aventis Recherche & Developpement
Immune System Diseases
Austria, France, Norway, Hungary, Bulgaria, Netherlands, Czechia, Slovakia, Germany, Lithuania, Greece, Belgium, Italy, Spain, Poland
09/02/2026
Phase II
A Phase 2 randomized, double-blind, placebo-controlled study to investigate efficacy, safety, immunogenicity, and pharmacokinetics, of GSK3862995B in participants with bronchiectasis
2025-522892-27-00Bronchiectasis
GSK PLC
Respiratory Tract Diseases
Denmark, France, Spain, Italy, Germany, Poland
09/02/2026
Phase IV
(23026) A prospective, single-arm, Phase 4 study to evaluate the course of serum transthyretin (TTR) level with acoramidis in adult patients with variant or wild-type transthyretin amyloidosis with cardiomyopathy (ATTR-CM) previously treated with tafamidis.
2025-521831-35-00Transthyretin Amyloid Cardiomyopathy (ATTR-CM)
Bayer Consumer Care AG
Cardiovascular Diseases
Austria, Germany, Italy, Belgium
07/02/2026
Phase III
Sodium-glucose cotransporter-2 inhibitors to stABiLizE coronary atherosclerosis pro-gression after acute Myocardial Infarction in women and men with diabetes mellitus
2025-523375-29-00diabetes mellitus, Myocardial Infarction
Humanitas Mirasole S.p.A.
Cardiovascular Diseases
Italy
06/02/2026
Phase II
A Phase IIb, Monocentric, Non-Profit, Open-label Trial for the Intrathecal Administration of AAV9/AP4M1 for Hereditary Spastic Paraplegia Type 50 (SPG50)
2025-522603-15-00Hereditary Spastic Paraplegia Type 50 (SPG50)
Azienda Socio Sanitaria Territoriale Papa Giovanni Xxiii
Congenital, Hereditary, and Neonatal Diseases and Abnormalities
Italy
06/02/2026
Phase II
Phase II study of Cemiplimab before and after standard chemoradiotherapy for patients with locally advanced cervical carcinoma. CADILLACC TRIAL
2025-521839-36-00locally advanced cervical carcinoma
DrugCemiplimab
Fondazione IRCCS Istituto Nazionale Dei Tumori
Female Urogenital Diseases and Pregnancy Complications
Italy
06/02/2026
Phase III
A Phase 3, Randomized, Multicenter, Open-Label Study of IDRX-42 (GSK6042981) versus Sunitinib in Participants with Metastatic and/or Unresectable Gastrointestinal Stromal Tumors (GIST) after Imatinib Therapy (StrateGIST 3)
2025-522229-37-00Gastrointestinal Neoplasms
Glaxosmithkline Research & Development Limited
Neoplasms
France, Romania, Spain, Netherlands, Norway, Belgium, Hungary, Italy, Poland, Germany
06/02/2026
Phase II
A Phase 2, Randomised, Double-masked, Placebo-controlled, Parallel-group, Multi-centre Study to Evaluate K1-70 in Patients with Active Thyroid Eye Disease in Europe
2024-519292-26-00Graves’ disease and active thyroid eye disease
Av7 Limited
Eye Diseases
Spain, Italy
05/02/2026
Phase II
An Open-Label Extension, Multi-centered, Phase 2 Trial to Describe the Safety and Efficacy of TEV-56286 (Emrusolmin) in Participants with Multiple System Atrophy
2025-521642-14-00Multiple System Atrophy
Teva Branded Pharmaceutical Products R&D LLC
Nervous System Diseases
France, Germany, Italy, Spain
04/02/2026
Phase II
An Open-label, Randomized, Multi-Center Study to Evaluate the Efficacy and Safety of Induction Treatment with Melphalan/HDS Followed by Consolidation Treatment with Eribulin or Vinorelbine or Capecitabine Versus Eribulin or Vinorelbine or Capecitabine Alone in Patients with Metastatic Breast Cancer with Liver Dominant Disease
2025-521966-91-00Refractory Metastatic Breast Cancer with Liver Dominant Dis…
Delcath Systems Inc.
Neoplasms
Italy, Spain, Sweden, France, Germany
04/02/2026
Phase III
A Phase 2b/3, Open-Label, Multicenter Trial Evaluating the Efficacy and Safety of Switching to Brelovitug for the Treatment of Chronic Hepatitis Delta Infection in Participants Receiving Bulevirtide (AZURE-3)
2025-522015-42-00Chronic Hepatitis D Infection
Mirum Pharmaceuticals Inc.
Virus Diseases
Czechia, Austria, Spain, Romania, Germany, Italy, France
03/02/2026
Phase III
ZENITH: A Phase 3 Global, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Zilebesiran in Addition to Standard of Care in Reducing Major Adverse Cardiovascular Events in Adult Patients with Hypertension Not Adequately Controlled and With Either Established Cardiovascular Disease or High Risk for Cardiovascular Disease
2025-522960-34-00Hypertension, Established cardiovascular disease, High card…
Alnylam Pharmaceuticals Inc.
Cardiovascular Diseases
Belgium, Hungary, Czechia, Austria, Germany, France, Greece, Spain, Romania, Netherlands, Italy, Poland, Slovakia, Sweden, Portugal, Denmark, Bulgaria
03/02/2026
Phase III
A Phase 3b/4 Randomized, Open-label, Efficacy Assessor-Blinded Study, to Evaluate the Efficacy and Safety of Upadacitinib for the Treatment of Adult Subjects with Moderate to Severe Atopic Dermatitis and Inadequate Response to Dupilumab (SWITCH-UP)
2025-523347-35-00Atopic Dermatitis
AbbVie Deutschland GmbH & Co. KG
Immune System Diseases
Spain, Italy, Romania
02/02/2026
Phase I
A clinical study of MK-1045 in people with lupus or rheumatoid arthritis (MK-1045-004)
2025-523412-36-00Systemic lupus erythematosus, Rheumatoid arthritis
Merck Sharp & Dohme LLC
Immune System Diseases
Italy, Belgium, Romania, Spain
02/02/2026
Phase II
A Phase 2b, Randomised, Double-Blind, Placebo-Controlled, Parallel-Arm Dose Finding Study Evaluating the Efficacy and Safety of SAB-142 for Delaying the Progression of Type 1 Diabetes (T1D) in Patients with Stage 3 New Onset of Type 1 Diabetes (NOT1D)
2025-521560-36-00Type 1 Diabetes
Sab Biotherapeutics Inc.
Nutritional and Metabolic Diseases
Austria, Germany, Poland, Italy, Denmark, Spain, Belgium, Finland, France, Lithuania, Slovenia
02/02/2026
Phase III
A Phase 2b/3, Adaptive, Randomized, Double-blind, Placebo-controlled, Multicenter Study to Assess the Efficacy and Safety of Danicamtiv in Participants with Symptomatic Genetic and Familial Dilated Cardiomyopathy (KINSHIP-DCM).
2025-522553-19-00Symptomatic genetic and familial dilated cardiomyopathy.
Kardigan Inc.
Cardiovascular Diseases
Spain, Denmark, Belgium, Hungary, Italy, Poland, France, Sweden, Netherlands
30/01/2026
Phase I/II
A Phase 1/2a Dose-Escalating Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ARO-DM1 in Subjects With Type 1 Myotonic Dystrophy Who are ≥18 to ≤65 Years
2024-513579-42-00Type 1 Myotonic Dystrophy
Sarepta Therapeutics Inc.
Nervous System Diseases
Spain, Germany, Belgium, Italy
29/01/2026
Phase III
A RANDOMIZED, PHASE 3, OPEN-LABEL STUDY OF NEOADJUVANT DAROVASERTIB IN SUBJECTS WITH PRIMARY NON-METASTATIC UVEAL MELANOMA (OptimUM-10)
2025-522387-32-00Uveal Melanoma
Ideaya Biosciences Inc.
Eye Diseases
France, Spain, Poland, Italy, Czechia, Belgium, Austria, Netherlands, Denmark, Germany
29/01/2026
Phase IV
Changes in Coronary Plaque Composition By Semaglutide Use in Diabetic Patients With Acute Coronary Syndrome: A Randomized Optical Coherence Tomography Trial - ARMYDA - 10 study
2025-523977-40-00non-ST-elevation myocardial infarction (NSTEMI); unstable a…
DrugSemaglutide
Azienda Ospedaliero-Universitaria Maggiore Della Carita
Cardiovascular Diseases
Italy
28/01/2026
Phase IV
Tailored antiplatelet secondary prevention in non-cardioembolic ischemic stroke: a phase IV gender-stratified randomized controlled trial (TAILOR trial)
2025-523065-16-00Non-cardioembolic ischemic stroke
Azienda Unita Sanitaria Locale Di Bologna
Cardiovascular Diseases
Italy
28/01/2026
Phase II
A Multi-Center, Double-Blind, Placebo-Controlled, Phase II Study Evaluating the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of RO7268489, A Monoacylglycerol Lipase Inhibitor, as Add-On Therapy to Ocrelizumab, in Participants with Progressive Forms of Multiple Sclerosis
2025-521636-10-00Progressive Forms of Multiple Sclerosis (PMS)
F. Hoffmann-La Roche AG
Nervous System Diseases
Germany, Spain, France, Hungary, Italy, Poland, Portugal
28/01/2026
Phase I
Study to look at the safety, tolerability, and how the body processes the study medicine WAL0623 after single or repeated doses, with or without food, in healthy volunteers
2024-516446-18-00Glomerular kidney diseases with proteinuria
Walden Biosciences Inc.
Male Urogenital Diseases
Italy
27/01/2026
Phase III
N1T-MC-MALO: A Master Protocol for a Randomized, Controlled, Clinical Trial of Multiple Pharmacologic Agents in Adult Participants With Metabolic Dysfunction-Associated Steatotic Liver Disease Who Are at Increased Risk of Developing Major Adverse Liver Outcomes (SYNERGY-Outcomes); N1T-MC-TZ01 Tirzepatide in participants with high-risk MASLD; N1T-MC-RT01 Retatrutide in participants with high-risk MASLD
2025-522674-36-00Metabolic Dysfunction-Associated Steatotic Liver Disease
Eli Lilly & Co.
Nutritional and Metabolic Diseases
Czechia, France, Netherlands, Bulgaria, Norway, Austria, Poland, Spain, Italy, Hungary, Germany, Romania, Sweden, Portugal, Belgium
27/01/2026
Phase I
A PK study to compare JPB898 (proposed nivolumab biosimilar) and US-licensed Opdivo® in participants with resected stage IIB, IIC, or III melanoma in the adjuvant setting
2025-521919-39-00Resected stage IIB, IIC, or III melanoma requiring adjuvant…
H e x a l AG
Neoplasms
Spain, Romania, Italy, Greece
27/01/2026
Phase III
A Phase 3, Randomized, Double-blind, Placebo-controlled, Multicenter, Parallelgroup Study to Evaluate the Efficacy and Safety of Treprostinil Palmitil Inhalation Powder in Participants with Pulmonary Hypertension Associated with Interstitial Lung Disease
2025-521558-40-00Pulmonary Hypertension Associated with Interstitial Lung Di…
DrugTreprostinil Palmitil
Insmed Inc.
Respiratory Tract Diseases
Portugal, Italy, Czechia, Poland, Denmark, Greece, Germany, Romania, Spain, France, Belgium, Austria
26/01/2026
Phase II
PASSION (olaParib mAintenance in chemotherapy-Sensitive metaStatic pancreatIc adenOcarciNoma - mPDAC): a phase II, proof of principle, study
2025-522530-31-01Patients with metastatic PDAC, who have not progressed foll…
DrugOlaparib
Universita' Degli Studi Di Verona
Neoplasms
Italy
26/01/2026
Phase III
An Operationally Seamless Phase 2/3 Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of Enlicitide Decanoate in Pediatric Participants with Heterozygous Familial Hypercholesterolemia
2024-519068-42-00​Heterozygous Familial Hypercholesterolemia​ in pediatric p…
Merck Sharp & Dohme LLC
Cardiovascular Diseases
Germany, Spain, Belgium, Czechia, Norway, France, Poland, Netherlands, Italy, Finland
26/01/2026
Phase II
Master Protocol: A Phase 1b / 2, Multicenter, Multi Arm Study of Evorpacept in Combination with Anti-cancer Therapies in Advanced / Metastatic Malignancies (ASPEN-09) Substudy Protocol: A Single-arm Phase 2 Multicenter Study of Evorpacept in Combination with Trastuzumab and Chemotherapy in Participants with Metastatic HER2-Positive Breast Cancer (ASPEN-09-03)
2025-522012-16-00Breast Cancer
Alx Oncology Holdings Inc.
Neoplasms
Spain, Italy, France
23/01/2026
Phase III
Phase 3 Study to Evaluate the Efficacy and Safety of Zodasiran in Adolescent and Adult Subjects with Homozygous Familial Hypercholesterolemia (YOSEMITE)
2025-521792-31-01Homozygous Familial Hypercholesterolemia (HoFH)
DrugZodasiran
Arrowhead Pharmaceuticals Inc.
Cardiovascular Diseases
Greece, France, Belgium, Germany, Netherlands, Austria, Sweden, Spain, Czechia, Italy
23/01/2026
Phase II
A Phase 2b Randomized, Open-Label Active Controlled Study Evaluating the Safety and Efficacy of oral VH4524184 Coadministered with Emtricitabine and Tenofovir Alafenamide in Treatment Naïve Viremic Persons with HIV-1.( INNOVATE Study)
2025-521918-26-00HIV Infections
Viiv Healthcare UK Limited
Virus Diseases
Spain, Belgium, France, Germany, Italy, Portugal, Poland
23/01/2026
Phase I/II
A First-in-Human, Double-Blind, Placebo-Controlled, Multiple Ascending Dose Study of Intrathecally Administered LTX-002 in Adult Participants with Amyotrophic Lateral Sclerosis
2025-522039-33-00Amyotrophic Lateral Sclerosis
Leal Therapeutics Inc.
Nervous System Diseases
Sweden, Italy, Germany, Netherlands
23/01/2026
Phase II
A phase II, open label, multicenter trial investigating Irinotecan plus cetuximab rechallenge compared with trifluridine/tipiracil plus bevacizumab as third line treatment in circulating tumor DNA molecularly selected metastatic colorectal cancer: the ROMANCE-GOIM trial
2025-521319-38-00metastatic colorectal cancer
Gruppo Oncologico Dell'Italia Meridionale
Neoplasms
Italy
19/01/2026
Phase III
Beamion LUNG-3: A randomized, controlled, multi-center trial evaluating zongertinib as an adjuvant monotherapy compared with standard of care in patients with early-stage, resectable non-small cell lung cancer (Stage II-IIIB) harboring tyrosine kinase domain activating HER2 mutations
2025-521284-12-00Non-small cell lung cancer
Boehringer Ingelheim International GmbH, Boehringer Ingelheim Espana S.A.
Neoplasms
Austria, Portugal, Netherlands, Greece, Belgium, Spain, Germany, France, Romania, Sweden, Italy, Denmark
19/01/2026
Phase III
IZABRIGHT-Lung01: A Randomized, Open-label, Phase 2/3 Study of Izalontamab Brengitecan (BMS-986507) versus Platinum-based Chemotherapy in Patients with EGFR-mutated Non-small Cell Lung Cancer and Disease Progression on EGFR Tyrosine Kinase Inhibitor Therapy
2025-521908-22-00EGFR-mutated Non-small Cell Lung Cancer
DrugsPegfilgrastim·Iza-bren·Pemetrexed·Cisplatin
Bristol-Myers Squibb Services Unlimited Company
Neoplasms
Poland, Germany, Italy, Norway, Netherlands, Belgium, Romania, France, Greece, Spain
19/01/2026
Phase III
A Phase 3b/4 Multi-center, Randomized, Open-label, Long-term Safety Study of Deucravacitinib in Comparison to Ustekinumab in Participants with Moderate-to-Severe Plaque Psoriasis (PRAGMATYK)
2023-503766-24-00Moderate to Severe Plaque Psoriasis
DrugsUstekinumab·Deucravacitinib
Bristol-Myers Squibb Services Unlimited Company
Immune System Diseases
Romania, Bulgaria, Germany, Spain, Czechia, France, Hungary, Italy, Sweden, Poland, Denmark, Belgium
19/01/2026
Phase IV
International multicentre, open-label, phase IV clinical trial to evaluate the efficacy, safety and effect on quality of life of bilastine in children with allergic rhinoconjunctivitis
2024-519550-36-00Allergic rhinoconjunctivitis
Faes Farma S.A., A. Menarini Industrie Farmaceutiche Riunite S.r.l.
Immune System Diseases
Poland, Spain, Italy
19/01/2026
Phase III
An open-label, parallel, Phase 3, two-arm study to investigate the efficacy and safety of fitusiran prophylaxis in male participants aged 1 to less than 12 years with hemophilia A or B with or without inhibitory antibodies to Factors VIII or IX
2025-521858-42-00Hemophilia
DrugFitusiran
Sanofi-Aventis Recherche & Developpement
Hemic and Lymphatic Diseases
Belgium, Italy, Romania, Germany, Hungary, Spain, Poland
15/01/2026
Phase III
A Phase 3, Randomized, Double-blind, Placebo-controlled, Study to Evaluate the Efficacy and Safety of Adjunctive KarXT for the Treatment of Mania, With or Without Mixed Features, in Individuals with Bipolar-I Disorder Taking Lithium, Valproate, or Lamotrigine
2025-521845-26-00BP-I mania or mania with mixed features
DrugKarXT
Bristol-Myers Squibb Services Unlimited Company
Mental Disorders
Romania, Poland, France, Italy, Denmark, Bulgaria
15/01/2026
Phase III
HOVON 181 AML: Bleximenib or Placebo in Combination with Standard Induction and Consolidation Therapy followed by Maintenance for the Treatment of Patients with Newly Diagnosed KMT2A-rearranged or NPM1-mutant Acute Myeloid Leukemia Eligible for Intensive Chemotherapy: a double-blind phase 3 study
2025-522767-15-00Acute Myeloid Leukemia
DrugBleximenib
Hemato-Oncologie voor Volwassenen Nederland (Hovon) Stichting
Neoplasms
Belgium, Netherlands, Germany, Austria, Denmark, Estonia, Finland, Ireland, Italy, Lithuania, Spain, Sweden, Norway, Poland
15/01/2026
Phase II
A phase 2, three-arm, randomized study of the efficacy of intratumorally administered L19IL2 or L19TNF or L19IL2/L19TNF, all in combination with systemic anti-PD1 pembrolizumab, in stage III and IV unresectable melanoma patients with resistance to or progressing upon anti-PD1 checkpoint inhibitors and with presence of injectable metastases
2024-519326-20-00Patients with diagnosis of unresectable clinical stage III …
Philogen S.p.A.
Neoplasms
Italy, Germany
14/01/2026
Phase III
A Phase 3, Randomized, Open-Label, Multicenter Study of Amivantamab in Addition to Carboplatin and Pembrolizumab, Compared to Standard of Care Platinum and Pembrolizumab and 5-FU, in Participants with Treatment-Naïve Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma
2025-521917-24-00Treatment-Naïve Recurrent/Metastatic Head and Neck Squamous…
Janssen Cilag International
Neoplasms
Italy, Portugal, Spain, Romania, Hungary, France, Czechia, Germany, Netherlands, Austria, Poland, Belgium
14/01/2026
Phase I
A Phase 1, Open-Label, Multicenter Study of INCB160058 in Participants With Myeloproliferative Neoplasms.
2024-520353-21-00Myeloproliferative Neoplasms
Incyte Corp.
Neoplasms
Norway, Germany, France, Italy
14/01/2026
Phase III
A Phase 3, Randomized, Open-label, Multicenter Study to Evaluate the Efficacy and Safety of Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab With or Without Bevacizumab Compared With Standard of Care as Firstline Maintenance Treatment for Participants With Persistent, Recurrent, or Newly Diagnosed Metastatic Cervical Cancer With PD-L1 CPS Greater Than or Equal to 1 (TroFuse-036/GOG-3123/ENGOT-cx22)
2025-521514-26-00Persistent, Recurrent, or Newly Diagnosed Metastatic Cervic…
Merck Sharp & Dohme LLC
Neoplasms
Greece, Ireland, France, Belgium, Czechia, Hungary, Austria, Spain, Sweden, Germany, Poland, Denmark, Italy
14/01/2026
Phase IV
Arthritis interception with Guselkumab in subclinical psoriatic arthritis patients in clinical transition from skin to joint disease: a randomized clinical trial.
2025-523551-54-00PSORIATIC ARTHRITIS PATIENTS IN CLINICAL TRANSITION
DrugsCiclosporin·Guselkumab
Azienda Sanitaria Universitaria Friuli Centrale
Musculoskeletal Diseases
Italy
14/01/2026
Phase II
A Phase IIa, Randomised, Double-blind, Placebo-controlled, Multicentre Study to Assess the Efficacy, Safety, and Tolerability of AZD4144 in Participants with Sepsis-associated Acute Kidney Injury (SERENIA)
2025-522232-13-00Sepsis-associated acute kidney injury (AKI)
DrugAZD4144
AstraZeneca AB
Not possible to specify
Germany, France, Spain, Italy, Belgium, Czechia, Greece, Denmark, Hungary
14/01/2026
Phase III
A Biomarker-Directed, Multi-Centre Phase II/III Study of ctDNA Response Adaptive Immuno-Chemotherapy in Lung Cancer - BR.36
2025-522084-15-00metastatic NSCLC patients
DrugsPemetrexed·Paclitaxel·Cisplatin·Carboplatin
IRCCS Istituto Nazionale Tumori Fondazione Pascale
Neoplasms
Italy
13/01/2026
Phase II
Evaluation of the Pharmacokinetics of Subcutaneous Administration of Piperacillin/Tazobactam: An Open-Label, Multicentric, Non-Inferiority Randomized Clinical Trial (STUPITA01)
2024-519663-17-01Infectious disease
Azienda Sanitaria Universitaria Friuli Centrale
Bacterial Infections and Mycoses
Italy
09/01/2026
Phase III
A Phase 2/3, multicenter, randomized open-label study of zanzalintinib vs everolimus in participants with previously treated, unresectable, locally advanced or metastatic neuroendocrine tumors
2025-521043-20-00Neuroendocrine tumors
Exelixis Inc.
Neoplasms
France, Poland, Netherlands, Belgium, Germany, Spain, Italy, Austria
09/01/2026
Phase III
A Randomized, Phase 2/3, Open-Label Study to Investigate the Efficacy and Safety of RP2 in Combination with Nivolumab versus Ipilimumab in Combination with Nivolumab in Immune Checkpoint Inhibitor-Naïve Adult Patients with Metastatic Uveal Melanoma
2023-508784-68-00metastatic uveal melanoma
DrugsRP2·Ipilimumab·Nivolumab
Replimune Inc.
Neoplasms
Germany, Italy, France, Spain, Poland
23/12/2025
Phase II
A Phase 2b, Randomized, Blinded Trial Investigating the Efficacy and Safety of Visugromab in combination with Nivolumab and Lenvatinib compared to Double Placebo and Lenvatinib in Participants with Unresectable or Metastatic Hepatocellular Carcinoma and Compensated Liver Function (Child-Pugh A) after Failure of First-Line Treatment that Included an Anti-PD-(L)1 Compound (GDFATHER-HCC-01)
2025-520675-86-00Unresectable or Metastatic Hepatocellular Carcinoma and Com…
CatalYm GmbH
Neoplasms
Germany, France, Italy, Spain
23/12/2025
Phase III
A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Intravenous Prasinezumab in Participants with Early-Stage Parkinson’s Disease
2025-522683-32-00Early-Stage Parkinson’s Disease (PD)
F. Hoffmann-La Roche AG
Nervous System Diseases
France, Austria, Portugal, Netherlands, Poland, Germany, Spain, Denmark, Italy
23/12/2025
Rows per page Showing 1–500 of 756
1 2 Next
Cite this view

Priya Life Science (2026). EU Clinical Trials Register (CTIS), filtered. Derived from the EMA Clinical Trials Information System. Retrieved 6 October 2026. https://priyalifescience.com/clinical-trials-europe/country/italy

Query this register directly
GET /api/export.php?register=trials-eu&format=json Try it now →

About this register

This register is built from the EU Clinical Trials Information System (CTIS), run by the European Medicines Agency: the single register for every trial authorised under the EU Clinical Trials Regulation (536/2014). CTIS held 12,561 trial records at the last sync on 06 Oct 2026, 03:17 UTC; this register shows the 2,557 most recently authorised of them, a stated recency window rather than the full archive. The list can be downloaded as CSV or JSON.

This page shows the 756 of those trials with a site in Italy.

How many recently authorised EU trials have a site in Italy?

756 of the 2,557 most recently authorised trials in this register list a site in Italy; 375 of them are Phase III. Trials are counted by authorisation on CTIS, not by recruitment status, which CTIS does not publish in the same form as ClinicalTrials.gov.

Summary by phase

Trials by phase (Italy), 756 trials
PhaseTrialsShare
Phase III37549.6%
Phase II23631.2%
Phase I/II678.9%
Phase I486.3%
Phase IV304%

Most active sponsors

Lead sponsors with the most trials (Italy)
Lead sponsorTrials
AstraZeneca AB35
Novartis Pharma AG28
Bristol-Myers Squibb Services Unlimited Company25
Merck Sharp & Dohme LLC25
Pfizer Inc.22
F. Hoffmann-La Roche AG21
Sanofi-Aventis Recherche & Developpement21
Amgen Inc.17
Glaxosmithkline Research & Development Limited17
Janssen Cilag International17
Listing here is informational and not medical advice; eligibility is determined by each study team. Looking for Irish sites? See the Ireland, UK or USA registers. For approved medicines, see the EMA Approvals Tracker.